Irinotecan Clinical Trials (2026): 1,344 Studies for Colorectal Cancer & Metastatic Colorectal Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1,344 Irinotecan clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 436 indications (including Colorectal Cancer & Metastatic Colorectal Cancer) and 177,253 total planned enrollment. 172 Phase 3 Irinotecan trials and 684 Phase 2, 15 Phase 4 are listed. 257 Irinotecan clinical trials are actively recruiting at 2,591 U.S. sites across 51 states. Most recent activity: NCT06450041 (Dec 2038).
Where to Participate: All Irinotecan Trial Sites in the U.S. (2,591 sites across 51 states)
Every actively recruiting Irinotecantrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT04322318 | Map |
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT06172296 | Map |
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT06401330 | Map |
| AL | Children's Hospital of Alabama | Birmingham35233 | NCT06620302 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294-3300 | NCT04657068 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT01042379 | Map |
| AL | University of Alabama at Birmingham (Children's of Alabama) | Birmingham35233 | NCT07194044 | Map |
| AL | University of Alabama/Children's of Alabama | Birmingham35233 | NCT06541262 | Map |
| AL | USA Health Strada Patient Care Center | Mobile36604 | NCT04322318 | Map |
| AL | USA Health Strada Patient Care Center | Mobile36604 | NCT06172296 | Map |
| AL | USA Health Strada Patient Care Center | Mobile36604 | NCT06401330 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT04205968 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT05677490 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT06998940 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT04205968 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT05677490 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT06998940 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT04205968 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05677490 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT06998940 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT04205968 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT05677490 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT06998940 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT04205968 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT05677490 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT06998940 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT04205968 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT04322318 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT05677490 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT06401330 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT06998940 | Map |
| AZ | Ironwood Cancer and Research Center | Chandler85224 | NCT06750094 | Map |
| AZ | Arizona Center for Cancer Care - Gilbert | Gilbert85297 | NCT06958328 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05863195 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT06662786 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT06750094 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT06958328 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT04205968 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05677490 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT04322318 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT06172296 | Map |
| AZ | Banner Children's at Desert | Mesa85202 | NCT06401330 | Map |
| AZ | Arizona Center for Cancer Care-Peoria | Peoria85381 | NCT06958328 | Map |
| AZ | Arizona Center for Cancer Care - Phoenix | Phoenix85027 | NCT06958328 | Map |
| AZ | Banner-University Medical Center Phoenix | Phoenix85006 | NCT05863195 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT06998940 | Map |
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT05999994 | Map |
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT05999994 | Map |
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT06541262 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT04322318 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT06172296 | Map |
| AZ | Phoenix Childrens Hospital | Phoenix85016 | NCT06401330 | Map |
| AZ | Arizona Center for Cancer Care - Scottsdale | Scottsdale85258 | NCT06958328 | Map |
| AZ | Mayo Clinic (Arizona) | Scottsdale85259 | NCT04657068 | Map |
| AZ | Research Site | Scottsdale85259 | NCT06792695 | Map |
| AZ | Banner Boswell Medical Center | Sun City85351 | NCT05863195 | Map |
| AZ | Arizona Center for Cancer Care-Surprise | Surprise85374 | NCT06958328 | Map |
| AZ | Arizona Center for Cancer Care | Tempe85284 | NCT06958328 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT04322318 | Map |
| AZ | Banner University Medical Center - Tucson | Tucson85719 | NCT06172296 | Map |
| AZ | University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) | Tucson85719 | NCT05319730 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT06998940 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT04205968 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT05677490 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT04205968 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT06958328 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT06998940 | Map |
| AR | St. Bernard's Medical Center | Jonesboro72401 | NCT06662786 | Map |
| AR | St. Bernard's Medical Center | Jonesboro72401 | NCT06750094 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT04322318 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT06172296 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202-3591 | NCT06401330 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT04205968 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT05677490 | Map |
| AR | University of Arkansas - Winthrop P. Rockefeller Cancer Institute | Little Rock72205 | NCT04657068 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT06998940 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT06662786 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT06750094 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT06998940 | Map |
| CA | Kaiser Permanente-Anaheim | Anaheim92806 | NCT04205968 | Map |
| CA | Kaiser Permanente-Deer Valley Medical Center | Antioch94531 | NCT05677490 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT06998940 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT04205968 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05677490 | Map |
| CA | Sutter Auburn Faith Hospital | Auburn95602 | NCT05677490 | Map |
| CA | Sutter Auburn Faith Hospital | Auburn95602 | NCT06998940 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT06998940 | Map |
| CA | AIS Cancer Center at San Joaquin Community Hospital | Bakersfield93301 | NCT06958328 | Map |
| CA | CBCC Global Research | Bakersfield93309 | NCT06662786 | Map |
| CA | CBCC Global Research | Bakersfield93309 | NCT06750094 | Map |
| CA | Kaiser Permanente-Baldwin Park | Baldwin Park91706 | NCT04205968 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT04205968 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT05677490 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT06958328 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT06998940 | Map |
| CA | Precision NextGen Oncology and Research | Beverly Hills90212 | NCT03715933 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT04205968 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT05677490 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT06998940 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT05677490 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT06958328 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT06998940 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT06958328 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT06998940 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT06998940 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT06998940 | Map |
| CA | Eden Hospital Medical Center | Castro Valley94546 | NCT05677490 | Map |
| CA | Eden Hospital Medical Center | Castro Valley94546 | NCT06998940 | Map |
| CA | UC Irvine Health Cancer Center-Newport | Costa Mesa92627 | NCT05677490 | Map |
| CA | Sutter Davis Hospital | Davis95616 | NCT05677490 | Map |
| CA | Sutter Davis Hospital | Davis95616 | NCT06998940 | Map |
| CA | University of California - Davis, Comprehensive Cancer Center | Davis95817 | NCT01042379 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT04322318 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT06172296 | Map |
| CA | Kaiser Permanente Downey Medical Center | Downey90242 | NCT06401330 | Map |
| CA | City of Hope | Duarte91010 | NCT03715933 | Map |
| CA | City of Hope | Duarte91010 | NCT01042379 | Map |
| CA | City of Hope | Duarte91010 | NCT06586515 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT06172296 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT04329494 | Map |
| CA | City of Hope National Medical Center | Duarte91010 | NCT05382559 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT05677490 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT06998940 | Map |
| CA | Kaiser Permanente-Fontana | Fontana92335 | NCT04205968 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT06958328 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT06998940 | Map |
| CA | Fresno Cancer Center | Fresno93720 | NCT05677490 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT05677490 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT05677490 | Map |
| CA | Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton | Fullerton92835 | NCT07409272 | Map |
| CA | Providence Medical Foundation | Fullerton92835 | NCT06644781 | Map |
| CA | Los Angeles Cancer Network | Glendale91204 | NCT06662786 | Map |
| CA | Los Angeles Cancer Network | Glendale91204 | NCT06750094 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT04205968 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT04205968 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT05677490 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT06958328 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06958328 | Map |
| CA | University of California San Diego | La Jolla92093-0698 | NCT01042379 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT04322318 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT06172296 | Map |
| CA | Loma Linda University Medical Center | Loma Linda92354 | NCT06401330 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT04322318 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT06172296 | Map |
| CA | Miller Children's and Women's Hospital Long Beach | Long Beach90806 | NCT06401330 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT06662786 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT06750094 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT04322318 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06172296 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06401330 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT04322318 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT06172296 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027-0700 | NCT06450041 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT06620302 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT04205968 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT04205968 | Map |
| CA | Keck Medicine of USC Koreatown | Los Angeles90020 | NCT05677490 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05677490 | Map |
| CA | Mattel Children's Hospital UCLA | Los Angeles90095 | NCT04322318 | Map |
| CA | Mattel Children's Hospital UCLA | Los Angeles90095 | NCT06172296 | Map |
| CA | Research Site | Los Angeles90089 | NCT06792695 | Map |
| CA | UCLA Hematology/Oncology - Santa Monica ( Site 4905) | Los Angeles90404 | NCT05319730 | Map |
| CA | University of California, Los Angeles UCLA | Los Angeles90404 | NCT05379595 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT01042379 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05677490 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT04657068 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06662786 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT06750094 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT03715933 | Map |
| CA | Yonemoto,Lisa | Los Angeles90095 | NCT05688215 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT04322318 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT06172296 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT06401330 | Map |
| CA | Mercy Cancer Center | Merced95340 | NCT06998940 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT05677490 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT05677490 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT05677490 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT06958328 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT06998940 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT06958328 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT06998940 | Map |
| CA | Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View94040 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View94040 | NCT06998940 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT04205968 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT05677490 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT06998940 | Map |
| CA | Hoag Mem Hosp Presbyterian | Newport Beach92663 | NCT07409272 | Map |
| CA | HOAG Memorial Hospital Presbyterian | Newport Beach92663 | NCT01042379 | Map |
| CA | USC Norris Oncology/Hematology-Newport Beach | Newport Beach92663 | NCT05677490 | Map |
| CA | Sutter Cancer Research Consortium | Novato94945 | NCT05677490 | Map |
| CA | Sutter Cancer Research Consortium | Novato94945 | NCT06998940 | Map |
| CA | Kaiser Permanente Oakland-Broadway | Oakland94611 | NCT05677490 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT04322318 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT05677490 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06172296 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06401330 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT04322318 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT06172296 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT06401330 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT06541262 | Map |
| CA | Kaiser Permanente-Ontario | Ontario91761 | NCT04205968 | Map |
| CA | Chao Family Comprehensive Cancer Center, University | Orange92868 | NCT05733689 | Map |
| CA | Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange92868 | NCT04920032 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT04322318 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT05999994 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT06172296 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT06401330 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT06620302 | Map |
| CA | Research Site | Orange92868 | NCT06219941 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT05677490 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT06958328 | Map |
| CA | University of California Irvine Medical Center | Orange92868 | NCT05365581 | Map |
| CA | Lucile Packard Children's Hospital Stanford University | Palo Alto94304 | NCT04322318 | Map |
| CA | Lucile Packard Children's Hospital Stanford University | Palo Alto94304 | NCT06172296 | Map |
| CA | Lucile Packard Children's Hospital Stanford University | Palo Alto94304 | NCT06401330 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT06958328 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT06998940 | Map |
| CA | Research Site | Palo Alto94304 | NCT06219941 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT06958328 | Map |
| CA | Stanford University | Palo Alto94304 | NCT06023641 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT04205968 | Map |
| CA | Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova95670 | NCT05677490 | Map |
| CA | Eisenhower Medical Center | Rancho Mirage92270 | NCT05677490 | Map |
| CA | Kaiser Permanente- Marshall Medical Offices | Redwood City94063 | NCT05677490 | Map |
| CA | Kaiser Permanente-Richmond | Richmond94801 | NCT05677490 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT04205968 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT06998940 | Map |
| CA | Rohnert Park Cancer Center | Rohnert Park94928 | NCT05677490 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT05677490 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT06958328 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT06998940 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT05677490 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT06958328 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT06998940 | Map |
| CA | The Permanente Medical Group-Roseville Radiation Oncology | Roseville95678 | NCT05677490 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT05677490 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT05677490 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT06998940 | Map |
| CA | South Sacramento Cancer Center | Sacramento95823 | NCT05677490 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT05677490 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT06172296 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT06958328 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT06998940 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT04322318 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06172296 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT06401330 | Map |
| CA | Investigative Site #101 | San Diego92037 | NCT06974110 | Map |
| CA | Kaiser Permanente-San Diego Mission | San Diego92108 | NCT04205968 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT04205968 | Map |
| CA | Rady Children's Hospital | San Diego92123 | NCT06541262 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT04322318 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT06172296 | Map |
| CA | Rady Children's Hospital - San Diego | San Diego92123 | NCT06401330 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT05677490 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT06958328 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT06998940 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT05677490 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT04322318 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT06172296 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT06401330 | Map |
| CA | UCSF Medical Center-Mission Bay | San Francisco94158 | NCT06620302 | Map |
| CA | University of California San Francisco (UCSF) | San Francisco94115 | NCT01042379 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT05694715 | Map |
| CA | University of California, San Francisco (UCSF) | San Francisco94110 | NCT03715933 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT05677490 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT05677490 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT06998940 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT04205968 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT05677490 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT06958328 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT06998940 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT05677490 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT05677490 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT06958328 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT06998940 | Map |
| CA | Sansum Clinic | Santa Barbara93105 | NCT04657068 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT06998940 | Map |
| CA | Santa Cruz Radiation Oncology Medical Group | Santa Cruz95065 | NCT05677490 | Map |
| CA | Santa Cruz Radiation Oncology Medical Group | Santa Cruz95065 | NCT06998940 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT06998940 | Map |
| CA | Sarcoma Oncology Center | Santa Monica90403 | NCT03715933 | Map |
| CA | UCLA | Santa Monica90404 | NCT06662786 | Map |
| CA | UCLA | Santa Monica90404 | NCT06750094 | Map |
| CA | UCLA Santa Monica Hematology Oncology | Santa Monica90404 | NCT05382559 | Map |
| CA | University of California, Los Angeles (UCLA) | Santa Monica90404 | NCT06586515 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT05677490 | Map |
| CA | Providence Medical Foundation | Santa Rosa95403 | NCT04657068 | Map |
| CA | Providence Medical Foundation | Santa Rosa95403 | NCT06662786 | Map |
| CA | Providence Medical Foundation | Santa Rosa95403 | NCT06750094 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT04205968 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT05677490 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT06998940 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT04205968 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT05677490 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT06998940 | Map |
| CA | Research Site | Santa Rosa95403 | NCT06219941 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT05677490 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT06958328 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT06998940 | Map |
| CA | Kaiser Permanente Cancer Treatment Center | South San Francisco94080 | NCT05677490 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT05677490 | Map |
| CA | Kaiser Permanente-Stockton | Stockton95210 | NCT05677490 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT06998940 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT05677490 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT06958328 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT06998940 | Map |
| CA | Torrance Memorial Physicians Network | Torrance90505 | NCT06662786 | Map |
| CA | Torrance Memorial Physicians Network | Torrance90505 | NCT06750094 | Map |
| CA | Kaiser Permanente Medical Center-Vacaville | Vacaville95688 | NCT05677490 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT05677490 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT05677490 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT06958328 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT06998940 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT05677490 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT06998940 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT04205968 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT04322318 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06172296 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06401330 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06620302 | Map |
| CO | Children's Hospital Colorado Anschutz Medical | Aurora80045 | NCT07549321 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05863195 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT01042379 | Map |
| CO | University of Colorado Denver Anschultz Medical Campus | Aurora80045 | NCT06750094 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT03715933 | Map |
| CO | Intermountain Health Platte Valley Hospital | Brighton80601 | NCT05677490 | Map |
| CO | Memorial Hospital North | Colorado Springs80920 | NCT06958328 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT06998940 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT06958328 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT06998940 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT06998940 | Map |
| CO | UCHealth Memorial Hospital Central | Colorado Springs80909 | NCT06958328 | Map |
| CO | AdventHealth Porter | Denver80210 | NCT06958328 | Map |
| CO | Cancer Center of Colorado at Sloan's Lake | Denver80204 | NCT04205968 | Map |
| CO | Cancer Center of Colorado at Sloan's Lake | Denver80204 | NCT05677490 | Map |
| CO | Children's Hospital of Colorado | Denver80218 | NCT05999994 | Map |
| CO | Denver HealthONE Drug Development Unit | Denver80218 | NCT05382559 | Map |
| CO | National Jewish Health-Main Campus | Denver80206 | NCT04205968 | Map |
| CO | National Jewish Health-Main Campus | Denver80206 | NCT05677490 | Map |
| CO | Rocky Mountain Cancer Center | Denver80218 | NCT04657068 | Map |
| CO | Rocky Mountain Cancer Center - Primary | Denver80218 | NCT07011576 | Map |
| CO | Rocky Mountain Cancer Centers | Denver80218 | NCT06662786 | Map |
| CO | Rocky Mountain Cancer Centers | Denver80218 | NCT06750094 | Map |
| CO | Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center | Denver80218 | NCT04322318 | Map |
| CO | Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center | Denver80218 | NCT06401330 | Map |
| CO | Saint Joseph Hospital - Cancer Centers of Colorado | Denver80218 | NCT04205968 | Map |
| CO | Saint Joseph Hospital - Cancer Centers of Colorado | Denver80218 | NCT05677490 | Map |
| CO | Sarah Cannon Research Institute at HealthOne | Denver80218 | NCT06586515 | Map |
| CO | Sarah Cannon Research Institute at HealthONE | Denver80218 | NCT04657068 | Map |
| CO | CommonSpirit Cancer Center Mercy | Durango81301 | NCT06998940 | Map |
| CO | Mercy Medical Center | Durango81301 | NCT06998940 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05677490 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05677490 | Map |
| CO | Lutheran Hospital - Cancer Centers of Colorado | Golden80401 | NCT05677490 | Map |
| CO | National Jewish Health-Western Hematology Oncology | Golden80401 | NCT04205968 | Map |
| CO | National Jewish Health-Western Hematology Oncology | Golden80401 | NCT05677490 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT04205968 | Map |
| CO | Saint Mary's Hospital and Regional Medical Center | Grand Junction81501 | NCT05677490 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05677490 | Map |
| CO | Good Samaritan Hospital - Cancer Centers of Colorado | Lafayette80026 | NCT04205968 | Map |
| CO | Good Samaritan Hospital - Cancer Centers of Colorado | Lafayette80026 | NCT05677490 | Map |
| CO | Saint Anthony Hospital | Lakewood80228 | NCT06998940 | Map |
| CO | AdventHealth Littleton | Littleton80122 | NCT06958328 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT06998940 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05677490 | Map |
| CO | AdventHealth Parker | Parker80138 | NCT06958328 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT06998940 | Map |
| CO | National Jewish Health-Northern Hematology Oncology | Thornton80260 | NCT04205968 | Map |
| CO | National Jewish Health-Northern Hematology Oncology | Thornton80260 | NCT05677490 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT06998940 | Map |
| CO | Intermountain Health Lutheran Hospital | Wheat Ridge80401 | NCT04205968 | Map |
| CO | Intermountain Health Lutheran Hospital | Wheat Ridge80401 | NCT05677490 | Map |
| CT | Hartford HealthCare - Avon | Avon06001 | NCT05677490 | Map |
| CT | Danbury Hospital | Danbury06810 | NCT06958328 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital-Hamden Care Center | Hamden06518 | NCT06958328 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT04322318 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT06172296 | Map |
| CT | Connecticut Children's Medical Center | Hartford06106 | NCT06401330 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT05677490 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT04205968 | Map |
| CT | Hartford HealthCare - Manchester | Manchester06042 | NCT05677490 | Map |
| CT | Midstate Medical Center | Meriden06451 | NCT05677490 | Map |
| CT | The Hospital of Central Connecticut | New Britain06050 | NCT05677490 | Map |
| CT | Smilow Cancer Center at Yale New Haven Hospital | New Haven06520-8028 | NCT05382559 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT04205968 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT01042379 | Map |
| CT | Yale University | New Haven06520 | NCT04322318 | Map |
| CT | Yale University | New Haven06520 | NCT06172296 | Map |
| CT | Yale University | New Haven06520 | NCT06401330 | Map |
| CT | Yale University School Of Medicine | New Haven06519 | NCT06662786 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT04205968 | Map |
| CT | Norwalk Hospital | Norwalk06856 | NCT06958328 | Map |
| CT | Eastern Connecticut Hematology & Oncology Assoc. | Norwich06360 | NCT06750094 | Map |
| CT | Smilow Cancer Hospital-Orange Care Center | Orange06477 | NCT04205968 | Map |
| CT | Stamford Hospital/Bennett Cancer Center | Stamford06904 | NCT06998940 | Map |
| CT | Smilow Cancer Hospital-Torrington Care Center | Torrington06790 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT04205968 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT04205968 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT05677490 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT06998940 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT05677490 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT06998940 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT05677490 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT06958328 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT06998940 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05677490 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06958328 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06998940 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05677490 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06958328 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06998940 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT05677490 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT06998940 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT04322318 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT06172296 | Map |
| DE | Alfred I duPont Hospital for Children | Wilmington19803 | NCT06401330 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT05677490 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT06958328 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT06998940 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT04322318 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT05999994 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT06172296 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT06401330 | Map |
| DC | Children's National Medical Center | Washington D.C.20010 | NCT06620302 | Map |
| DC | George Washington University Medical Center | Washington D.C.20037 | NCT05677490 | Map |
| DC | Georgetown Univ Medical Center Lombardi Cancer Center | Washington D.C.20007 | NCT06662786 | Map |
| DC | Georgetown University Hospital | Washington D.C.20007 | NCT05382559 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT01042379 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT04322318 | Map |
| DC | MedStar Georgetown University Hospital | Washington D.C.20007 | NCT05677490 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT05677490 | Map |
| DC | MedStar Washington Hospital Center | Washington D.C.20010 | NCT06958328 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT06586515 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05677490 | Map |
| FL | Mount Sinai Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05677490 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05863195 | Map |
| FL | Schulze Family Foundation Cancer Clinic - Bonita Health Center | Bonita Springs34135 | NCT05677490 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05863195 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05863195 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT04322318 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT06172296 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT06401330 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT04205968 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT05677490 | Map |
| FL | Florida Cancer Specialists | Fort Myers33901 | NCT04657068 | Map |
| FL | Florida Cancer Specialists South | Fort Myers33901 | NCT06662786 | Map |
| FL | Florida Cancer Specialists South | Fort Myers33901 | NCT06750094 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT04322318 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT05999994 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT06172296 | Map |
| FL | Golisano Children's Hospital of Southwest Florida | Fort Myers33908 | NCT06401330 | Map |
| FL | Regional Cancer Center-Lee Memorial Health System | Fort Myers33905 | NCT05677490 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT04322318 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06172296 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06401330 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06958328 | Map |
| FL | University of Florida | Gainesville32610 | NCT05669339 | Map |
| FL | University of Florida | Gainesville32611 | NCT06541262 | Map |
| FL | University of Florida | Gainesville32610 | NCT07194044 | Map |
| FL | University of Florida, Davis Cancer Center | Gainesville32610 | NCT05382559 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT04322318 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT05677490 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT06172296 | Map |
| FL | Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood33021 | NCT06401330 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood33021 | NCT05863195 | Map |
| FL | Baptist MD Anderson Cancer Institute | Jacksonville32207 | NCT07409272 | Map |
| FL | Cancer Specialists of North Florida | Jacksonville32256 | NCT04657068 | Map |
| FL | Mayo Clinic (Florida) | Jacksonville32224 | NCT04657068 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT04329494 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224 | NCT05999994 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT04322318 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT06172296 | Map |
| FL | Nemours Children's Clinic-Jacksonville | Jacksonville32207 | NCT06401330 | Map |
| FL | Jupiter Medical Center | Jupiter33458 | NCT05677490 | Map |
| FL | Florida Cancer Specialist | Lake Mary32746 | NCT05382559 | Map |
| FL | The Watson Clinic | Lakeland33805 | NCT05677490 | Map |
| FL | The Watson Clinic | Lakeland33805 | NCT06998940 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT04322318 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT06172296 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT06401330 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT06541262 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05863195 | Map |
| FL | University of Miami | Miami33136 | NCT05412082 | Map |
| FL | University of Miami | Miami33136 | NCT07096362 | Map |
| FL | University of Miami | Miami33136 | NCT07194044 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04322318 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05863195 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06172296 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT06401330 | Map |
| FL | Mount Sinai Medical Center | Miami Beach33140 | NCT05677490 | Map |
| FL | AdventHealth Cancer Institute | Orlando32804 | NCT06750094 | Map |
| FL | AdventHealth Medical Group Oncology and Hematology at Orlando | Orlando32804 | NCT06662786 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT06172296 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT04322318 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT06172296 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT06401330 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT06541262 | Map |
| FL | Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute | Orlando32827 | NCT06586515 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT04322318 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT06172296 | Map |
| FL | Nemours Children's Hospital | Orlando32827 | NCT06401330 | Map |
| FL | Memorial Hospital West | Pembroke Pines33028 | NCT05677490 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT04322318 | Map |
| FL | Nemours Children's Clinic - Pensacola | Pensacola32504 | NCT06401330 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05863195 | Map |
| FL | Florida Cancer Specialists | Sarasota34232 | NCT04657068 | Map |
| FL | Florida Cancer Specialists & Research Institute Sarasota | Sarasota34232-6422 | NCT05382559 | Map |
| FL | All Children's Hospital Johns Hopkins Medicine | St. Petersburg33701 | NCT06541262 | Map |
| FL | Florida Cancer Specialists North Region | St. Petersburg33701-4553 | NCT06662786 | Map |
| FL | Florida Cancer Specialists North Region | St. Petersburg33701-4553 | NCT06750094 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT04322318 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT06172296 | Map |
| FL | Johns Hopkins All Children's Hospital | St. Petersburg33701 | NCT06401330 | Map |
| FL | H. Lee Moffitt Cancer Center and Research Institute | Tampa33612 | NCT01042379 | Map |
| FL | Investigative Site #128 | Tampa33612 | NCT06974110 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT01042379 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06835387 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07194044 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT04322318 | Map |
| FL | Saint Joseph's Hospital/Children's Hospital-Tampa | Tampa33607 | NCT06401330 | Map |
| FL | St. Joseph's Children's Hospital | Tampa33614 | NCT06541262 | Map |
| FL | Tampa General Hospital | Tampa33606 | NCT04322318 | Map |
| FL | Florida Cancer Specialists | West Palm Beach33401 | NCT04657068 | Map |
| FL | Florida Cancer Specialists East | West Palm Beach33401-3406 | NCT06662786 | Map |
| FL | Florida Cancer Specialists East | West Palm Beach33401-3406 | NCT06750094 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT04322318 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT06172296 | Map |
| FL | Saint Mary's Medical Center | West Palm Beach33407 | NCT06401330 | Map |
| GA | University Cancer And Blood Center LLC | Athens30607 | NCT06750094 | Map |
| GA | Children's Healthcare of Atlanta | Atlanta30322 | NCT05400603 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT04322318 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT06172296 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT06401330 | Map |
| GA | Children's Healthcare of Atlanta - Arthur M Blank Hospital | Atlanta30329 | NCT06620302 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT05863195 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06958328 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06998940 | Map |
| GA | Emory University - Winship Cancer Institute | Atlanta30322 | NCT03715933 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06958328 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06998940 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT05863195 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06958328 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06998940 | Map |
| GA | Emory University School of Medicine | Atlanta30322 | NCT06586515 | Map |
| GA | Grady Health System | Atlanta30303 | NCT06958328 | Map |
| GA | Grady Memorial Hospital | Atlanta30303 | NCT06662786 | Map |
| GA | Grady Memorial Hospital | Atlanta30303 | NCT06750094 | Map |
| GA | Piedmont Cancer Institute | Atlanta30318 | NCT06750094 | Map |
| GA | Piedmont Hospital | Atlanta30309 | NCT06958328 | Map |
| GA | Winship Cancer Institute Emory University | Atlanta30322 | NCT06662786 | Map |
| GA | Winship Cancer Institute Emory University | Atlanta30322 | NCT06750094 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322 | NCT01042379 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT04322318 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT06401330 | Map |
| GA | Emory Decatur Hospital | Decatur30033 | NCT06998940 | Map |
| GA | Emory Johns Creek Hospital | Johns Creek30097 | NCT06998940 | Map |
| GA | Atrium Health Navicent | Macon31201 | NCT04322318 | Map |
| GA | Atrium Health Navicent | Macon31201 | NCT06401330 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT04322318 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT06172296 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT06401330 | Map |
| GA | Memorial Health University Medical Center | Savannah31404 | NCT06958328 | Map |
| GA | Tift Regional Medical Center | Tifton31794 | NCT05677490 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05677490 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT06958328 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT05677490 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT06958328 | Map |
| HI | Queen's Cancer Center - Pearlridge | ‘Aiea96701 | NCT05677490 | Map |
| HI | Queen's Cancer Center - Pearlridge | ‘Aiea96701 | NCT06958328 | Map |
| HI | The Cancer Center of Hawaii-Pali Momi | ‘Aiea96701 | NCT06958328 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT05677490 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT06958328 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05677490 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT06958328 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT05677490 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT04322318 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06172296 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06401330 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96813 | NCT06541262 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06958328 | Map |
| HI | Kuakini Medical Center | Honolulu96817 | NCT06958328 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT05677490 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT06958328 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT05677490 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT06958328 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT05677490 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT06958328 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05677490 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT06958328 | Map |
| HI | The Cancer Center of Hawaii-Liliha | Honolulu96817 | NCT06958328 | Map |
| HI | University of Hawaii Cancer Center | Honolulu96813 | NCT06958328 | Map |
| HI | Straub Medical Center - Kahului Clinic | Kahului96732 | NCT05677490 | Map |
| HI | Wilcox Memorial Hospital and Kauai Medical Clinic | Lihue96766 | NCT06958328 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT04205968 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04205968 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04322318 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06401330 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06998940 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT04205968 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05677490 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT04205968 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05677490 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06998940 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT04205968 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT06998940 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT04205968 | Map |
| ID | Idaho Urologic Institute-Meridian | Meridian83642 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT04205968 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT06998940 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04205968 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT04205968 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT06998940 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT04205968 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05677490 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06998940 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT04205968 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05677490 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06998940 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT04205968 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05677490 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT06998940 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT04205968 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT05677490 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT06662786 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT06750094 | Map |
| IL | Illinois Cancer Specialists | Arlington Heights60005 | NCT07011576 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT05677490 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT04205968 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT05677490 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06958328 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05677490 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT04205968 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05677490 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT06958328 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT06998940 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT04205968 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05677490 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT06958328 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT06998940 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT04205968 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT05677490 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT06998940 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT04205968 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT05677490 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT06998940 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT04205968 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05677490 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT06958328 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT06998940 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04205968 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05677490 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT06958328 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT06998940 | Map |
| IL | Saint Mary's Hospital | Centralia62801 | NCT04205968 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05677490 | Map |
| IL | Ann & Robert H Lurie Children's Hospital of Chicago | Chicago60611 | NCT05999994 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago60611 | NCT04796012 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT05677490 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT04322318 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT06172296 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT06401330 | Map |
| IL | Lurie Children's Hospital-Chicago | Chicago60611 | NCT06620302 | Map |
| IL | Mount Sinai Hospital Medical Center | Chicago60608 | NCT05677490 | Map |
| IL | Northwestern University | Chicago60611 | NCT05365581 | Map |
| IL | Northwestern University | Chicago60611 | NCT05863195 | Map |
| IL | Northwestern University | Chicago60611 | NCT06958328 | Map |
| IL | The University of Chicago | Chicago60637 | NCT04361708 | Map |
| IL | University of Chicago | Chicago60453 | NCT01042379 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT04205968 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT04322318 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05677490 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05863195 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06172296 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06401330 | Map |
| IL | University of Illinois | Chicago60612 | NCT05677490 | Map |
| IL | University of Illinois | Chicago60612 | NCT06172296 | Map |
| IL | University of Illinois | Chicago60612 | NCT06401330 | Map |
| IL | University of Illinois | Chicago60612 | NCT06958328 | Map |
| IL | University of Illinois Cancer Center | Chicago60612 | NCT06835387 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05677490 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04205968 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05677490 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06958328 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06998940 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04205968 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05677490 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06958328 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06998940 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04205968 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05677490 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06958328 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06998940 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT06958328 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT04205968 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05677490 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT06998940 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05677490 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04205968 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05677490 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06958328 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06998940 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04205968 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05677490 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06958328 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06998940 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05677490 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT04205968 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05677490 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT06958328 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT06998940 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT04205968 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05677490 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT06958328 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT06998940 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT06958328 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT06958328 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT06958328 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05677490 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05677490 | Map |
| IL | Hope and Healing Cancer Services | Hinsdale60521 | NCT04657068 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT04205968 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05677490 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT06958328 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT06998940 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT06958328 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05677490 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05677490 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT04205968 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05677490 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT06958328 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT06998940 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04205968 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05677490 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06958328 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06998940 | Map |
| IL | Loyola University | Maywood60153 | NCT01042379 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT04322318 | Map |
| IL | Trinity Medical Center | Moline61265 | NCT05677490 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT04205968 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT05677490 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT04205968 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05677490 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT06998940 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05677490 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT06998940 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04205968 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05677490 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06958328 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06998940 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT04205968 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT05677490 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT06958328 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT06998940 | Map |
| IL | Northwestern Medicine Oak Brook | Oak Brook60523 | NCT06958328 | Map |
| IL | Advocate Children's Hospital-Oak Lawn | Oak Lawn60453 | NCT04322318 | Map |
| IL | Advocate Children's Hospital-Oak Lawn | Oak Lawn60453 | NCT06172296 | Map |
| IL | Advocate Children's Hospital-Oak Lawn | Oak Lawn60453 | NCT06401330 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05677490 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT04205968 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05677490 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT04205968 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05677490 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT06958328 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT06998940 | Map |
| IL | Advocate Children's Hospital-Park Ridge | Park Ridge60068 | NCT04322318 | Map |
| IL | Advocate Children's Hospital-Park Ridge | Park Ridge60068 | NCT06172296 | Map |
| IL | Advocate Children's Hospital-Park Ridge | Park Ridge60068 | NCT06401330 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05677490 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT04205968 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05677490 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT06958328 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT06998940 | Map |
| IL | Illinois CancerCare | Peoria61615 | NCT06662786 | Map |
| IL | Illinois CancerCare | Peoria61615 | NCT06750094 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT04205968 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05677490 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT06958328 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT06998940 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT04205968 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT05677490 | Map |
| IL | OSF Children's Hospital of Illinois | Peoria61637 | NCT06172296 | Map |
| IL | OSF Saint Francis Medical Center | Peoria61637 | NCT06958328 | Map |
| IL | Saint Jude Midwest Affiliate | Peoria61637 | NCT04322318 | Map |
| IL | Saint Jude Midwest Affiliate | Peoria61637 | NCT06401330 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT04205968 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05677490 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT06958328 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT06998940 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT04205968 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT05677490 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT06998940 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT04205968 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05677490 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT06958328 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT06998940 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT05677490 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05863195 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04205968 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04322318 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05677490 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06172296 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06958328 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06998940 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04205968 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05677490 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06958328 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06998940 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04205968 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05677490 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06958328 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06998940 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04205968 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05677490 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06958328 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06998940 | Map |
| IL | The Carle Foundation Hospital | Urbana61801 | NCT04205968 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT06958328 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT04205968 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05677490 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT06958328 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT06998940 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT04205968 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT05677490 | Map |
| IL | City Of Hope - Chicago /ID# 279814 | Zion60099 | NCT07490301 | Map |
| IN | IU Health North Hospital | Carmel46032 | NCT05863195 | Map |
| IN | Northwest Cancer Center - Crown Point | Crown Point46307 | NCT05677490 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05677490 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT05677490 | Map |
| IN | Fort Wayne Medical Oncology & Hematology | Fort Wayne46804 | NCT06662786 | Map |
| IN | Goshen Center for Cancer Care | Goshen46526 | NCT06958328 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT05677490 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT05677490 | Map |
| IN | Ascension Saint Vincent Indianapolis Hospital | Indianapolis46260 | NCT04322318 | Map |
| IN | Community Health Network | Indianapolis46250 | NCT04657068 | Map |
| IN | Community Health Network | Indianapolis46250 | NCT06586515 | Map |
| IN | Franciscan Health | Indianapolis46237 | NCT06750094 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT05863195 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT04322318 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT06172296 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT06401330 | Map |
| IN | Riley Hospital for Children | Indianapolis46202 | NCT06620302 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT05677490 | Map |
| IN | The Community Hospital | Munster46321 | NCT05677490 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT05677490 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT05677490 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT05677490 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT06998940 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT05677490 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT06998940 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04205968 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT06958328 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT04205968 | Map |
| IA | University of Iowa Healthcare Cancer Services Quad Cities | Bettendorf52722 | NCT05677490 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04205968 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT05677490 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06998940 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT05677490 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06998940 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT04205968 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT06998940 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04205968 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT06958328 | Map |
| IA | Heartland Oncology and Hematology LLP | Council Bluffs51503 | NCT05677490 | Map |
| IA | Methodist Jennie Edmundson Hospital | Council Bluffs51503 | NCT05677490 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT04205968 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT06998940 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT04322318 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT06172296 | Map |
| IA | Blank Children's Hospital | Des Moines50309 | NCT06401330 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04205968 | Map |
| IA | Iowa Lutheran Hospital | Des Moines50316 | NCT04205968 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04205968 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT05677490 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT06958328 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04205968 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT06998940 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04205968 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT06958328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04205968 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT06958328 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT05677490 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT06998940 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT04205968 | Map |
| IA | University of Iowa Hospital | Iowa City52242 | NCT06662786 | Map |
| IA | University of Iowa Hospitals and Clinics | Iowa City52242 | NCT06750094 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT04205968 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT04322318 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT05677490 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT06172296 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT06401330 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT05677490 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT06998940 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Pella | Pella50219 | NCT05677490 | Map |
| IA | Mission Cancer Blood | Waukee50263 | NCT06662786 | Map |
| IA | Mission Cancer Blood | Waukee50263 | NCT06750094 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04205968 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05677490 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT06958328 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT04205968 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT06998940 | Map |
| IA | Methodist West Hospital | West Des Moines50266-7700 | NCT04205968 | Map |
| IA | The Iowa Clinic PC | West Des Moines50266 | NCT04205968 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT04205968 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT05677490 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT04205968 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT05677490 | Map |
| KS | HaysMed | Hays67601 | NCT05677490 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06958328 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT05677490 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT06958328 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT05677490 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT06958328 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT06958328 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT05677490 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT04205968 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT05677490 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT05677490 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT06958328 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT05677490 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT06958328 | Map |
| KS | University of Kansas Cancer Center | Westwood66205 | NCT05365581 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06958328 | Map |
| KS | University of Kansas Medical Center | Westwood66205 | NCT05382559 | Map |
| KS | Cancer Center of Kansas | Wichita67214 | NCT06662786 | Map |
| KS | Cancer Center of Kansas | Wichita67214 | NCT06750094 | Map |
| KS | Wesley Medical Center | Wichita67214 | NCT06172296 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT06998940 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT06998940 | Map |
| KY | Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care | Edgewood41017 | NCT07409272 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT06998940 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT06998940 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT06998940 | Map |
| KY | University of Kentucky | Lexington40506 | NCT05391126 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT04322318 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05863195 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT06172296 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT06958328 | Map |
| KY | Saint Joseph London | London40741 | NCT06998940 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT04322318 | Map |
| KY | Norton Children's Hospital | Louisville40202 | NCT06172296 | Map |
| KY | Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine | Louisville40202 | NCT06541262 | Map |
| KY | Research Site | Louisville40202 | NCT06219941 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT05677490 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT05677490 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT06998940 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT06998940 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT06750094 | Map |
| LA | Our Lady of the Lake | Baton Rouge70808 | NCT04657068 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT06998940 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT06998940 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT04322318 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT06172296 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT06401330 | Map |
| LA | Ochsner Clinic Foundation | New Orleans70121 | NCT06662786 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT06401330 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT05677490 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT04322318 | Map |
| ME | Eastern Maine Medical Center | Bangor04401 | NCT06172296 | Map |
| ME | MaineHealth Coastal Cancer Treatment Center | Bath04530 | NCT06958328 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT04205968 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT06958328 | Map |
| ME | MaineHealth Cancer Care Center of York County | Sanford04073 | NCT06958328 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT04322318 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT06172296 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT06401330 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT06958328 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT06958328 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT04322318 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05677490 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06172296 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06401330 | Map |
| MD | MedStar Franklin Square Medical Center | Baltimore21237 | NCT06662786 | Map |
| MD | MedStar Franklin Square Medical Center | Baltimore21237 | NCT06750094 | Map |
| MD | Research Site | Baltimore21224 | NCT06792695 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center | Baltimore21231 | NCT06941857 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT04322318 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT06172296 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT06401330 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT06958328 | Map |
| MD | Sinai Hospital of Baltimore | Baltimore21215 | NCT06998940 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT06172296 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT06401330 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT06995872 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT06172296 | Map |
| MD | Maryland Oncology Hematology | Columbia21044 | NCT07011576 | Map |
| MD | Maryland Oncology Hematology - Primary | Columbia21044 | NCT04657068 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT05677490 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT06998940 | Map |
| MD | Frederick Health Hospital - James M Stockman Cancer Institute | Frederick21702-4337 | NCT06662786 | Map |
| MD | Frederick Health Hospital - James M Stockman Cancer Institute | Frederick21702 | NCT06750094 | Map |
| MD | Northwest Hospital Center | Randallstown21133 | NCT06998940 | Map |
| MD | William E Kahlert Regional Cancer Center/Sinai Hospital | Westminster21157 | NCT06958328 | Map |
| MD | William E Kahlert Regional Cancer Center/Sinai Hospital | Westminster21157 | NCT06998940 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05382559 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT04796012 | Map |
| MA | Boston Children's Hospital | Boston02115 | NCT07027748 | Map |
| MA | Boston Medical Center | Boston02118 | NCT05677490 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05382559 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06586515 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04322318 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05677490 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06172296 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06401330 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06620302 | Map |
| MA | Dana-Farber Cancer Institute | Boston02115 | NCT07027748 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07024615 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT06172296 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT06401330 | Map |
| MA | Dana-Farber Cancer Institute at Boston Medical Center - Brighton | Brighton02135 | NCT05677490 | Map |
| MA | Dana-Farber Cancer Institute at Foxborough | Foxborough02035 | NCT05677490 | Map |
| MA | Dana Farber-Merrimack Valley | Methuen01844 | NCT05677490 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at Milford Regional | Milford01757 | NCT05677490 | Map |
| MA | Dana-Farber/Brigham and Women's Cancer Center at South Shore | South Weymouth02190 | NCT05677490 | Map |
| MA | Baystate Medical Center | Springfield01199 | NCT06401330 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT04322318 | Map |
| MA | UMass Memorial Medical Center - University Campus | Worcester01655 | NCT06401330 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Alpena | Alpena49707 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Alpena | Alpena49707 | NCT05677490 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT04322318 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT06172296 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT06401330 | Map |
| MI | C S Mott Children's Hospital | Ann Arbor48109 | NCT06620302 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04205968 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05677490 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT06958328 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT03715933 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06662786 | Map |
| MI | University of Michigan Comprehensive Cancer Center | Ann Arbor48109 | NCT04205968 | Map |
| MI | University of Michigan Health System | Ann Arbor48103 | NCT05379595 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05863195 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT06750094 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT06958328 | Map |
| MI | VA Ann Arbor Healthcare System | Ann Arbor48105 | NCT06662786 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT04205968 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT06998940 | Map |
| MI | McLaren Cancer Institute-Bay City | Bay City48706 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04205968 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06958328 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04205968 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05677490 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT06958328 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT06958328 | Map |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT04205968 | — |
| MI | Henry Ford Cancer Institute-Downriver | Brownstown48183 | NCT06958328 | — |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04205968 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06958328 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04205968 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05677490 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT06958328 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04205968 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05677490 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT06958328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04205968 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06958328 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04205968 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT04205968 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT05677490 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT04205968 | Map |
| MI | Henry Ford Macomb Hospital-Clinton Township | Clinton Township48038 | NCT06958328 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05677490 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT04205968 | Map |
| MI | Henry Ford Medical Center-Fairlane | Dearborn48126 | NCT06958328 | Map |
| MI | Barbara Ann Karmanos Cancer Institute | Detroit48201 | NCT06586515 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT04322318 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT06172296 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT06401330 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT04205968 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT05677490 | Map |
| MI | Henry Ford Health System | Detroit48202 | NCT06644781 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT04205968 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06662786 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06750094 | Map |
| MI | Henry Ford Hospital | Detroit48202 | NCT06958328 | Map |
| MI | Investigative Site #120 | Detroit48201 | NCT06974110 | Map |
| MI | Wayne State University/Karmanos Cancer Institute | Detroit48201 | NCT05677490 | Map |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT04205968 | — |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT05677490 | — |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT05677490 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06998940 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05677490 | Map |
| MI | Weisberg Cancer Treatment Center | Farmington Hills48334 | NCT05677490 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04205968 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05677490 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT04205968 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT05677490 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04205968 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05677490 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT04205968 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Flint | Flint48532 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Gladwin | Gladwin48624 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Gladwin | Gladwin48624 | NCT05677490 | Map |
| MI | Cancer And Hematology Centers of Western Michigan PC | Grand Rapids49503 | NCT06750094 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT04205968 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05863195 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT06958328 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT06998940 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT04205968 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT04322318 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06172296 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06401330 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06958328 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06998940 | Map |
| MI | Helen DeVos Children's Hospital | Grand Rapids48503 | NCT01356290 | Map |
| MI | South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids49546 | NCT06586515 | Map |
| MI | Start Midwest | Grand Rapids49503 | NCT06662786 | Map |
| MI | START Midwest Michigan, PC | Grand Rapids49546 | NCT03715933 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT04205968 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT06958328 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT06998940 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT04205968 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT04205968 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT04205968 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT05677490 | Map |
| MI | Allegiance Health | Jackson49201 | NCT04205968 | Map |
| MI | Allegiance Health | Jackson49201 | NCT06958328 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT04205968 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT06958328 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT06998940 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT04205968 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT06998940 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04205968 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT04322318 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06172296 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06401330 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06958328 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06998940 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT04205968 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT06958328 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT06998940 | Map |
| MI | Herbert-Herman Cancer Center, Sparrow Hospital | Lansing48912 | NCT01042379 | Map |
| MI | Karmanos Cancer Institute at McLaren Greater Lansing | Lansing48910 | NCT05677490 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT04205968 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05677490 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT06958328 | Map |
| MI | McLaren Cancer Institute-Lapeer Region | Lapeer48446 | NCT05677490 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04205968 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05677490 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06958328 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT04205968 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05677490 | Map |
| MI | Henry Ford Warren Hospital - Breast Macomb | Macomb48044 | NCT04205968 | Map |
| MI | Henry Ford Warren Hospital - Breast Macomb | Macomb48044 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT05677490 | Map |
| MI | McLaren Cancer Institute-Macomb | Mount Clemens48043 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Mount Pleasant | Mount Pleasant48858 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Mount Pleasant | Mount Pleasant48858 | NCT05677490 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT04205968 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT06998940 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT04205968 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT06998940 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT04205968 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT06998940 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT04205968 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT04205968 | Map |
| MI | Henry Ford Medical Center-Columbus | Novi48377 | NCT06958328 | Map |
| MI | McLaren Cancer Institute-Northern Michigan | Petoskey49770 | NCT05677490 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT04205968 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT05677490 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04205968 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT05677490 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT06958328 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04205968 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT05677490 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04205968 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05677490 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06958328 | Map |
| MI | McLaren-Port Huron | Port Huron48060 | NCT05677490 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT04205968 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT06998940 | Map |
| MI | Cancer Care Associates PC | Royal Oak48073 | NCT05677490 | Map |
| MI | Comprehensive Medical Center PLLC | Royal Oak48073 | NCT05677490 | Map |
| MI | Corewell Health Children's | Royal Oak48073 | NCT04322318 | Map |
| MI | Corewell Health Children's | Royal Oak48073 | NCT06172296 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05677490 | Map |
| MI | Hematology Oncology Consultants PC-Royal Oak | Royal Oak48073 | NCT05677490 | Map |
| MI | Oakland Colon Rectal Associates | Royal Oak48067 | NCT05677490 | Map |
| MI | Oakland Medical Group | Royal Oak48073 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT06958328 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT04205968 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT06998940 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT04205968 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT06998940 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT04205968 | Map |
| MI | Premier Hematology Oncology Care | Sterling Heights48312 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04205968 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT05677490 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT06958328 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT04205968 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT06998940 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05677490 | Map |
| MI | Hematology Oncology Consultants PC-Troy | Troy48098 | NCT05677490 | Map |
| MI | Michigan Institute of Urology-Town Center | Troy48084 | NCT05677490 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT04205968 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford Madison Heights Hospital - Breast | Warren48093 | NCT04205968 | Map |
| MI | Henry Ford Madison Heights Hospital - Breast | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT04205968 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT05677490 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT04205968 | Map |
| MI | Henry Ford West Bloomfield Hospital | West Bloomfield48322 | NCT06958328 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT04205968 | Map |
| MI | Henry Ford Wyandotte Hospital | Wyandotte48192 | NCT06958328 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT04205968 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT06958328 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT06998940 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04205968 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05677490 | Map |
| MI | Trinity Health Ann Arbor Hospital | Ypsilanti48197 | NCT05382559 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04205968 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05677490 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06958328 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT04205968 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT05677490 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT06998940 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT04205968 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT05677490 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT06998940 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05677490 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT06958328 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT04205968 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT05677490 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT06998940 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT04205968 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT05677490 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT04205968 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology PA-Chaska | Chaska55318 | NCT05677490 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04205968 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05677490 | Map |
| MN | Minnesota Oncology - Coon Rapids | Coon Rapids55433 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Crosslake Clinic | Crosslake56442 | NCT04205968 | Map |
| MN | Essentia Health - Saint Joseph's Crosslake Clinic | Crosslake56442 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Crosslake Clinic | Crosslake56442 | NCT06998940 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT04205968 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05677490 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06998940 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT04205968 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT05677490 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT06998940 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT04205968 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05677490 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06998940 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT04205968 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT05677490 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT06998940 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT04205968 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT05677490 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT06998940 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT04205968 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05677490 | Map |
| MN | Minnesota Oncology - Edina | Edina55435 | NCT05677490 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT04205968 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT05677490 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT06998940 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT04205968 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT05677490 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT06998940 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT04205968 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05677490 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06998940 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT04205968 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT05677490 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT06998940 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT04205968 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05677490 | Map |
| MN | Minnesota Oncology - Maple Grove | Maple Grove55369 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology | Maple Grove55369 | NCT04657068 | Map |
| MN | Minnesota Oncology Hematology - Primary | Maple Grove55369 | NCT07011576 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT04205968 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT05677490 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT04205968 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05677490 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04205968 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05677490 | Map |
| MN | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis55404 | NCT04322318 | Map |
| MN | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis55404 | NCT06172296 | Map |
| MN | Children's Hospitals and Clinics of Minnesota - Minneapolis | Minneapolis55404 | NCT06401330 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT04205968 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT05677490 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT04205968 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT05677490 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT01042379 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT04322318 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06172296 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06401330 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06620302 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT04205968 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT05677490 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT04205968 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT05677490 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT06998940 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT04205968 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT05677490 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT04205968 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT05677490 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT06998940 | Map |
| MN | Essentia Health - Saint Joseph's Pequot Lakes Clinic | Pequot Lakes56472 | NCT04205968 | Map |
| MN | Essentia Health - Saint Joseph's Pequot Lakes Clinic | Pequot Lakes56472 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Pequot Lakes Clinic | Pequot Lakes56472 | NCT06998940 | Map |
| MN | Essentia Health - Saint Joseph's Pine River Clinic | Pine River56474 | NCT04205968 | Map |
| MN | Essentia Health - Saint Joseph's Pine River Clinic | Pine River56474 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Pine River Clinic | Pine River56474 | NCT06998940 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT04205968 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT05677490 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT04205968 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT05677490 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT01042379 | Map |
| MN | Mayo Clinic (Minnesota) | Rochester55905 | NCT04657068 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04322318 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05863195 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06172296 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06381154 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06401330 | Map |
| MN | Mayo Clinic in Rochester, Minnesota | Rochester55905 | NCT07415031 | Map |
| MN | Research Site | Rochester55905 | NCT06792695 | Map |
| MN | Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud56303 | NCT05677490 | Map |
| MN | HealthPartners Frauenshuh Cancer Center | Saint Louis Park55426 | NCT07409272 | Map |
| MN | Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center | Saint Louis Park55416 | NCT01042379 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04205968 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05677490 | Map |
| MN | HealthPartners Cancer Center at Regions Hospital | Saint Paul55101 | NCT07409272 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04205968 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05677490 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04205968 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05677490 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT04205968 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05677490 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06998940 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT04205968 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Staples Clinic | Staples56479 | NCT04205968 | Map |
| MN | Essentia Health - Saint Joseph's Staples Clinic | Staples56479 | NCT05677490 | Map |
| MN | Essentia Health - Saint Joseph's Staples Clinic | Staples56479 | NCT06998940 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT04205968 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT05677490 | Map |
| MN | Sanford Thief River Falls Medical Center | Thief River Falls56701 | NCT05677490 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT04205968 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05677490 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06998940 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT04205968 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT05677490 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT04205968 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT05677490 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT04205968 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT05677490 | Map |
| MN | Sanford Cancer Center Worthington | Worthington56187 | NCT05677490 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT04205968 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT05677490 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06958328 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT06998940 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT04205968 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06958328 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT06998940 | Map |
| MS | Hattiesburg Clinic | Hattiesburg39401 | NCT05379595 | Map |
| MS | Hattiesburg Clinic | Hattiesburg39401 | NCT06662786 | Map |
| MS | Hattiesburg Clinic | Hattiesburg39401 | NCT06750094 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT04322318 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT06172296 | Map |
| MS | University of Mississippi Medical Center | Jackson39216 | NCT06401330 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT04205968 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06958328 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT06998940 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT04205968 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06958328 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT06998940 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT04205968 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06958328 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT06998940 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT04205968 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT05677490 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT04205968 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT05677490 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT04205968 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT05677490 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT04205968 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT05677490 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04205968 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05677490 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06998940 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05863195 | Map |
| MO | Missouri Cancer Associates | Columbia65201 | NCT07011576 | Map |
| MO | University of Missouri Children's Hospital | Columbia65212 | NCT04322318 | Map |
| MO | University of Missouri Children's Hospital | Columbia65212 | NCT06172296 | Map |
| MO | University of Missouri Children's Hospital | Columbia65212 | NCT06401330 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05863195 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04205968 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05677490 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT06998940 | Map |
| MO | Freeman Health System | Joplin64804 | NCT04205968 | Map |
| MO | Freeman Health System | Joplin64804 | NCT05677490 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT04205968 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT05677490 | Map |
| MO | Children's Mercy Hospital | Kansas City64108 | NCT05999994 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT04322318 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT06172296 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT06401330 | Map |
| MO | Children's Mercy Hospitals and Clinics | Kansas City64108 | NCT06541262 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT05677490 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT06958328 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT06958328 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT04205968 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT05677490 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT04205968 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT05677490 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT04205968 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT05677490 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT04205968 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT05677490 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04205968 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05677490 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT06998940 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT04205968 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT05677490 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT04205968 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05677490 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT04322318 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT06401330 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT06541262 | Map |
| MO | Investigative Site #110 | St Louis63108 | NCT06974110 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04205968 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04322318 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05677490 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06172296 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04205968 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05677490 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT04205968 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT05677490 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04205968 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05677490 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06998940 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05863195 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05863195 | Map |
| MO | Washington University | St Louis63110 | NCT04657068 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05382559 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT04322318 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05863195 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06172296 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06401330 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06620302 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06835387 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07155200 | Map |
| MO | Washington University School Of Medicine | St Louis63110 | NCT06662786 | Map |
| MO | Washington University School Of Medicine | St Louis63110 | NCT06750094 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04205968 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05677490 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT06998940 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT04205968 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05677490 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT06998940 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT04205968 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT05677490 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT04205968 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05677490 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06998940 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT04205968 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05677490 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06998940 | Map |
| MT | Intermountain Health West End Clinic | Billings59106 | NCT04205968 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT04205968 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT05677490 | Map |
| MT | Saint Vincent Healthcare | Billings59101 | NCT04205968 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT04205968 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05677490 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06998940 | Map |
| MT | Saint James Community Hospital and Cancer Treatment Center | Butte59701 | NCT04205968 | Map |
| MT | Saint James Community Hospital and Cancer Treatment Center | Butte59701 | NCT05677490 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT04205968 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05677490 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06998940 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT04205968 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT05677490 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT06998940 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT04205968 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT05677490 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT06998940 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT05677490 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT06998940 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT04205968 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05677490 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06998940 | Map |
| MT | Community Medical Center | Missoula59804 | NCT04205968 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05677490 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06998940 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT04205968 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT05677490 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT06998940 | Map |
| NE | Nebraska Medicine-Bellevue | Bellevue68123 | NCT05677490 | Map |
| NE | CHI Health Saint Francis | Grand Island68803 | NCT06998940 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT06998940 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT06998940 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT06998940 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT06998940 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT04322318 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT06172296 | Map |
| NE | Children's Hospital and Medical Center of Omaha | Omaha68114 | NCT06401330 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT06998940 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT06750094 | Map |
| NE | Nebraska Cancer Specialists Midwest Cancer Center | Omaha68130 | NCT06662786 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT05677490 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT05677490 | Map |
| NE | Nebraska Medicine-Village Pointe | Omaha68118 | NCT06958328 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT05677490 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT04322318 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05677490 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06172296 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06401330 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06958328 | Map |
| NV | Carson Tahoe Regional Medical Center | Carson City89703 | NCT04205968 | Map |
| NV | Carson Tahoe Regional Medical Center | Carson City89703 | NCT05677490 | Map |
| NV | Cancer and Blood Specialists-Henderson | Henderson89052 | NCT04205968 | Map |
| NV | Cancer and Blood Specialists-Henderson | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Henderson | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Horizon Ridge | Henderson89052 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Horizon Ridge | Henderson89052 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson89074 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Southeast Henderson | Henderson89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Green Valley | Henderson89074 | NCT04205968 | Map |
| NV | Las Vegas Urology - Green Valley | Henderson89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Pebble | Henderson89074 | NCT04205968 | Map |
| NV | Las Vegas Urology - Pebble | Henderson89074 | NCT05677490 | Map |
| NV | Oncology Las Vegas - Henderson | Henderson89074 | NCT04205968 | Map |
| NV | Oncology Las Vegas - Henderson | Henderson89074 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Seven Hills | Henderson89052 | NCT04205968 | Map |
| NV | Urology Specialists of Nevada - Green Valley | Henderson89074 | NCT04205968 | Map |
| NV | Urology Specialists of Nevada - Green Valley | Henderson89074 | NCT05677490 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT04205968 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT04322318 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05677490 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT06172296 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT06401330 | Map |
| NV | Ann M Wierman MD LTD | Las Vegas89128 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89148 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada | Las Vegas89169 | NCT06662786 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Central Valley | Las Vegas89169 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas89128 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada - Town Center | Las Vegas89144 | NCT05677490 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT04205968 | Map |
| NV | Comprehensive Cancer Centers of Nevada-Summerlin | Las Vegas89144 | NCT05677490 | Map |
| NV | Hope Cancer Care of Nevada | Las Vegas89103 | NCT04205968 | Map |
| NV | Hope Cancer Care of Nevada | Las Vegas89103 | NCT05677490 | Map |
| NV | Las Vegas Prostate Cancer Center | Las Vegas89113 | NCT04205968 | Map |
| NV | Las Vegas Prostate Cancer Center | Las Vegas89113 | NCT05677490 | Map |
| NV | Las Vegas Urology - Cathedral Rock | Las Vegas89128 | NCT04205968 | Map |
| NV | Las Vegas Urology - Cathedral Rock | Las Vegas89128 | NCT05677490 | Map |
| NV | Las Vegas Urology - Pecos | Las Vegas89074 | NCT04205968 | Map |
| NV | Las Vegas Urology - Pecos | Las Vegas89074 | NCT05677490 | Map |
| NV | Las Vegas Urology - Smoke Ranch | Las Vegas89128 | NCT04205968 | Map |
| NV | Las Vegas Urology - Smoke Ranch | Las Vegas89128 | NCT05677490 | Map |
| NV | Las Vegas Urology - Sunset | Las Vegas89113 | NCT04205968 | Map |
| NV | Las Vegas Urology - Sunset | Las Vegas89113 | NCT05677490 | Map |
| NV | Oncology Las Vegas - Tenaya | Las Vegas89128 | NCT04205968 | Map |
| NV | Oncology Las Vegas - Tenaya | Las Vegas89128 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT04205968 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89148 | NCT04205968 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05677490 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT04205968 | Map |
| NV | OptumCare Cancer Care at MountainView | Las Vegas89128 | NCT05677490 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT04205968 | Map |
| NV | Radiation Oncology Centers of Nevada Central | Las Vegas89106 | NCT05677490 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT04205968 | Map |
| NV | Radiation Oncology Centers of Nevada Southeast | Las Vegas89119 | NCT05677490 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT04205968 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT04322318 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT05677490 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT04205968 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT04322318 | Map |
| NV | Sunrise Hospital and Medical Center | Las Vegas89109 | NCT05677490 | Map |
| NV | University Cancer Center | Las Vegas89169 | NCT04205968 | Map |
| NV | University Cancer Center | Las Vegas89169 | NCT05677490 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT04205968 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT04322318 | Map |
| NV | University Medical Center of Southern Nevada | Las Vegas89102 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Central | Las Vegas89106 | NCT04205968 | Map |
| NV | Urology Specialists of Nevada - Central | Las Vegas89106 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Northwest | Las Vegas89128 | NCT04205968 | Map |
| NV | Urology Specialists of Nevada - Northwest | Las Vegas89128 | NCT05677490 | Map |
| NV | Urology Specialists of Nevada - Southwest | Las Vegas89113 | NCT04205968 | Map |
| NV | Urology Specialists of Nevada - Southwest | Las Vegas89113 | NCT05677490 | Map |
| NV | Hope Cancer Care of Nevada-Pahrump | Pahrump89048 | NCT04205968 | Map |
| NV | Hope Cancer Care of Nevada-Pahrump | Pahrump89048 | NCT05677490 | Map |
| NV | Radiation Oncology Associates | Reno89509 | NCT04205968 | Map |
| NV | Radiation Oncology Associates | Reno89509 | NCT05677490 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT04205968 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT04322318 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT05677490 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06958328 | Map |
| NV | Saint Mary's Regional Medical Center | Reno89503 | NCT04205968 | Map |
| NV | Saint Mary's Regional Medical Center | Reno89503 | NCT05677490 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04205968 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04322318 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06172296 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06401330 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT06958328 | Map |
| NH | The Dana-Farber Cancer Institute at Londonderry | Londonderry03053 | NCT05677490 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT05863195 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT06958328 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT06958328 | Map |
| NJ | Jefferson Cherry Hill Hospital | Cherry Hill08002 | NCT05677490 | Map |
| NJ | Jefferson Cherry Hill Hospital | Cherry Hill08002 | NCT06958328 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT06662786 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT06750094 | Map |
| NJ | Trinitas Hospital and Comprehensive Cancer Center | Elizabeth07202 | NCT05806931 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT04322318 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06172296 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06401330 | Map |
| NJ | Hackensack University Medical Center | Hackensack07601 | NCT06541262 | Map |
| NJ | RWJBarnabas Health Jersey City Medical Center | Jersey City07302 | NCT05806931 | Map |
| NJ | RWJBarnabas Health - Monmouth Medical Center Southern Campus | Lakewood08701 | NCT05806931 | Map |
| NJ | Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) | Livingston07039 | NCT05806931 | Map |
| NJ | RWJBarnabas Health - Monmouth Medical Center | Long Branch07740 | NCT05806931 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05863195 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06958328 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT05863195 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06958328 | Map |
| NJ | Atlantic Health System | Morristown07960 | NCT06835387 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT04322318 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT06172296 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT06401330 | Map |
| NJ | Jersey Shore Medical Center | Neptune City07753 | NCT06401330 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08901 | NCT06662786 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT01042379 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05806931 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT04322318 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT06172296 | Map |
| NJ | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital | New Brunswick08903 | NCT06401330 | Map |
| NJ | RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick08903 | NCT05806931 | Map |
| NJ | Saint Peter's University Hospital | New Brunswick08901 | NCT04322318 | Map |
| NJ | Saint Peter's University Hospital | New Brunswick08901 | NCT06172296 | Map |
| NJ | Saint Peter's University Hospital | New Brunswick08901 | NCT06401330 | Map |
| NJ | Newark Beth Israel Medical Center | Newark07112 | NCT04322318 | Map |
| NJ | Newark Beth Israel Medical Center | Newark07112 | NCT06401330 | Map |
| NJ | Saint Joseph's Regional Medical Center | Paterson07503 | NCT04322318 | Map |
| NJ | Saint Joseph's Regional Medical Center | Paterson07503 | NCT06172296 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT05677490 | Map |
| NJ | RWJBarnabas Health - Robert Wood Johnson University Hospital | Somerset08873 | NCT05806931 | Map |
| NJ | RWJBarnabas Health - Community Medical Center | Toms River08755 | NCT05806931 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT04322318 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87102 | NCT06662786 | Map |
| NY | Albany Medical Center | Albany12208 | NCT04322318 | Map |
| NY | Albany Medical Center | Albany12208 | NCT06172296 | Map |
| NY | Albany Medical Center | Albany12208 | NCT06401330 | Map |
| NY | New York-Presbyterian/Brooklyn Methodist Hospital | Brooklyn11215 | NCT05677490 | Map |
| NY | New York-Presbyterian/Brooklyn Methodist Hospital | Brooklyn11215 | NCT06958328 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT01042379 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05382559 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT04322318 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05863195 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06172296 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06401330 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06821997 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT07214298 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05863195 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06958328 | Map |
| NY | Research Site | Commack11725 | NCT06219941 | Map |
| NY | Hematology Oncology Associates of Central New York | East Syracuse13057 | NCT04657068 | Map |
| NY | Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) | East Syracuse13057 | NCT05319730 | Map |
| NY | Memorial Sloan Kettering Westchester | East White Plains10604 | NCT05863195 | Map |
| NY | Memorial Sloan Kettering Westchester | East White Plains10604 | NCT06958328 | Map |
| NY | The New York Hospital Medical Center of Queens | Flushing11355 | NCT05677490 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT05677490 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT04329494 | Map |
| NY | Northwell Health Cancer Institute at Huntington | Greenlawn11740 | NCT05677490 | Map |
| NY | Northwell Health Cancer Institute | Lake Success11042 | NCT04657068 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT05677490 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06172296 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06401330 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06958328 | Map |
| NY | NYU Long Island Mineola | Mineola11501 | NCT07409272 | Map |
| NY | Perlmutter Cancer Center at NYU Long Island | Mineola11501 | NCT06662786 | Map |
| NY | Perlmutter Cancer Center at NYU Long Island | Mineola11501 | NCT06750094 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT05677490 | Map |
| NY | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park11040 | NCT04322318 | Map |
| NY | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park11040 | NCT06172296 | Map |
| NY | The Steven and Alexandra Cohen Children's Medical Center of New York | New Hyde Park11040 | NCT06401330 | Map |
| NY | Columbia University - Herbert Irving Comprehensive Cancer Center | New York10032 | NCT05382559 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT01042379 | Map |
| NY | David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York10021 | NCT03715933 | Map |
| NY | David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York10065 | NCT06586515 | Map |
| NY | Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York10032 | NCT05379595 | Map |
| NY | Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York10032 | NCT06662786 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center / NYU Langone Health | New York10016 | NCT01042379 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06172296 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06401330 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06958328 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT07409272 | Map |
| NY | Lenox Hill Hospital | New York10075 | NCT05677490 | Map |
| NY | Manhattan Eye Ear and Throat Hospital | New York10065 | NCT05677490 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05365581 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05382559 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04322318 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05863195 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05999994 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06401330 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06528496 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06620302 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06958328 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07024615 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT05004116 | Map |
| NY | Mount Sinai | New York10003 | NCT06662786 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT04322318 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05863195 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT06958328 | Map |
| NY | Mount Sinai West | New York10009 | NCT06662786 | Map |
| NY | Mount Sinai West | New York10019 | NCT06958328 | Map |
| NY | New York University (NYU) Langone Medical Center | New York10016 | NCT06586515 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT04322318 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT06172296 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT06620302 | Map |
| NY | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York10032 | NCT06958328 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT04322318 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT05677490 | Map |
| NY | NYU Langone Long Island Clinical Research Associates | New York10016 | NCT05379595 | Map |
| NY | NYU Langone Medical Center - NYU Medical Oncology Associates | New York10016 | NCT05365581 | Map |
| NY | NYU Langone Medical Center NYU Hematology Associates | New York10016 | NCT06662786 | Map |
| NY | NYU Langone Medical Center NYU Hematology Associates | New York10016 | NCT06750094 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT05677490 | Map |
| NY | Research Site | Rochester14618 | NCT06792695 | Map |
| NY | University of Rochester | Rochester14642 | NCT04205968 | Map |
| NY | University of Rochester | Rochester14642 | NCT04322318 | Map |
| NY | University of Rochester | Rochester14642 | NCT05677490 | Map |
| NY | University of Rochester | Rochester14642 | NCT06172296 | Map |
| NY | University of Rochester | Rochester14642 | NCT06401330 | Map |
| NY | University of Rochester Wilmot Cancer Institute | Rochester14642 | NCT01042379 | Map |
| NY | New York Cancer and Blood Specialists | Shirley11967 | NCT06662786 | Map |
| NY | New York Cancer and Blood Specialists | Shirley11967 | NCT06750094 | Map |
| NY | Phelps Memorial Hospital Center | Sleepy Hollow10591 | NCT05677490 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT04322318 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT05677490 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT06401330 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT04322318 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT06172296 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT06401330 | Map |
| NY | Montefiore Einstein Comprehensive Cancer Center | The Bronx10461 | NCT06662786 | Map |
| NY | Montefiore Einstein Comprehensive Cancer Center | The Bronx10461 | NCT06750094 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT01042379 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT04322318 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT06172296 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT06958328 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT05677490 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT06958328 | Map |
| NY | Montefiore Medical Center-Weiler Hospital | The Bronx10461 | NCT05677490 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT05863195 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT06958328 | Map |
| NY | New York Medical College | Valhalla10595 | NCT04322318 | Map |
| NY | New York Medical College | Valhalla10595 | NCT06172296 | Map |
| NY | New York Medical College | Valhalla10595 | NCT06401330 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT05677490 | Map |
| NY | White Plains Hospital Center for Cancer Care - Oncology | White Plains10601 | NCT07409272 | Map |
| NC | Atrium Health Stanly/LCI-Albemarle | Albemarle28002 | NCT04205968 | Map |
| NC | Mission Hospital | Asheville28801 | NCT04322318 | Map |
| NC | Mission Hospital | Asheville28801 | NCT06172296 | Map |
| NC | Duke Cancer Center Cary | Cary27518 | NCT04205968 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT05677490 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06172296 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06401330 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06958328 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27599 | NCT06662786 | Map |
| NC | University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT03977233 | Map |
| NC | Atrium Health Pineville/LCI-Pineville | Charlotte28210 | NCT04205968 | Map |
| NC | Atrium Health University City/LCI-University | Charlotte28262 | NCT04205968 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04205968 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT04322318 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06172296 | Map |
| NC | Carolinas Medical Center/Levine Cancer Institute | Charlotte28203 | NCT06401330 | Map |
| NC | Levine Cancer Institute-SouthPark | Charlotte28211 | NCT04205968 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT04322318 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT06172296 | Map |
| NC | Novant Health Presbyterian Medical Center | Charlotte28204 | NCT06401330 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT06998940 | Map |
| NC | Atrium Health Cabarrus/LCI-Concord | Concord28025 | NCT04205968 | Map |
| NC | Duke Children's Hospital and Health Center | Durham27710 | NCT05365581 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT04205968 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06586515 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT04322318 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05863195 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06172296 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06401330 | Map |
| NC | Duke University Medical Center - Duke Cancer Center | Durham27710 | NCT07024615 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT06998940 | Map |
| NC | East Carolina University | Greenville27834 | NCT04322318 | Map |
| NC | East Carolina University | Greenville27834 | NCT05677490 | Map |
| NC | East Carolina University | Greenville27834 | NCT06172296 | Map |
| NC | East Carolina University | Greenville27834 | NCT06401330 | Map |
| NC | Margaret R Pardee Memorial Hospital | Hendersonville28791 | NCT05677490 | Map |
| NC | University of North Carolina-Hillsborough Campus | Hillsborough27278 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT05677490 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT06998940 | Map |
| NC | Atrium Health Union/LCI-Union | Monroe28112 | NCT04205968 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT05677490 | Map |
| NC | FirstHealth of the Carolinas-Moore Regional Hospital | Pinehurst28374 | NCT06998940 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT04205968 | Map |
| NC | Duke Cancer Center Raleigh | Raleigh27609 | NCT05863195 | Map |
| NC | Investigative Site #131 | Raleigh27710 | NCT06974110 | Map |
| NC | Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT01042379 | Map |
| NC | Wake Forest University Baptist Health | Winston-Salem27103 | NCT05365581 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT04322318 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05863195 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06172296 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT06401330 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05677490 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT06958328 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT04205968 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT05677490 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT06998940 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT04322318 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05677490 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06172296 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06958328 | Map |
| ND | Sanford Medical Center Fargo | Fargo58104 | NCT05677490 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05677490 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT06958328 | Map |
| ND | Sanford South University Medical Center | Fargo58103 | NCT05677490 | Map |
| ND | Southpointe-Sanford Medical Center Fargo | Fargo58103 | NCT05677490 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT04205968 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT05677490 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT06998940 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT04322318 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT06172296 | Map |
| OH | Children's Hospital Medical Center of Akron | Akron44308 | NCT06401330 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT05677490 | Map |
| OH | Gabrail Cancer Center | Canton44718 | NCT06662786 | Map |
| OH | Gabrail Cancer Center | Canton44718 | NCT06750094 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05677490 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT06958328 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT06998940 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT05677490 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT06998940 | Map |
| OH | Cincinnati Children's Hospital | Cincinnati45229 | NCT04796012 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT03715933 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT04322318 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06172296 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06401330 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Cincinnati45229 | NCT06620302 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT06998940 | Map |
| OH | Oncology Hematology Care Primary | Cincinnati45242 | NCT04657068 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT06998940 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT06998940 | Map |
| OH | University of Cincinnati (UC) - Cancer Institute | Cincinnati45267 | NCT06586515 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT06958328 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT06998940 | Map |
| OH | Case Western | Cleveland44106 | NCT05382559 | Map |
| OH | Cleveland Clinic | Cleveland44106 | NCT01042379 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06586515 | Map |
| OH | Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion | Cleveland44111 | NCT06662786 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT04322318 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06172296 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT04322318 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT06172296 | Map |
| OH | Rainbow Babies and Childrens Hospital | Cleveland44106 | NCT06401330 | Map |
| OH | Taussig Cancer Insititute Cleveland Clinic | Cleveland44195 | NCT06662786 | Map |
| OH | University Hospital of Cleveland | Cleveland44106 | NCT06750094 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06662786 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT05677490 | Map |
| OH | Mount Carmel Health Center West | Columbus43222 | NCT05677490 | Map |
| OH | Nationwide Children's Hosp | Columbus43205-2664 | NCT05999994 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT04211675 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT04322318 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT06172296 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT06450041 | Map |
| OH | Nationwide Children's Hospital | Columbus43205 | NCT07194044 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05677490 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05863195 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06958328 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT05677490 | Map |
| OH | The Ohio State University, Stefanie Spielman Comprehensive Breast Center | Columbus43212 | NCT01042379 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT04322318 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT06172296 | Map |
| OH | Dayton Children's Hospital | Dayton45404 | NCT06401330 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05677490 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT06958328 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT06998940 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05677490 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT06958328 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT06998940 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05677490 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT06958328 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT06998940 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT06958328 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05677490 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT06958328 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT06998940 | Map |
| OH | Central Ohio Breast and Endocrine Surgery | Gahanna43230 | NCT05677490 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05677490 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT06958328 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT06998940 | Map |
| OH | Mount Carmel Grove City Hospital | Grove City43123 | NCT05677490 | Map |
| OH | Zangmeister Center Grove City | Grove City43123 | NCT05677490 | Map |
| OH | Cleveland Clinic Cancer Center Independence Family Health Center | Independence44131 | NCT06662786 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT05677490 | Map |
| OH | Saint Rita's Medical Center | Lima45801 | NCT05677490 | Map |
| OH | Cleveland Clinic Cancer Center Mansfield | Mansfield44906 | NCT06662786 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT05677490 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT05677490 | Map |
| OH | Taylor Cancer Research Center | Maumee43537 | NCT04657068 | Map |
| OH | Cleveland Clinic Cancer Center Hillcrest Hospital | Mayfield Heights44124 | NCT06662786 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT05677490 | Map |
| OH | Mount Carmel New Albany Surgical Hospital | New Albany43054 | NCT05677490 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT05677490 | Map |
| OH | Newark Radiation Oncology | Newark43055 | NCT05677490 | Map |
| OH | Mercy Health - Perrysburg Hospital | Perrysburg43551 | NCT05677490 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT05677490 | Map |
| OH | Cleveland Clinic Cancer Centers Sandusky | Sandusky44870 | NCT06662786 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT05677490 | Map |
| OH | Springfield Regional Medical Center | Springfield45504 | NCT05677490 | Map |
| OH | Cleveland Clinic Cancer Center Strongsville | Strongsville44136 | NCT06662786 | Map |
| OH | ProMedica Flower Hospital | Sylvania43560 | NCT06958328 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT05677490 | Map |
| OH | Mercy Health - Saint Vincent Hospital | Toledo43608 | NCT05677490 | Map |
| OH | Mercy Health Sylvania Radiation Oncology Center | Toledo43623 | NCT05677490 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT04322318 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT06172296 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT06401330 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT06958328 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05677490 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT06958328 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT06998940 | Map |
| OH | Cleveland Clinic Cancer Center South Pointe Hospital | Warrensville Heights44122 | NCT06662786 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT06958328 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT06998940 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT05677490 | Map |
| OH | Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center | Wilmington45177 | NCT05677490 | Map |
| OH | Wooster Milltown Specialty and Surgery Center | Wooster44691 | NCT06662786 | Map |
| OH | Saint Elizabeth Youngstown Hospital | Youngstown44501 | NCT05863195 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT05677490 | Map |
| OK | Cancer Centers of Southwest Oklahoma Research | Lawton73505 | NCT04205968 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04205968 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT05677490 | Map |
| OK | Stephenson Cancer Center | Oklahoma City73104 | NCT04657068 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04205968 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04322318 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05677490 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06172296 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06401330 | Map |
| OK | Natalie Warren Bryant Cancer Center at Saint Francis | Tulsa74136 | NCT06172296 | Map |
| OR | Saint Alphonsus Cancer Care Center-Baker City | Baker City97814 | NCT04205968 | Map |
| OR | Saint Alphonsus Cancer Care Center-Baker City | Baker City97814 | NCT05677490 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT04205968 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT05677490 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT06998940 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT04205968 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT05677490 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT06998940 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT04205968 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT05677490 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT06998940 | Map |
| OR | Oncology Associates of Oregon - Primary | Eugene97401 | NCT07011576 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT04205968 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT05677490 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT06998940 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04205968 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05677490 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06998940 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT04205968 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05677490 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04205968 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05677490 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06998940 | Map |
| OR | Investigative Site #121 | Portland97239 | NCT06974110 | Map |
| OR | Legacy Emanuel Children's Hospital | Portland97227 | NCT04322318 | Map |
| OR | Legacy Emanuel Children's Hospital | Portland97227 | NCT06172296 | Map |
| OR | Legacy Emanuel Children's Hospital | Portland97227 | NCT06401330 | Map |
| OR | Northwest Cancer Specialists - Compass | Portland97213 | NCT07011576 | Map |
| OR | Oregon Health & Science Institute (OHSU) | Portland97239 | NCT01042379 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT04657068 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT03715933 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05382559 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04322318 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05863195 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06172296 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06401330 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06958328 | Map |
| OR | Oregon Health And Science University | Portland97239 | NCT06662786 | Map |
| OR | Oregon Health And Science University | Portland97239 | NCT06750094 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04205968 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05677490 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06998940 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04205968 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05677490 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06998940 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT04205968 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT05677490 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT06998940 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04205968 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT04322318 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05677490 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05863195 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06172296 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT04205968 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05677490 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT05677490 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT06958328 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT06998940 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT04322318 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT05677490 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06172296 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06401330 | Map |
| PA | Geisinger Medical Center | Danville17822 | NCT06958328 | Map |
| PA | Geisinger Cancer Center Dickson City | Dickson City18519 | NCT05677490 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT04205968 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05677490 | Map |
| PA | Saint Vincent Hospital | Erie16544 | NCT05863195 | Map |
| PA | Geisinger Medical Center-Cancer Center Hazleton | Hazleton18201 | NCT05677490 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT04205968 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT05677490 | Map |
| PA | Penn State Children's Hospital | Hershey17033 | NCT04322318 | Map |
| PA | Penn State Children's Hospital | Hershey17033 | NCT06401330 | Map |
| PA | Penn State Milton S. Hershey Medical Center and Children's Hospital | Hershey17033 | NCT06541262 | Map |
| PA | Jefferson Hospital | Jefferson Hills15025 | NCT05863195 | Map |
| PA | Jefferson Hospital | Jefferson Hills15025 | NCT06958328 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT05677490 | Map |
| PA | Geisinger Medical Oncology-Lewisburg | Lewisburg17837 | NCT06958328 | Map |
| PA | Lewistown Hospital | Lewistown17044 | NCT05677490 | Map |
| PA | Forbes Hospital | Monroeville15146 | NCT05863195 | Map |
| PA | Forbes Hospital | Monroeville15146 | NCT06958328 | Map |
| PA | Paoli Memorial Hospital | Paoli19301 | NCT06958328 | Map |
| PA | Alliance Cancer Specialists at Main Line | Penn Wynne19096 | NCT06750094 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT04796012 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT04322318 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06172296 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06401330 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104-4318 | NCT06450041 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06620302 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT07549321 | Map |
| PA | Children's Hospital of Philadelphia- Center for Childhood Cancer Research | Philadelphia19104 | NCT03715933 | Map |
| PA | Einstein Medical Center Philadelphia | Philadelphia19141 | NCT05677490 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05800587 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05863195 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06662786 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06750094 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT06958328 | Map |
| PA | Saint Christopher's Hospital for Children | Philadelphia19134 | NCT04322318 | Map |
| PA | Saint Christopher's Hospital for Children | Philadelphia19134 | NCT06172296 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06662786 | Map |
| PA | Thomas Jefferson University | Philadelphia19107 | NCT06750094 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06958328 | Map |
| PA | Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization | Philadelphia19107 | NCT04657068 | Map |
| PA | University of Pennsylvania (U Penn) | Philadelphia19104 | NCT01042379 | Map |
| PA | University of Pennsylvania / Abramson Cancer Center | Philadelphia19104 | NCT04657068 | Map |
| PA | University of Pennsylvania Abramson Cancer Center | Philadelphia19106 | NCT03715933 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT05863195 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT06958328 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT04322318 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT06172296 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT06401330 | Map |
| PA | Children's Hospital of Pittsburgh of UPMC | Pittsburgh15224 | NCT06620302 | Map |
| PA | University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center | Pittsburgh15232 | NCT06586515 | Map |
| PA | University Of Pittsburgh Medical Center UPMC Hillman Cancer Center | Pittsburgh15232 1301 | NCT06662786 | Map |
| PA | University Of Pittsburgh Medical Center UPMC Hillman Cancer Center | Pittsburgh15232 1301 | NCT06750094 | Map |
| PA | UPMC Children's Hospital of Pittsburgh | Pittsburgh15224 | NCT05999994 | Map |
| PA | UPMC Hillman Cancer Center-UPMC ( Site 4904) | Pittsburgh15232 | NCT05319730 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT05863195 | Map |
| PA | West Penn Hospital | Pittsburgh15224 | NCT06958328 | Map |
| PA | Geisinger Cancer Services-Pottsville | Pottsville17901 | NCT05677490 | Map |
| PA | Community Medical Center | Scranton18510 | NCT05677490 | Map |
| PA | Reading Hospital | West Reading19611 | NCT05677490 | Map |
| PA | Reading Hospital | West Reading19611 | NCT06958328 | Map |
| PA | Wexford Health and Wellness Pavilion | Wexford15090 | NCT05863195 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT05677490 | Map |
| PA | Geisinger Wyoming Valley/Henry Cancer Center | Wilkes-Barre18711 | NCT06958328 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT05677490 | Map |
| PA | Alliance Cancer Specialists | Wynnewood19096 | NCT07011576 | Map |
| RI | Hasbro Children's Hospital | Providence02903 | NCT06541262 | Map |
| RI | Lifespan Cancer Institute | Providence02906 | NCT05999994 | Map |
| RI | Research Site | Providence02903 | NCT06219941 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT04322318 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06172296 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT06401330 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT04205968 | Map |
| SC | Hollings Cancer Center at Medical University of South Carolina | Charleston29425 | NCT07076212 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT04322318 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT05677490 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06172296 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT06958328 | Map |
| SC | Medical University of South Carolina Hollings Cancer Center | Charleston29425 | NCT07076212 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT04322318 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT06172296 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT06401330 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT04205968 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT04322318 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT06172296 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT06401330 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT04205968 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT04205968 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT04205968 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT06958328 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT06958328 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT04205968 | Map |
| SC | Levine Cancer Institute-Rock Hill | Rock Hill29732 | NCT04205968 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT04205968 | Map |
| SD | Avera Cancer Institute-Aberdeen | Aberdeen57401 | NCT05677490 | Map |
| SD | Avera Cancer Institute - Mitchell | Mitchell57301 | NCT05677490 | Map |
| SD | Avera Cancer Institute at Pierre | Pierre57501 | NCT05677490 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05677490 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT06998940 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT05677490 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05677490 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT06958328 | Map |
| SD | Sanford Clinical Research | Sioux Falls57104 | NCT01042379 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT04322318 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05677490 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06172296 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06401330 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06958328 | Map |
| SD | Avera Cancer Institute at Yankton | Yankton57078 | NCT05677490 | Map |
| TN | T C Thompson Children's Hospital | Chattanooga37403 | NCT06401330 | Map |
| TN | Tennessee Oncology Chattanooga | Chattanooga37404 | NCT06750094 | Map |
| TN | Tennessee Oncology, PLLC | Chattanooga37404 | NCT04657068 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT04205968 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06958328 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT06998940 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT04322318 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT06172296 | Map |
| TN | East Tennessee Childrens Hospital | Knoxville37916 | NCT06401330 | Map |
| TN | Baptist Cancer Center | Memphis38120 | NCT06644781 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT04205968 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06958328 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT06998940 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT04322318 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT06172296 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT06401330 | Map |
| TN | Saint Jude Children's Research Hospital | Memphis38105 | NCT06620302 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT06023641 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT06450041 | Map |
| TN | St. Jude Children's Research Hospital | Memphis38105 | NCT07085338 | Map |
| TN | Monroe Carrell Jr. Children's Hospital at Vanderbilt | Nashville37232 | NCT06541262 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT06586515 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT04657068 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06644781 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06662786 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06750094 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07011576 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT06750094 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT04322318 | Map |
| TN | The Children's Hospital at TriStar Centennial | Nashville37203 | NCT06172296 | Map |
| TN | USO - US Oncology Research Network | Nashville37203 | NCT06586515 | Map |
| TN | Vanderbilt Ingram Cancer Center | Nashville37232 | NCT05379595 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT05382559 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT06750094 | Map |
| TN | Vanderbilt University School of Medicine | Nashville37232 | NCT03715933 | Map |
| TN | Vanderbilt University School of Medicine | Nashville37215 | NCT06586515 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT04322318 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05863195 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06172296 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06401330 | Map |
| TX | Texas Oncology West Texas | Abilene79606 | NCT06662786 | Map |
| TX | Texas Oncology West Texas | Abilene79606 | NCT06750094 | Map |
| TX | Texas Tech University Health Sciences Center-Amarillo | Amarillo79106 | NCT04322318 | Map |
| TX | Texas Tech University Health Sciences Center-Amarillo | Amarillo79106 | NCT06401330 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT04322318 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT06172296 | Map |
| TX | Dell Children's Medical Center of Central Texas | Austin78723 | NCT06401330 | Map |
| TX | Dell Children's Medical Group SFC-HEM/ONC | Austin78723 | NCT01356290 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT04657068 | Map |
| TX | Texas Oncology - Central/South Texas | Austin78705 | NCT07011576 | Map |
| TX | Houston Methodist San Jacinto Hospital | Baytown77521 | NCT06958328 | Map |
| TX | Texas Oncology - Gulf Coast | Beaumont77702 | NCT07011576 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT06958328 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT04322318 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT06172296 | Map |
| TX | Driscoll Children's Hospital | Corpus Christi78411 | NCT06401330 | Map |
| TX | Houston Methodist Cypress Hospital | Cypress77429 | NCT06958328 | Map |
| TX | Children's Medical Center | Dallas75235 | NCT06541262 | Map |
| TX | Investigative Site #127 | Dallas75230 | NCT06974110 | Map |
| TX | Mary Crowley Cancer Research | Dallas75230 | NCT04657068 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT04322318 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT06172296 | Map |
| TX | Medical City Dallas Hospital | Dallas75230 | NCT06401330 | Map |
| TX | Parkland Health and Hospital System | Dallas75235 | NCT06750094 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05677490 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT05863195 | Map |
| TX | Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas75246 | NCT04657068 | Map |
| TX | Texas Oncology DFW | Dallas75246 | NCT06662786 | Map |
| TX | Texas Oncology DFW | Dallas75246 | NCT06750094 | Map |
| TX | The University of Texas Southwestern Medical Center | Dallas75235 | NCT04796012 | Map |
| TX | University of Texas Southwestern | Dallas75235 | NCT06450041 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06835387 | Map |
| TX | University of Texas Southwestern Medical Center at Dallas | Dallas75390-9063 | NCT05999994 | Map |
| TX | UT Southwestern | Dallas75390 | NCT06662786 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT05365581 | Map |
| TX | UT Southwestern Medical Center | Dallas75390 | NCT06750094 | Map |
| TX | UT Southwestern Medical Center at Dallas | Dallas75390 | NCT07409272 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05677490 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT05863195 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT04322318 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05863195 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT06172296 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT06401330 | Map |
| TX | El Paso Children's Hospital | El Paso79905 | NCT04322318 | Map |
| TX | El Paso Children's Hospital | El Paso79905 | NCT06172296 | Map |
| TX | Texas Oncology - Northeast Texas | Flower Mound75028 | NCT04657068 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT04322318 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06172296 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06401330 | Map |
| TX | Cook Children's Medical Center | Fort Worth76104 | NCT06450041 | Map |
| TX | John Peter Smith Hospital | Fort Worth76104 | NCT06644781 | Map |
| TX | Tarrant County Hospital District/JPS Health Network | Fort Worth76104 | NCT05677490 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05677490 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT05863195 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT04322318 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06172296 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06401330 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06620302 | Map |
| TX | Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center | Houston77030 | NCT06958328 | Map |
| TX | Ben Taub General Hospital | Houston77030 | NCT06958328 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT06958328 | Map |
| TX | Houston Methodist West Hospital | Houston77094 | NCT06958328 | Map |
| TX | Investigative Site #129 | Houston77030 | NCT06974110 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05062317 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04199026 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04205968 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04322318 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06006273 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT06958328 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05379595 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06586515 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06662786 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06750094 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT06958328 | Map |
| TX | Methodist Willowbrook Hospital | Houston77070 | NCT06958328 | Map |
| TX | Research Site | Houston77030 | NCT06219941 | Map |
| TX | Research Site | Houston77030 | NCT06792695 | Map |
| TX | Texas Children's Hospital | Houston77030 | NCT04796012 | Map |
| TX | University of Texas MD Anderson Cancer Center | Houston77030 | NCT05999994 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT03715933 | Map |
| TX | UT MD Anderson Cancer Center | Houston77030 | NCT06172296 | Map |
| TX | MD Anderson League City | League City77573 | NCT06958328 | Map |
| TX | Covenant Children's Hospital | Lubbock79410 | NCT04322318 | Map |
| TX | Covenant Children's Hospital | Lubbock79410 | NCT06172296 | Map |
| TX | Covenant Children's Hospital | Lubbock79410 | NCT06401330 | Map |
| TX | UMC Cancer Center / UMC Health System | Lubbock79415 | NCT04322318 | Map |
| TX | UMC Cancer Center / UMC Health System | Lubbock79415 | NCT06172296 | Map |
| TX | UMC Cancer Center / UMC Health System | Lubbock79415 | NCT06401330 | Map |
| TX | Houston Methodist Saint John Hospital | Nassau Bay77058 | NCT06958328 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05677490 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT05863195 | Map |
| TX | Baylor Scott & White Medical Center | Round Rock77845 | NCT06750094 | Map |
| TX | Baylor Scott and White Health 1 | Round Rock78665 | NCT06662786 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT04322318 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT06172296 | Map |
| TX | Children's Hospital of San Antonio | San Antonio78207 | NCT06401330 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT04322318 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT06172296 | Map |
| TX | Methodist Children's Hospital of South Texas | San Antonio78229 | NCT06401330 | Map |
| TX | NEXT Oncology | San Antonio78229 | NCT05382559 | Map |
| TX | South Texas Accelerated Research Therapeutics (START) | San Antonio78229 | NCT06586515 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT04657068 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT06662786 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT06750094 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT04322318 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT06172296 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT06401330 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT06958328 | Map |
| TX | Houston Methodist Sugar Land Hospital | Sugar Land77479 | NCT06958328 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT06958328 | Map |
| TX | Baylor Scott and White Health | Temple76508 | NCT06662786 | Map |
| TX | Scott And White Memorial Hospital | Temple76508 | NCT06750094 | Map |
| TX | Houston Methodist The Woodlands Hospital | The Woodlands77385 | NCT06958328 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT07011576 | Map |
| TX | Texas Oncology - Northeast Texas /ID# 280417 | Tyler75702 | NCT07490301 | Map |
| TX | UT Health East Texas HOPE Cancer Center | Tyler75701 | NCT06750094 | Map |
| UT | Farmington Health Center | Farmington84025 | NCT05677490 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06586515 | Map |
| UT | Huntsman Cancer Institute, University of Utah | Salt Lake City84112 | NCT01042379 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT05677490 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT04322318 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT06172296 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT06401330 | Map |
| UT | Primary Children's Hospital | Salt Lake City84113 | NCT06541262 | Map |
| UT | University of Utah Sugarhouse Health Center | Salt Lake City84106 | NCT05677490 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT04657068 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT07409272 | Map |
| VT | Central Vermont Medical Center/National Life Cancer Treatment | Berlin Corners05602 | NCT05677490 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT05677490 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT06172296 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT06401330 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT05677490 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT04205968 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT06958328 | Map |
| VA | Inova Alexandria Hospital | Alexandria22304 | NCT06958328 | Map |
| VA | Virginia Cancer Specialists | Arlington22201 | NCT06662786 | Map |
| VA | Virginia Cancer Specialists | Arlington22201 | NCT06750094 | Map |
| VA | University of Virginia | Charlottesville22903 | NCT03715933 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT04322318 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05677490 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06172296 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06401330 | Map |
| VA | UVA Emily Couric Cancer Center | Charlottesville22903 | NCT07409272 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT05677490 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT06958328 | Map |
| VA | Inova Fair Oaks Hospital | Fairfax22033 | NCT06998940 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05677490 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT06958328 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT06998940 | Map |
| VA | Inova Schar Cancer Institute Dept of Fairfax Hospital | Fairfax22031 | NCT06662786 | Map |
| VA | NEXT Oncology - Virginia | Fairfax22031 | NCT03715933 | Map |
| VA | NEXT Oncology - Virginia Cancer Specialists | Fairfax22031 | NCT05382559 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT04657068 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT06644781 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT07409272 | Map |
| VA | Virginia Cancer Specialists - Fairfax /ID# 280415 | Fairfax22031 | NCT07490301 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT04322318 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05677490 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT06401330 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT06958328 | Map |
| VA | Inova Loudoun Hospital | Leesburg20176 | NCT06958328 | Map |
| VA | Centra Alan B Pearson Regional Cancer Center | Lynchburg24501 | NCT05677490 | Map |
| VA | Bon Secours Memorial Regional Medical Center | Mechanicsville23116 | NCT06958328 | Map |
| VA | Bon Secours Saint Francis Medical Center | Midlothian23114 | NCT06958328 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT04322318 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT06401330 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT07011576 | Map |
| VA | Naval Medical Center - Portsmouth | Portsmouth23708-2197 | NCT06172296 | Map |
| VA | Bon Secours Cancer Institute at Reynolds Crossing | Richmond23230 | NCT06958328 | Map |
| VA | Bon Secours Saint Mary's Hospital | Richmond23226 | NCT06958328 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT06662786 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT06750094 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05677490 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04322318 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05677490 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06401330 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06662786 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06750094 | Map |
| VA | Virginia Cancer Institute | Richmond23229 | NCT05677490 | Map |
| VA | Virginia Commonwealth University | Richmond23284 | NCT06541262 | Map |
| VA | Virginia Commonwealth University | Richmond23298 | NCT06835387 | Map |
| VA | Carilion Children's | Roanoke24014 | NCT04322318 | Map |
| VA | Carilion Children's | Roanoke24014 | NCT06401330 | Map |
| VA | Blue Ridge Cancer Care (Oncology & Hematology Associates of Southwest VA) | Salem24153 | NCT07011576 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT04205968 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT06998940 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT04205968 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT05677490 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT06998940 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT04205968 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT06998940 | Map |
| WA | Swedish Cancer Institute Edmonds | Edmonds98026 | NCT06662786 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04205968 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05677490 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT06998940 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT04205968 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT05677490 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT06998940 | Map |
| WA | Swedish Cancer Institute Issaquah | Issaquah98029 | NCT06662786 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04205968 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05677490 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT06998940 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT04205968 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT05677490 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT06998940 | Map |
| WA | Providence Regional Cancer System | Lacey98503 | NCT06750094 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT04205968 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05677490 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT06998940 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT04205968 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT05677490 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT06998940 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT04205968 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT05677490 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT06998940 | Map |
| WA | Valley Medical Center | Renton98055 | NCT04205968 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05677490 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06586515 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06958328 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06998940 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109 | NCT06662786 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109 | NCT06750094 | Map |
| WA | Seattle Children's | Seattle98105 | NCT04796012 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT04322318 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06172296 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06401330 | Map |
| WA | Seattle Children's Hospital | Seattle98105 | NCT06620302 | Map |
| WA | Seattle Children's Hospital Research Foundation | Seattle98105 | NCT05999994 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT06662786 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT04205968 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT05677490 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT06998940 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT04205968 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT05677490 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT06998940 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04205968 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05677490 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06998940 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT06958328 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT06998940 | Map |
| WA | Virginia Mason Franciscan Health - Virginia Mason Medical Center | Seattle98101 | NCT07409272 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT05365581 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT04205968 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT05677490 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT06998940 | Map |
| WA | Saint Michael Cancer Center | Silverdale98383 | NCT06998940 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT04205968 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT05677490 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT06998940 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT04205968 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT05677490 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT06998940 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT04205968 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT05677490 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT06998940 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT04322318 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT06172296 | Map |
| WA | Providence Sacred Heart Medical Center and Children's Hospital | Spokane99204 | NCT06401330 | Map |
| WA | Madigan Army Medical Center | Tacoma98431 | NCT04322318 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT04322318 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT06172296 | Map |
| WA | Mary Bridge Children's Hospital and Health Center | Tacoma98405 | NCT06401330 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT04205968 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT05677490 | Map |
| WA | PeaceHealth Southwest Medical Center | Vancouver98664 | NCT06998940 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT04205968 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05677490 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT06998940 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT04205968 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT05677490 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT04322318 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05677490 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT04322318 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT06172296 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT06958328 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT06172296 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT05677490 | Map |
| WI | Langlade Hospital and Cancer Center | Antigo54409 | NCT06958328 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT04205968 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05677490 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06998940 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT04205968 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT05677490 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT06998940 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05677490 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT04205968 | Map |
| WI | Marshfield Clinic-Chippewa Center | Chippewa Falls54729 | NCT05677490 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05677490 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04205968 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05677490 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT06958328 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05677490 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06998940 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT04322318 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06401330 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06998940 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT04205968 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT05677490 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT06998940 | Map |
| WI | Tamarack Health Hayward Medical Center | Hayward54843 | NCT04205968 | Map |
| WI | Tamarack Health Hayward Medical Center | Hayward54843 | NCT05677490 | Map |
| WI | Tamarack Health Hayward Medical Center | Hayward54843 | NCT06998940 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05677490 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05677490 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06998940 | Map |
| WI | Marshfield Medical Center - Ladysmith | Ladysmith54848 | NCT04205968 | Map |
| WI | Marshfield Medical Center - Ladysmith | Ladysmith54848 | NCT05677490 | Map |
| WI | University of Wisconsin - Carbone Cancer Center | Madison53792 | NCT06586515 | Map |
| WI | University of Wisconsin Carbone Cancer Center | Madison52792 | NCT05854498 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05863195 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04322318 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05863195 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06172296 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT06401330 | Map |
| WI | University of Wisconsin Hospital | Madison53792 | NCT05382559 | Map |
| WI | William S. Middleton Memorial VA | Madison53705 | NCT06662786 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05677490 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04205968 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04322318 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05677490 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06172296 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT06958328 | Map |
| WI | Aspirus Medford Hospital | Medford54451 | NCT05677490 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT06958328 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05677490 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05677490 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05677490 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT04322318 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT06172296 | Map |
| WI | Children's Hospital of Wisconsin | Milwaukee53226 | NCT06401330 | Map |
| WI | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee53226 | NCT05365581 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06958328 | Map |
| WI | Medical College Of Wisconsin | Milwaukee53226 | NCT06750094 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04205968 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05677490 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT04205968 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Neillsville | Neillsville54456 | NCT05677490 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT04205968 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05677490 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT06958328 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT04205968 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06998940 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - James Beck Cancer Center | Rhinelander54501 | NCT06958328 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT04205968 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05677490 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT06958328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06998940 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT05677490 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06998940 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05677490 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT04205968 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT05677490 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT06998940 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - Stevens Point | Stevens Point54481 | NCT06958328 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04205968 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05677490 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT06958328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05677490 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06998940 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05677490 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT04205968 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT05677490 | Map |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT06998940 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05677490 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT04205968 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT05677490 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT04205968 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05677490 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT05677490 | Map |
| WI | Aspirus Regional Cancer Center | Wausau54401 | NCT06958328 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT04205968 | Map |
| WI | Marshfield Clinic-Wausau Center | Wausau54401 | NCT05677490 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05677490 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05677490 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT06958328 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04205968 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05677490 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT06958328 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT05677490 | Map |
| WI | Aspirus Cancer Care - Wisconsin Rapids | Wisconsin Rapids54494 | NCT06958328 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT04205968 | Map |
| WI | Marshfield Clinic - Wisconsin Rapids Center | Wisconsin Rapids54494 | NCT05677490 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT05677490 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT06998940 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT04205968 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT05677490 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT06998940 | Map |
Irinotecan clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 3 | 5 | 1 | 2 | 11 | |||||
| P1 | 24 | 10 | 185 | 24 | 3 | 6 | 14 | 266 | ||
| P1/P2 | 29 | 6 | 1 | 53 | 19 | 8 | 12 | 11 | 139 | |
| P2 | 72 | 42 | 1 | 308 | 79 | 16 | 3 | 38 | 125 | 684 |
| P2/P3 | 3 | 2 | 10 | 1 | 4 | 20 | ||||
| P3 | 35 | 18 | 68 | 12 | 1 | 13 | 25 | 172 | ||
| P4 | 2 | 5 | 1 | 5 | 2 | 15 | ||||
| N/A | 11 | 4 | 3 | 4 | 4 | 11 | 37 |
Recruiting Irinotecan clinical trials (257)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | P2 | Neuroblastoma | 62 | Dec 2024 |
| NCT06023641 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | P2 | Rhabdomyosarcoma | 135 | Mar 2024 |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | P1/P2 | Childhood Cancer | 90 | Jul 2024 |
| NCT06541262 | CX-4945Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | P1/P2 | Neuroblastoma | 104 | Oct 2024 |
| NCT07521605 | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer | P2 | Rectal Cancer Patients | 44 | May 2026 |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | P3 | Metastatic Colorectal Carcinoma | 408 | Oct 2023 |
| NCT04221035 | HR-NBL2High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | P3 | High-Risk Neuroblastoma | 800 | Nov 2019 |
| NCT07444918 | Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors | P2 | Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) | 33 | Mar 2026 |
| NCT07570914 | Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | P2 | Colorectal Cancer Liver Metastases (CRLM) | 28 | May 2026 |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer | P2 | Advanced Rectal Cancer | 30 | Nov 2025 |
| NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | P2/P3 | Metastatic Colorectal Cancer (CRC) | 408 | May 2026 |
| NCT06662786 | OrigAMI-2A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | P3 | Colorectal Neoplasms | 1,000 | Oct 2024 |
| NCT01042379 | I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | P2 | Breast Neoplasms | 5,000 | Mar 2010 |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | P1/P2 | Childhood Fibrolamellar Carcinoma | 81 | Jun 2025 |
| NCT05314998 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | P3 | Pancreatic Ductal Adenocarcinoma | 394 | Jan 2025 |
| NCT07490301 | IVA Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma | P2/P3 | Metastatic Pancreatic Ductal Adenocarcinoma | 900 | Apr 2026 |
| NCT07466316 | IR RMSA Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | P3 | Rhabdomyosarcoma | 342 | Jun 2026 |
| NCT07549321 | SHINEA Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients | P2/P3 | High-Risk Neuroblastoma | 144 | Apr 2026 |
| NCT07346157 | PNOC044Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease | P1/P2 | Medulloblastoma | 69 | Jul 2026 |
| NCT07381764 | ROMANCE - GOIMROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" | P2 | Metastatic Colorectal Cancer (CRC) | 150 | Mar 2026 |
| NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | P3 | Metastatic Appendix Carcinoma | 129 | Jul 2026 |
| NCT02813135 | ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | Pediatric Cancer | 472 | Aug 2016 |
| NCT06401330 | FHWTA Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | P3 | Stage I Mixed Cell Type Kidney Wilms Tumor | 1,656 | Apr 2025 |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | P3 | Locally Advanced Pancreatic Adenocarcinoma | 94 | May 2026 |
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | P3 | Intrahepatic Cholangiocarcinoma (Icc) | 138 | Jan 2026 |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | SCLC, Extensive Stage | 100 | Dec 2025 |
| NCT07334301 | BEACON2A Multi-Arm, Platform Trial For Relapsed Neuroblastoma | P1/P2 | Relapsed Neuroblastoma | 160 | Nov 2024 |
| NCT07194044 | METTSEOMetastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | P1 | Metastatic Ewing Sarcoma | 15 | Feb 2026 |
| NCT07389265 | CAPRI-3 GOIMContinuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | P3 | Metastatic Colorectal Cancer (mCRC) | 480 | Oct 2025 |
| NCT05379595 | OrigAMI-1A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | P1/P2 | Advanced or Metastatic Colorectal Cancer | 225 | Jul 2022 |
| NCT06958328 | LAP100Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | P3 | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma | 356 | Aug 2025 |
| NCT07328425 | ISG-TULIPSClinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS | P2 | Desmoplastic Small Round Cell Tumor | 20 | Nov 2025 |
| NCT07096362 | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma | P2 | Metastatic Pancreatic Ductal Adenocarcinoma | 50 | Sep 2025 |
| NCT04625907 | FaR-RMSFaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | P1/P2 | Rhabdomyosarcoma | 1,672 | Sep 2020 |
| NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | P2 | Platinum-resistant Recurrent Ovarian Cancer | 30 | May 2026 |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | P1 | Advanced Solid Tumors | 762 | May 2025 |
| NCT01356290 | MEMMATAntiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors | P2 | Medulloblastoma Recurrent | 232 | Apr 2014 |
| NCT07094893 | ARIEL-ENGICAnti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | P4 | Colorectal Cancer | 280 | Apr 2026 |
| NCT06928584 | Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer | P2 | Locally Recurrent Rectal Cancer | 221 | Mar 2025 |
| NCT07183865 | NOVELTY-RHypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) | P2 | Locally Recurrent Rectal Cancer | 44 | Mar 2025 |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | P2 | Pancreatic Ductal Adenocarcinoma (PDAC) | 45 | Jun 2019 |
| NCT06897644 | PANThEONGemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. | P3 | Pancreatic Adenocarcinoma Advanced or Metastatic | 340 | Mar 2025 |
| NCT07518147 | CLDNA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | P3 | Gastric Cancer | 438 | May 2026 |
| NCT07356973 | OPTICALIrinotecan-ChemoSeed in Surgically Resectable Glioblastoma | P2 | Glioblastoma | 147 | Mar 2026 |
| NCT07417735 | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma | P3 | Locally Advanced/Metastatic/Recurrent ESCC | 436 | Mar 2026 |
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | P3 | Ganglioneuroblastoma, Nodular | 478 | Apr 2024 |
| NCT04861558 | EFFIPECEfficacy of Hyperthermic Intraperitoneal Chemotherapy | P3 | Colorectal Cancer | 213 | May 2021 |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | P2 | Locally Advanced Pancreatic Adenocarcinoma | 25 | Dec 2024 |
| NCT07076212 | Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma | P2 | Metastatic Pancreatic Adenocarcinoma | 52 | Apr 2026 |
| NCT06644781 | ESCCA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | P3 | Esophageal Squamous Cell Carcinoma | 510 | Mar 2025 |
| NCT07325214 | Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer | N/A | Pancreatic Cancer | 136 | Apr 2026 |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | P3 | Pancreatic Cancer | 614 | Feb 2026 |
| NCT07099794 | IIA Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | P2 | Biliary Tract Cancer (BTC) | 90 | Aug 2025 |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | P2 | Lung Cancer | 280 | Feb 2023 |
| NCT06547203 | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study | P2 | Colorectal Cancer Metastatic | 34 | Jul 2024 |
| NCT06528496 | N10N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | P2 | High-risk Neuroblastoma | 45 | Jul 2024 |
| NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | P3 | Esophageal Squamous Cell Carcinoma (ESCC) | 466 | Apr 2026 |
| NCT07397819 | Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy | P1/P2 | Malignant Ascites | 48 | Nov 2025 |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | P1 | Ewing Sarcoma | 411 | Oct 2018 |
| NCT06995872 | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | P1 | Neuroblastoma | 40 | Oct 2025 |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 30 | Nov 2025 |
| NCT06750094 | OrigAMI-3A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | P3 | Colorectal Neoplasms | 700 | Dec 2024 |
| NCT05319730 | MK-3475A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | P1/P2 | Esophageal Squamous Cell Carcinoma | 230 | May 2023 |
| NCT06733038 | AtezoTRIBE2FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | P3 | Colorectal Cancer | 238 | Nov 2024 |
| NCT06571461 | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer | P3 | Pancreatic Cancer | 408 | Sep 2024 |
| NCT06586515 | MOONRAY-01MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | P1 | Pancreatic Ductal Adenocarcinoma | 630 | Sep 2024 |
| NCT07364422 | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | P1/P2 | Gastric Cancer (GC) | 49 | Feb 2026 |
| NCT07395063 | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | P2 | Metastatic Colorectal Cancer (CRC) | 68 | Feb 2026 |
| NCT07085338 | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma | P2 | Neuroblastoma Recurrent | 54 | Nov 2025 |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | P1/P2 | Small-cell Lung Cancer | 42 | Dec 2025 |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | P3 | Colorectal Adenocarcinoma | 560 | May 2025 |
| NCT07595913 | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma | P3 | Neuroendocrine Carcinoma | 240 | Jul 2026 |
| NCT07606599 | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure | P3 | Biliary Tract Cancer | 398 | May 2026 |
| NCT07582315 | PANKU-BTC01A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) | P3 | Biliary Tract Cancer | 538 | May 2026 |
| NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | P3 | Advanced Esophageal Squamous Cell Carcinoma | 440 | Apr 2026 |
| NCT07391566 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | P1/P2 | Metastatic Colorectal Cancer (mCRC) | 99 | Mar 2026 |
| NCT07318831 | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children | P2 | Neuroblastoma (NB) | 27 | Jan 2026 |
| NCT07238283 | IIIrinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer | P3 | First-line Treatment of Metastatic Pancreatic Cancer | 662 | Dec 2025 |
| NCT07474103 | SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC | N/A | Rectal Cancer, Adenocarcinoma | 49 | Nov 2025 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | Pancreatic Cancer | 20 | Sep 2025 |
| NCT04199026 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | N/A | Metastatic Sarcoma | 20 | Feb 2025 |
| NCT06751394 | TRACERPreoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer | P2 | Recurrent Rectal Cancer | 44 | Jan 2025 |
| NCT06006273 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | P1 | Refractory Solid Tumors | 48 | Aug 2023 |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | P1 | Solid Tumor | 681 | Jun 2022 |
| NCT07258147 | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases | P2 | Lung Cancer (SCLC) | 30 | Oct 2026 |
| NCT07059338 | HERBICDual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | P2 | HER2 Positive | 34 | Jul 2025 |
| NCT07235202 | PDACA Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy | P1/P2 | Pancreatic Ductal Adenocarcinoma (PDAC) | 45 | Dec 2025 |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | P2 | Colon Cancer | 124 | Nov 2024 |
| NCT07375563 | NB-NK-2026Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma | P3 | Neuroblastoma (NB) | 5 | Nov 2025 |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | P3 | Advanced Esophageal Adenocarcinoma | 382 | Jan 2023 |
| NCT07150403 | Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Carcinoma (mCRC) | 74 | Dec 2025 |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | P3 | Relapsed Small Cell Lung Cancer | 686 | Mar 2024 |
| NCT05412082 | SMART TNTSMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | P1 | Locally Advanced Rectal Cancer | 25 | Oct 2022 |
| NCT05384821 | MetroWilmsMetronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) | P1/P2 | Wilms Tumor | 28 | Sep 2022 |
| NCT07284134 | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. | P3 | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | 560 | Dec 2025 |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | P1/P2 | Metastatic Pancreatic Ductal Adenocarcinoma | 35 | Feb 2026 |
| NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | P3 | Metastatic Colorectal Cancer (mCRC) | 252 | Oct 2025 |
| NCT06846346 | GRACIETesting Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | P2 | Metastatic Esophageal Adenocarcinoma | 88 | Nov 2025 |
| NCT02885753 | OSCARSystemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | P3 | Colorectal Neoplasms | 348 | Dec 2016 |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | P4 | Small Cell Lung Cancer | 24 | Mar 2024 |
| NCT07123441 | IIA Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | P2 | Colorectal Cancer | 300 | Sep 2025 |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | P2 | Small Cell Lung Cancer | 46 | Jun 2025 |
| NCT06490536 | The Sagittarius Trial | P3 | Colon Cancer Stage II | 700 | Oct 2024 |
| NCT06485739 | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma | P4 | Neuroendocrine Tumors | 20 | Jul 2024 |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | P2 | Small Bowel Adenocarcinoma | 36 | Jun 2025 |
| NCT07543744 | A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI | P1 | Metastatic Colorectal Cancer | 180 | Apr 2025 |
| NCT05004116 | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | P1/P2 | Advanced Cancer | 77 | Aug 2021 |
| NCT07309185 | Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy | P2 | Stomach Neoplasms | 66 | Jul 2024 |
| NCT06361316 | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer | N/A | Pancreatic Cancer | 53 | Apr 2024 |
| NCT05854498 | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 50 | Oct 2023 |
| NCT07051785 | ARKFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | P2 | Colorectal Cancer (CRC) | 68 | Jul 2025 |
| NCT06210971 | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | P2 | Rectal Cancer | 60 | Feb 2024 |
| NCT07150247 | Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer | P2 | BRAF V600 Colorectal Cancer | 20 | Jun 2025 |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | P3 | Relapsed Small Cell Lung Cancer | 180 | Sep 2024 |
| NCT06509126 | IMPROVE-2Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer | P3 | Colorectal Cancer Stage IV | 500 | Jun 2024 |
| NCT06792695 | CANTORA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 120 | Mar 2025 |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | P1 | Advanced Solid Tumor | 132 | Jul 2025 |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | P1 | Gastric Adenocarcinoma | 398 | Jun 2022 |
| NCT06250972 | PTCA199-11Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer | P3 | Pancreatic Adenocarcinoma | 210 | May 2024 |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | P3 | Small Cell Lung Cancer Extensive Stage | 450 | Jun 2025 |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | P2 | Intrahepatic Cholangiocarcinoma (Icc) | 68 | Oct 2024 |
| NCT07062536 | mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line | P2 | Biliary Cancer Metastatic | 130 | Jun 2026 |
| NCT07524374 | IISHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy | P2 | ESCC | 33 | Mar 2026 |
| NCT06649292 | SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | P3 | Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 524 | Nov 2024 |
| NCT07229846 | QL1706A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | P2 | Colorectal Cancer | 30 | Feb 2026 |
| NCT06827717 | IIPhase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma | P2 | Ewing Sarcoma | 29 | Apr 2025 |
| NCT07474727 | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | P2 | Colorectal Cancer | 180 | Apr 2026 |
| NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | P1 | Esophageal Squamous Cell Carcinoma | 12 | Jun 2024 |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | P2 | Solid Tumors | 170 | May 2026 |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | Advanced Esophageal Carcinoma | 63 | Feb 2025 |
| NCT07457775 | Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS | P2 | Soft Tissue Sarcoma (Excluding GIST) | 24 | Mar 2026 |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | P1 | Pancreatic Ductal Adenocarcinoma | 25 | Oct 2025 |
| NCT05694715 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | P1 | Metastatic Solid Tumor | 24 | May 2023 |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | P2 | Recurrent or Metastatic Nasopharyngeal Carcinoma | 208 | Jun 2025 |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | P1 | Colon Adenocarcinoma | 22 | Aug 2021 |
| NCT04329494 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | P1 | Clinical Stage IV Gastric Cancer AJCC v8 | 49 | Aug 2020 |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | P1/P2 | Osteosarcoma | 56 | Mar 2026 |
| NCT07314385 | NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer | P1 | Pancreatic Adenocarcinoma Metastatic | 24 | Jan 2026 |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | P4 | Neuroendocrine Carcinomas (NEC) | 45 | Jun 2025 |
| NCT06820762 | IIIrinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | P2 | SCLC | 40 | Feb 2025 |
| NCT06749691 | LIAESLiposomal Irinotecan and Apatinib in ES-SCLC | P2 | Small Cell Lung Cancer Extensive Stage | 30 | Dec 2024 |
| NCT06513455 | Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | P1/P2 | Pancreatic Cancer | 132 | Sep 2024 |
| NCT06578052 | Irinotecan Liposome in Combination With Capecitabine | N/A | Pancreatic Cancer | 20 | Aug 2024 |
| NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | P2 | Neuroblastoma | 120 | Jun 2023 |
| NCT04211675 | STINGNK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | P1/P2 | Relapsed Neuroblastoma | 31 | Sep 2022 |
| NCT05472259 | NALPACA Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | P2 | Metastatic Pancreatic Ductal Adenocarcinoma | 134 | May 2022 |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | P1/P2 | Advanced Cancer | 442 | Jan 2021 |
| NCT06739928 | IIIrinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | P2 | Small Cell Lung Cancer Extensive Stage | 120 | Jan 2025 |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | P3 | Esophageal Squamous Cell Carcinoma | 490 | Feb 2024 |
| NCT07027748 | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | P1 | Neuroblastoma | 18 | Jun 2025 |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | P1/P2 | Pancreatic Cancer | 96 | Apr 2024 |
| NCT06501664 | Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC | P3 | Esophageal Cancer | 360 | Aug 2024 |
| NCT06894797 | Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. | N/A | Locally Advanced Rectal Cancer | 68 | Apr 2025 |
| NCT06540326 | Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab | P2 | Colorectal Cancer Metastatic | 100 | Nov 2024 |
| NCT06657690 | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC | P2 | Recurrent or Metastatic Nasopharyngeal Carcinoma | 56 | Nov 2024 |
| NCT06499610 | Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer | P4 | Gastric Cancer | 44 | Jul 2024 |
| NCT06365008 | Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer | P2 | Unresectable/Metastatic Gastric Cancer | 40 | Apr 2024 |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | P2 | Gastric Cancer | 224 | Dec 2023 |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | P3 | Hepatoblastoma | 330 | Mar 2021 |
| NCT06478043 | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC | P2 | Extensive-stage Small-cell Lung Cancer | 54 | Sep 2024 |
| NCT05424692 | PTCDrug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer | N/A | Colon Cancer | 200 | Sep 2021 |
| NCT06577376 | A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | P1/P2 | Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | 252 | Aug 2024 |
| NCT07047560 | IILiposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | P2 | Colorectal Cancer (CRC) | 46 | Sep 2024 |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | P2 | Metastatic Small Intestinal Adenocarcinoma | 94 | Jun 2020 |
| NCT07044921 | IIClinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. | P2 | Colorectal Cancer Metastatic | 30 | Sep 2024 |
| NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | P1 | Advanced Microsatellite Stable Colorectal Carcinoma | 30 | Jul 2026 |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | P2 | Anaplastic Kidney Wilms Tumor | 256 | Oct 2020 |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | P2 | Small Cell Lung Cancer | 31 | Jan 2026 |
| NCT07011576 | FRUITFULA Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | P2 | Colon Cancer | 60 | Sep 2025 |
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | P2 | Gastric Cancer | 33 | Aug 2025 |
| NCT07104604 | Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement | P1 | Rectal Cancer | 59 | Aug 2025 |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | P1 | Gastroesophageal Adenocarcinoma | 20 | Jun 2025 |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | P4 | Small Cell Lung Cancer | 31 | Apr 2025 |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | N/A | Small Cell Lung Cancer | 60 | Jul 2024 |
| NCT06123494 | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen | P3 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | 360 | Jan 2024 |
| NCT06714357 | VICTORIAValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer | P2 | Colorectal Cancer Metastatic | 130 | Mar 2025 |
| NCT05391126 | GENOCAREGENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | N/A | Colorectal Cancer | 178 | Sep 2022 |
| NCT04361708 | I-FLOATSafety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | P1 | Pancreatic Adenocarcinoma | 54 | May 2020 |
| NCT05999994 | CAMPFIREA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | P2 | Neoplasms | 105 | Jan 2020 |
| NCT07092306 | NALIRI-VTA Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma | P2 | Ewing's Sarcoma | 74 | Aug 2025 |
| NCT05806931 | SCOTISequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | P2 | Colon Cancer | 50 | May 2023 |
| NCT07441369 | Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | P2 | Liver Metastases From Colorectal Cancer (mCRC) | 16 | May 2026 |
| NCT05669339 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 12 | Dec 2024 |
| NCT06405139 | Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | P2 | Colorectal Cancer | 36 | May 2024 |
| NCT06370754 | FD-IMPACTNewly Emerging Immunotherapy for Pancreatic Cancer Treatment | P1/P2 | Pancreatic Cancer | 117 | Apr 2024 |
| NCT06375473 | MA-PC-RWS-011Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients | — | Pancreatic Cancer | 3,000 | Apr 2024 |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | P1/P2 | Solid Tumor | 10 | Feb 2023 |
| NCT06332950 | IISafety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | P1/P2 | Extensive-stage Small-cell Lung Cancer | 80 | Apr 2024 |
| NCT06210360 | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX | P2 | Pancreatic Cancer | 134 | Feb 2024 |
| NCT06782685 | Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV | P1/P2 | Advanced Pancreatic Cancer (Part 1) | 138 | Jun 2024 |
| NCT05688215 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | P1/P2 | Borderline Resectable Pancreatic Adenocarcinoma | 56 | Mar 2023 |
| NCT06821997 | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial | P2 | Borderline Resectable Pancreatic Ductal Adenocarcinoma | 20 | Mar 2026 |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | P2 | Colorectal Cancer | 173 | Jan 2024 |
| NCT05062317 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | P2 | Liver Metastases | 120 | Apr 2022 |
| NCT04796012 | VITASVITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | P1/P2 | Solid Tumor | 23 | Apr 2023 |
| NCT04689347 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | P1/P2 | Metastatic Colorectal Cancer | 27 | Jan 2021 |
| NCT06656091 | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | P3 | Advanced Oesophageal Squamous Cell Carcinoma | 450 | Oct 2024 |
| NCT06172036 | CAPT-02Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab | P2 | Neoadjuvant Chemotherapy | 180 | Jan 2024 |
| NCT06166589 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | P2 | Previously AG Chemotherapy Treated Pancreatic Cancer | 19 | Jan 2024 |
| NCT07060014 | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | P1 | Advanced Small Intestine Cancer | 22 | Jul 2025 |
| NCT06763029 | VICPROIRIIrinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer | P2 | Colorectal Cancer Metastatic | 36 | Feb 2025 |
| NCT06710821 | Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors | P1 | Solid Tumor Cancer | 40 | Dec 2024 |
| NCT06700603 | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | P2 | Pancreatic Cancer | 48 | Nov 2024 |
| NCT06643793 | IIEvaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC | P2 | Colorectal Neoplasms Malignant | 30 | Nov 2024 |
| NCT06531278 | Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety | P2 | Pancreatic Cancer Metastatic to Liver | 40 | Jul 2024 |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | N/A | Biliary Tract Carcinoma | 30 | Jul 2024 |
| NCT06341296 | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 86 | Jun 2024 |
| NCT06258642 | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | N/A | Small Cell Lung Cancer Recurrent | 39 | Apr 2024 |
| NCT05400603 | Aflac-NBL-2002Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma | P1 | Neuroblastoma | 24 | Nov 2023 |
| NCT05727163 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | P2 | Colorectal Cancer Metastatic | 194 | Jul 2022 |
| NCT04443543 | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer | P2 | Rectal Cancer | 222 | Jun 2020 |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | P2 | Nanoliposomal Irinotecan | 30 | Apr 2024 |
| NCT05962502 | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | P2 | Metastatic Colorectal Cancer | 54 | Aug 2023 |
| NCT05148767 | UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer | P4 | Rectal Cancer Stage III | 606 | Jan 2022 |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | P3 | Esophageal Cancer | 416 | Jan 2021 |
| NCT06340204 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | P1 | Ewing Sarcoma | 44 | Mar 2024 |
| NCT06801730 | NALIRIBVRGIrinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma | P2 | Glioma | 38 | Jan 2025 |
| NCT06394713 | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | P1/P2 | Advanced Malignant Neoplasm | 60 | Jun 2024 |
| NCT06514313 | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. | P2 | Soft Tissue Sarcoma | 110 | Jul 2024 |
| NCT06055179 | XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) | N/A | Xiao Chai Hu Tang | 98 | Mar 2024 |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | P2 | Cholangiocarcinoma | 51 | Aug 2024 |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | P2/P3 | Stomach Cancer | 286 | Apr 2022 |
| NCT06697366 | Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer | P2 | Gastric Cancer | 27 | Nov 2024 |
| NCT06699459 | NICRRBTCIrinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC | P2 | Biliary Tract Carcinoma | 76 | Nov 2024 |
| NCT05462236 | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | P2 | Metastatic Colorectal Cancer | 120 | Apr 2023 |
| NCT06192680 | Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | P2 | Colorectal Cancer | 63 | Apr 2024 |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | P1/P2 | Metastatic Colorectal Cancer | 70 | Oct 2022 |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | Gastric Cancer | 550 | Sep 2020 |
| NCT06769425 | HS-10502HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | P1 | Recurrent Ovarian Cancer | 157 | May 2025 |
| NCT06321081 | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | P2 | RAS Mutation | 60 | Mar 2024 |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | P1/P2 | Metastatic Colorectal Cancer | 20 | Aug 2024 |
| NCT06443307 | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | — | Colorectal Cancer | 933 | Jul 2024 |
| NCT04034173 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | P2 | Treatment Related Cancer | 120 | Aug 2019 |
| NCT05457829 | Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study | P2 | Rhabdomyosarcoma, Child | 88 | Dec 2023 |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | P1/P2 | Colorectal Cancer | 74 | Jun 2024 |
| NCT07056777 | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | P1/P2 | Gastrointestinal Cancer | 186 | Mar 2025 |
| NCT06387810 | undeterminedIrinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer | P2 | Borderline Resectable Pancreatic Cancer | 45 | Apr 2024 |
| NCT05978492 | A Study of TXN10128 in Subjects With Solid Tumors | P1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | 96 | Jul 2023 |
| NCT07542002 | Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study | P2 | Pancreatic Cancer | 37 | Mar 2025 |
| NCT04776655 | LIBImAbStudy in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | P3 | Colorectal Cancer | 280 | Apr 2021 |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study. | P1/P2 | Neuroblastoma | 125 | Aug 2021 |
| NCT06486545 | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | N/A | Advanced Gastric Cancer | 18 | Aug 2024 |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | P2 | Advanced Esophageal Squamous Cell Carcinoma | 138 | Mar 2024 |
| NCT06139211 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | P1/P2 | Advanced Solid Tumor | 186 | Jan 2024 |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | P1/P2 | GEP-NET | 52 | Aug 2025 |
| NCT07204574 | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | P1/P2 | CRC | 40 | May 2025 |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | P2 | Pancreatic Cancer | 87 | Jun 2024 |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | P2 | Pancreatic Ductal Adenocarcinoma | 20 | Dec 2023 |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | P2 | Pancreatic Cancer | 78 | May 2023 |
| NCT05319639 | POFIPhase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | P1/P2 | Gastric Cancer Stage IV | 51 | Feb 2023 |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | P2 | Metastatic Colorectal Cancer | 44 | Mar 2022 |
| NCT06760117 | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors | P1 | Pediatric Solid Tumor | 39 | Jan 2022 |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | P2 | Glioblastoma, Recurrent | 109 | Feb 2020 |
| NCT06766266 | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment | P1 | Non-Muscle Invasive Bladder Urothelial Carcinoma | 18 | Jan 2025 |
| NCT05628038 | TORCH-RThe Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer | P2 | Recurrent Rectal Cancer | 93 | Nov 2022 |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | P1/P2 | Solid Tumor | 300 | Apr 2019 |
Irinotecan clinical trials by indication
Colorectal Cancer (182)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07094893 | ARIEL-ENGIC | P4 | not yet recruiting | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status |
| NCT04861558 | EFFIPEC | P3 | recruiting | Efficacy of Hyperthermic Intraperitoneal Chemotherapy |
| NCT06733038 | AtezoTRIBE2 | P3 | recruiting | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. |
| NCT07123441 | II | P2 | not yet recruiting | A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer |
| NCT07229846 | QL1706 | P2 | not yet recruiting | A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation |
| NCT07474727 | — | P2 | not yet recruiting | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer |
| NCT05391126 | GENOCARE | N/A | recruiting | GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care |
| NCT00492999 | — | P2 | active not recruiting | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver |
| + 174 more, see All trials below. | ||||
Metastatic Colorectal Cancer (89)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04587128 | — | P2 | active not recruiting | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC |
| NCT07559760 | — | P2 | recruiting | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer |
| NCT07543744 | — | P1 | recruiting | A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI |
| NCT05382442 | — | P2 | active not recruiting | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer |
| NCT05854498 | — | P2 | recruiting | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer |
| NCT06792695 | CANTOR | P2 | recruiting | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer |
| NCT04689347 | — | P1/P2 | recruiting | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. |
| NCT06341296 | — | P2 | recruiting | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer |
| + 81 more, see All trials below. | ||||
Pancreatic Cancer (50)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07325214 | — | N/A | not yet recruiting | Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer |
| NCT07409272 | — | P3 | recruiting | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer |
| NCT04927780 | PREOPANC-3 | P3 | active not recruiting | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer |
| NCT06571461 | — | P3 | not yet recruiting | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer |
| NCT07173387 | RAD-NALIRIFOX | P2 | active not recruiting | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer |
| NCT06941857 | — | P2 | recruiting | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer |
| NCT06361316 | — | N/A | recruiting | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer |
| NCT06625320 | RASolute 302 | P3 | active not recruiting | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) |
| + 42 more, see All trials below. | ||||
Gastric Cancer (39)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07518147 | CLDN | P3 | recruiting | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment |
| NCT06499610 | — | P4 | not yet recruiting | Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer |
| NCT06219941 | — | P2 | recruiting | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 |
| NCT07085273 | — | P2 | not yet recruiting | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer |
| NCT04725994 | — | P1/P2 | active not recruiting | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer |
| NCT06697366 | — | P2 | not yet recruiting | Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer |
| NCT06346392 | — | P3 | active not recruiting | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 |
| NCT04342910 | — | P3 | recruiting | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC |
| + 31 more, see All trials below. | ||||
Esophageal Cancer (36)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06501664 | — | P3 | not yet recruiting | Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC |
| NCT04415853 | — | P3 | recruiting | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer |
| NCT03764553 | LyRICX | P2 | active not recruiting | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer |
| NCT00137852 | — | P2 | completed | Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer |
| NCT02358863 | mEGA | N/A | terminated | Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach |
| NCT00394433 | TPCA | P2 | completed | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer |
| NCT00400114 | — | P2 | completed | Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer |
| NCT00524186 | — | P1 | terminated | Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer |
| + 28 more, see All trials below. | ||||
Unspecified Adult Solid Tumor, Protocol Specific (31)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00731276 | — | P1 | completed | Irinotecan in Treating Asian Patients With Solid Tumors |
| NCT00547547 | — | P1 | completed | High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer |
| NCT00005791 | — | P1 | completed | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| NCT00004051 | — | P1 | completed | Irinotecan in Treating Patients With Advanced Solid Tumors |
| NCT00054288 | — | P1 | completed | Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors |
| NCT00112892 | — | P1 | completed | Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors |
| NCT00544063 | — | P1 | unknown | Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer |
| NCT00026195 | — | P1 | completed | Irinotecan in Treating Aging Patients With Solid Tumors |
| + 23 more, see All trials below. | ||||
Lung Cancer (30)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05800587 | — | P2 | recruiting | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer |
| NCT00620269 | — | P2 | unknown | Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III |
| NCT01654081 | — | P2 | withdrawn | A Protocol of Irinotecan for Carcinoma of the Lung |
| NCT00465907 | — | P2 | terminated | Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer |
| NCT00059761 | — | P1 | completed | Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
| NCT00072527 | — | P2 | completed | Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
| NCT00469898 | — | P2 | completed | Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| NCT00045162 | S0124 | P3 | completed | S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer |
| + 22 more, see All trials below. | ||||
Colorectal Neoplasms (28)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06662786 | OrigAMI-2 | P3 | recruiting | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer |
| NCT06750094 | OrigAMI-3 | P3 | recruiting | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy |
| NCT02885753 | OSCAR | P3 | recruiting | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
| NCT05239741 | MK-3475 | P3 | active not recruiting | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) |
| NCT02087475 | — | P3 | unknown | Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin |
| NCT03142516 | OPALO | P2 | completed | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status |
| NCT01930864 | — | P2 | unknown | Metformin Plus Irinotecan for Refractory Colorectal Cancer |
| NCT02842580 | HIGH-LIGHT | P2 | terminated | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer |
| + 20 more, see All trials below. | ||||
Small Cell Lung Cancer (20)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06467786 | — | P4 | recruiting | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer |
| NCT07004712 | — | P2 | not yet recruiting | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer |
| NCT07376499 | — | P2 | not yet recruiting | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction |
| NCT06951841 | — | P4 | not yet recruiting | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction |
| NCT06462105 | — | N/A | not yet recruiting | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer |
| NCT05731518 | ES-SCLC | P1/P2 | unknown | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) |
| NCT05595889 | — | P2 | unknown | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer |
| NCT04985201 | — | P2 | unknown | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy |
| + 12 more, see All trials below. | ||||
Brain and Central Nervous System Tumors (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00099125 | — | P2 | completed | Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| NCT00562419 | — | P2 | unknown | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan |
| NCT00138216 | — | P1 | completed | Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors |
| NCT00003484 | — | P1 | completed | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors |
| NCT00268359 | — | P2 | completed | Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas |
| NCT00352521 | DCE-MRI | P2 | completed | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma |
| NCT00027612 | — | P1/P2 | completed | Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme |
| NCT00003134 | — | P2 | completed | Irinotecan in Treating Patients With Recurrent Glioma |
| + 10 more, see All trials below. | ||||
Neuroblastoma (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06450041 | — | P2 | recruiting | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial |
| NCT06541262 | CX-4945 | P1/P2 | recruiting | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors |
| NCT06995872 | — | P1 | recruiting | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma |
| NCT06013618 | — | P2 | recruiting | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma |
| NCT07027748 | — | P1 | recruiting | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma |
| NCT05400603 | Aflac-NBL-2002 | P1 | recruiting | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma |
| NCT02308527 | BEACON | P2 | completed | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children |
| NCT05027386 | — | P1/P2 | recruiting | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study. |
| + 9 more, see All trials below. | ||||
Colorectal Cancer Metastatic (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06547203 | — | P2 | recruiting | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study |
| NCT06540326 | — | P2 | recruiting | Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab |
| NCT07044921 | II | P2 | recruiting | Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. |
| NCT06714357 | VICTORIA | P2 | recruiting | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer |
| NCT06763029 | VICPROIRI | P2 | recruiting | Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer |
| NCT05727163 | — | P2 | recruiting | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients |
| NCT04595266 | LIVERPEARL | P2 | active not recruiting | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease |
| NCT01910610 | STRATEGIC-1 | P3 | unknown | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer |
| + 9 more, see All trials below. | ||||
Esophageal Squamous Cell Carcinoma (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06644781 | ESCC | P3 | recruiting | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) |
| NCT05319730 | MK-3475 | P1/P2 | recruiting | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) |
| NCT06491134 | — | P1 | not yet recruiting | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma |
| NCT06194734 | — | P3 | recruiting | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer |
| NCT06304974 | — | P3 | active not recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) |
| NCT05461794 | — | P2 | terminated | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma |
| NCT03387904 | — | P2 | unknown | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma |
| NCT03797625 | — | P2 | completed | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas |
| + 5 more, see All trials below. | ||||
Pancreatic Adenocarcinoma (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06250972 | PTCA199-11 | P3 | recruiting | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer |
| NCT04361708 | I-FLOAT | P1 | recruiting | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies |
| NCT04539808 | — | P2 | active not recruiting | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer |
| NCT03483038 | — | P2 | active not recruiting | A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma |
| NCT03528785 | nITRo | P2 | unknown | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer |
| NCT02562716 | S1505 | P2 | completed | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery |
| NCT03665441 | Trybeca-1 | P3 | completed | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC |
| NCT01897454 | — | P2 | terminated | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer |
| + 5 more, see All trials below. | ||||
Glioblastoma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07356973 | OPTICAL | P2 | not yet recruiting | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma |
| NCT01086345 | — | Early P1 | terminated | Radiosurgery Plus Bevacizumab in Glioblastoma |
| NCT00921167 | — | P2 | completed | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas |
| NCT00762255 | — | P1 | completed | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma |
| NCT00597402 | XRT | P2 | completed | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas |
| NCT01308632 | — | P2/P3 | unknown | Metronomic Temozolamide in Patients With Recurrent Glioblastoma |
| NCT00132158 | — | P1 | completed | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors |
| NCT00611728 | — | P1 | completed | Ph I SU011248 + Irinotecan in Treatment of Pts w MG |
| + 3 more, see All trials below. | ||||
Sarcoma (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00077285 | — | P2 | active not recruiting | Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma |
| NCT01189643 | — | Early P1 | active not recruiting | Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor |
| NCT03139331 | — | P1 | completed | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma |
| NCT00354744 | — | P3 | completed | High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma |
| NCT01380275 | DI | P2 | unknown | Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. |
| NCT00996346 | — | P1 | terminated | Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas |
| NCT00509860 | — | P2 | completed | Irinotecan (Camptosar) in Patients With Advanced Sarcomas |
| NCT00003955 | — | P2 | completed | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma |
| + 3 more, see All trials below. | ||||
Metastatic Pancreatic Adenocarcinoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07076212 | — | P2 | recruiting | Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma |
| NCT04233866 | — | P2 | active not recruiting | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread |
| NCT05383352 | SIRACUSA | P1 | completed | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas |
| NCT01959139 | S1313 | P1/P2 | completed | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
| NCT02890355 | — | P2 | completed | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer |
| NCT02620865 | — | P1/P2 | completed | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer |
| NCT02231723 | — | P1 | completed | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer |
| NCT02324543 | GTX | P1/P2 | completed | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer |
| + 2 more, see All trials below. | ||||
Rectal Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06210971 | — | P2 | recruiting | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer |
| NCT07104604 | — | P1 | recruiting | Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement |
| NCT04443543 | — | P2 | not yet recruiting | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer |
| NCT06300489 | — | P1 | unknown | Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer |
| NCT05868317 | — | P2 | unknown | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer |
| NCT01650428 | BACCHUS | P2 | completed | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery |
| NCT00972881 | EXCITE | P1/P2 | completed | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer |
| NCT01269216 | FL | P2 | completed | A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer |
| + 2 more, see All trials below. | ||||
Solid Tumors (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07415031 | — | P2 | recruiting | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies |
| NCT01528046 | — | P1 | completed | Metformin in Children With Relapsed or Refractory Solid Tumors |
| NCT03503604 | — | P1 | unknown | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors |
| NCT01634555 | IMC-1121B | P2 | completed | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI |
| NCT01593228 | — | P3 | completed | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial |
| NCT02395068 | — | P1 | unknown | Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors |
| NCT01009073 | — | P1 | completed | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects |
| NCT00186979 | — | P1 | completed | Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors |
| + 1 more, see All trials below. | ||||
Colon Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06652412 | — | P2 | not yet recruiting | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC |
| NCT05722327 | MRTX849 | P1 | active not recruiting | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer |
| NCT05424692 | PTC | N/A | recruiting | Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer |
| NCT07011576 | FRUITFUL | P2 | recruiting | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) |
| NCT05806931 | SCOTI | P2 | recruiting | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer |
| NCT02138617 | — | P2 | completed | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer |
| NCT00766220 | — | P2 | withdrawn | Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver |
| NCT00336856 | — | P2 | completed | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy |
| + 1 more, see All trials below. | ||||
Advanced Solid Tumors (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06963502 | — | P1 | not yet recruiting | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors |
| NCT05083481 | — | P1/P2 | terminated | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors |
| NCT02611024 | — | P1/P2 | completed | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors |
| NCT05824455 | JS109 | P1/P2 | terminated | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors |
| NCT05086848 | — | P1 | completed | A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors |
| NCT05086822 | — | P1 | completed | A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors |
| NCT01520389 | — | P1 | completed | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment |
| NCT00861328 | — | P1 | completed | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin |
| + 1 more, see All trials below. | ||||
Neoplasms (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06967155 | — | P2 | active not recruiting | A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer |
| NCT04607421 | — | P3 | active not recruiting | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer |
| NCT05999994 | CAMPFIRE | P2 | recruiting | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer |
| NCT02720068 | MK-4280 | P1 | completed | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) |
| NCT00811993 | — | P1 | terminated | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors |
| NCT00954512 | — | P1/P2 | terminated | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) |
| NCT00960063 | — | P1 | terminated | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) |
| NCT00057473 | — | P2 | completed | A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors |
| + 1 more, see All trials below. | ||||
Stomach Neoplasms (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07309185 | — | P2 | recruiting | Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy |
| NCT04393584 | RusGCG-01 | P2/P3 | unknown | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma |
| NCT03061058 | — | P3 | unknown | Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC |
| NCT01928290 | FOLFIRINOX | P2 | completed | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer |
| NCT03400592 | NIEGA | P2 | unknown | Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma |
| NCT02662959 | — | P2 | unknown | Irinotecan as 3rd Line Therapy in Gastric Cancer |
| NCT00813072 | — | P2 | completed | Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT00512681 | TIROX2 | P2 | completed | A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer |
| + 1 more, see All trials below. | ||||
Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03678883 | — | P2 | active not recruiting | 9-ING-41 in Patients With Advanced Cancers |
| NCT03368859 | — | P2 | terminated | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab |
| NCT01653470 | — | P1 | completed | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors |
| NCT00418938 | — | P2 | completed | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial |
| NCT00060567 | — | P1 | completed | Dose-Finding Study of E7070 in Combination With Irinotecan |
| NCT00364143 | — | P1 | completed | Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors |
| NCT00110357 | — | P1 | completed | Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
| NCT00062842 | — | P1 | completed | Study of Irinotecan on a Weekly Schedule in Children |
| + 1 more, see All trials below. | ||||
Breast Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03562390 | — | P2 | unknown | Irinotecan for Advanced and Metastatic Breast Cancer |
| NCT00617539 | — | P2 | completed | Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases |
| NCT00693719 | — | P2 | completed | Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer |
| NCT00303992 | — | P2 | completed | Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer |
| NCT00079118 | — | P2 | completed | Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer |
| NCT00275041 | — | P2 | completed | Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer |
| NCT00003351 | — | P2 | completed | Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer |
| NCT00083148 | — | P1 | completed | Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer |
| + 1 more, see All trials below. | ||||
Biliary Tract Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07606599 | — | P3 | not yet recruiting | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure |
| NCT07582315 | PANKU-BTC01 | P3 | not yet recruiting | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) |
| NCT03785873 | — | P1/P2 | completed | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer |
| NCT03778593 | — | P2 | completed | FOLFIRINOX for 2nd-line Treatment of BTC |
| NCT02720601 | — | P2 | withdrawn | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers |
| NCT03110510 | BTC | P2 | withdrawn | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study |
| NCT01494363 | — | P2 | unknown | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
| NCT00832689 | — | P2 | completed | Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer |
Pancreatic Ductal Adenocarcinoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05314998 | — | P3 | not yet recruiting | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature |
| NCT06607185 | — | P1 | active not recruiting | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors |
| NCT06586515 | MOONRAY-01 | P1 | recruiting | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors |
| NCT07024615 | — | P1 | recruiting | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer |
| NCT06467565 | — | P2 | recruiting | NALIRIFOX as Induction Therapy in LAPC |
| NCT05546853 | LAP-NET1 | P1 | completed | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma |
| NCT04752696 | — | P2 | completed | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT03316326 | — | P2 | unknown | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer |
Ewing Sarcoma (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03715933 | — | P1 | recruiting | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas |
| NCT06827717 | II | P2 | recruiting | Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma |
| NCT06340204 | — | P1 | recruiting | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma |
| NCT01858168 | — | P1 | completed | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma |
| NCT03709680 | — | P2 | active not recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors |
| NCT04067115 | U01CA236220 | P1/P2 | completed | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients |
| NCT03495921 | VITA | P3 | terminated | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide |
| NCT02044120 | — | P1 | completed | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma |
Locally Advanced Rectal Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05412082 | SMART TNT | P1 | recruiting | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer |
| NCT05253846 | ShorTrip | P2 | active not recruiting | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 |
| NCT06894797 | — | N/A | recruiting | Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. |
| NCT02605265 | CinClare | P3 | completed | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 |
| NCT04411537 | — | P2 | unknown | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer |
| NCT04411524 | — | P2 | unknown | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer |
| NCT04394598 | — | P2 | unknown | A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer |
| NCT03702985 | — | P2 | unknown | Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer |
Solid Tumor (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05382559 | — | P1 | recruiting | A Study of ASP3082 in Adults With Advanced Solid Tumors |
| NCT05381038 | — | P1/P2 | recruiting | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI |
| NCT04796012 | VITAS | P1/P2 | recruiting | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors |
| NCT03872947 | — | P1 | active not recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors |
| NCT03866525 | — | P1/P2 | recruiting | OH2 Oncolytic Viral Therapy in Solid Tumors |
| NCT04569916 | — | P2 | unknown | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors |
| NCT00786669 | VITAC | P1 | completed | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors |
| NCT00215501 | — | P1 | completed | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies |
Advanced Solid Tumor (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06974110 | — | P1 | recruiting | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors |
| NCT06139211 | — | P1/P2 | recruiting | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
| NCT06509906 | — | P1 | terminated | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) |
| NCT05148195 | — | P2 | terminated | A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors |
| NCT04088604 | LY01610 | P1 | completed | Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors |
| NCT02157792 | — | P1 | completed | M6620 First in Human Study |
| NCT00502567 | — | P1 | completed | A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors |
Metastatic Pancreatic Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06532344 | — | P1 | active not recruiting | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer |
| NCT04753879 | — | P2 | active not recruiting | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
| NCT06538207 | — | P1 | completed | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer |
| NCT03693677 | FUNGEMAX | P2 | completed | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI |
| NCT05363007 | SINAI | P2 | unknown | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma |
| NCT03487016 | FOOTPATH | P2 | unknown | First-line Therapy in Metastatic PDAC |
| NCT04101929 | — | P2 | unknown | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen |
Advanced Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05004116 | — | P1/P2 | recruiting | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer |
| NCT04657068 | — | P1/P2 | recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors |
| NCT04943627 | BRAVA | P3 | withdrawn | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) |
| NCT02331251 | — | P1/P2 | terminated | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
| NCT02423954 | NivoPlus | P1/P2 | terminated | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) |
| NCT00708773 | — | P1 | completed | Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors |
| NCT01347866 | — | P1 | terminated | Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer |
Advanced Colorectal Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929652 | — | P1/P2 | unknown | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer |
| NCT04324476 | — | P2 | unknown | A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer |
| NCT03126071 | — | P2 | unknown | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer |
| NCT04337879 | — | P1/P2 | unknown | A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer |
| NCT01859858 | — | P1 | completed | Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors |
| NCT00637091 | EGFR | P2 | completed | Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions |
| NCT00312000 | — | P3 | completed | Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma |
Colorectal Carcinoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04988191 | — | P1/P2 | unknown | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer |
| NCT02376452 | — | P2 | unknown | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients |
| NCT02935764 | — | P3 | unknown | FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients |
| NCT01394939 | — | P1/P2 | completed | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma |
| NCT01286818 | FOLFIRI | P1 | completed | A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) |
| NCT00361244 | — | P1/P2 | terminated | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer |
| NCT00176774 | — | P2 | completed | Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma |
Glioblastoma Multiforme (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03119064 | 329 | P1/P2 | terminated | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma |
| NCT02060955 | — | P2 | terminated | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan |
| NCT00967330 | — | P2 | completed | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma |
| NCT00979017 | — | P2 | completed | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme |
| NCT00817284 | GBM | P2 | completed | Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) |
| NCT00984438 | BCNU | P1/P2 | withdrawn | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme |
Adenocarcinoma of the Gastroesophageal Junction (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01498289 | S1201 | P2 | completed | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer |
| NCT02485834 | — | P2 | terminated | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer |
| NCT00991952 | — | P2 | completed | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery |
| NCT00061932 | — | P2 | completed | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach |
| NCT00084617 | — | P2 | completed | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
| NCT00084604 | — | P2 | completed | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
Adenocarcinoma of the Colon (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02046538 | — | P2 | withdrawn | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer |
| NCT00079274 | — | P3 | completed | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer |
| NCT00551421 | — | P1/P2 | completed | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer |
| NCT00052585 | — | P2 | terminated | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer |
| NCT00005818 | — | P1/P2 | completed | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer |
| NCT00003835 | — | P3 | completed | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer |
Unspecified Childhood Solid Tumor, Protocol Specific (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01141244 | — | P1 | completed | Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
| NCT00008424 | — | P1 | completed | Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants |
| NCT00006095 | — | P1 | completed | Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy |
| NCT00016861 | — | P1 | completed | Irinotecan in Treating Children With Refractory or Progressive Solid Tumors |
| NCT00024284 | — | P1 | completed | Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors |
| NCT00004919 | — | P1 | completed | Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy |
Metastatic Colorectal Cancer (mCRC) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07389265 | CAPRI-3 GOIM | P3 | recruiting | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer |
| NCT07391566 | — | P1/P2 | not yet recruiting | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation |
| NCT07134205 | — | P3 | not yet recruiting | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer |
| NCT03829462 | NEXT-REGIRI | P3 | active not recruiting | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients |
| NCT06089330 | — | P2 | unknown | A Study of JMT101 in Patients With Metastatic Colorectal Cancer |
Colorectal Adenocarcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06951503 | — | P3 | recruiting | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer |
| NCT04094688 | SOLARIS | P3 | active not recruiting | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer |
| NCT03368963 | — | P1/P2 | active not recruiting | TAS102 in Combination With NAL-IRI in Advanced GI Cancers |
| NCT03369041 | — | N/A | unknown | Study of the Practice of Debiri in France |
| NCT02292758 | — | P2 | completed | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery |
Relapsed Small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06128837 | — | P3 | recruiting | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer |
| NCT06496048 | — | P3 | recruiting | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC |
| NCT04543916 | — | P1/P2 | withdrawn | Venetoclax and Irinotecan in Relapsed/Refractory SCLC |
| NCT05153239 | LAGOON | P3 | completed | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) |
| NCT04757779 | — | P2 | unknown | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer |
Gastric Adenocarcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04581473 | — | P1/P2 | active not recruiting | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
| NCT05365581 | — | P1 | recruiting | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer |
| NCT03141034 | — | P2 | completed | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma |
| NCT04074343 | — | P1 | completed | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma |
| NCT00062374 | — | P2 | completed | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction |
Liver Metastases (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05062317 | — | P2 | recruiting | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases |
| NCT02110953 | — | P1 | terminated | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver |
| NCT01631539 | — | N/A | withdrawn | Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC |
| NCT01320683 | — | P2 | terminated | Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer |
| NCT01285102 | — | P1 | terminated | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer |
Recurrent Colon Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01941173 | — | N/A | withdrawn | Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy |
| NCT01205022 | — | P1 | completed | Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
| NCT00499369 | — | P3 | terminated | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy |
| NCT00134069 | — | P1 | completed | Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer |
| NCT00077298 | — | P2 | completed | Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer |
Rhabdomyosarcoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06023641 | — | P2 | recruiting | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease |
| NCT07466316 | IR RMS | P3 | not yet recruiting | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) |
| NCT04625907 | FaR-RMS | P1/P2 | recruiting | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma |
| NCT01871766 | — | P2 | active not recruiting | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
Metastatic Pancreatic Ductal Adenocarcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07490301 | IV | P2/P3 | recruiting | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT07096362 | — | P2 | recruiting | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT07214298 | — | P1/P2 | recruiting | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT05472259 | NALPAC | P2 | recruiting | A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) |
Small-cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155200 | — | P1/P2 | recruiting | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) |
| NCT05049863 | — | P1 | terminated | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) |
| NCT04173325 | — | P1 | terminated | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer |
| NCT03613753 | — | P2 | unknown | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer |
Pancreatic Neoplasms (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06538623 | HAIC | P2 | completed | Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer |
| NCT02558868 | — | P2 | completed | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer |
| NCT01413022 | — | P1 | completed | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
| NCT00220649 | — | P1 | completed | Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas |
Small Cell Lung Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04453930 | — | P2 | unknown | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy(Irinotecan Plus Platinum)and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer(SCLC) |
| NCT01941316 | — | P1/P2 | completed | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients |
| NCT01977235 | TDICC | P2 | unknown | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer |
| NCT00143455 | R | P3 | completed | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer |
Liver Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03668418 | xenoZ | N/A | unknown | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos |
| NCT00980239 | — | P1 | completed | HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver |
| NCT00087282 | — | P2 | completed | Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer |
| NCT00287976 | — | P2 | unknown | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma |
Esophageal Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03933449 | MK-3475 | P3 | completed | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study |
| NCT02564263 | MK-3475 | P3 | completed | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) |
| NCT03099382 | — | P3 | completed | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer |
| NCT00590031 | — | P2 | completed | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. |
Stomach Neoplasm (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02527785 | — | P2 | completed | Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer |
| NCT00509964 | — | P2 | unknown | Second-Line Irinotecan vs. ILF for AGC |
| NCT00320294 | — | P2 | unknown | ILF With/Without Cisplatin for Advanced Gastric Cancer |
| NCT00144378 | — | P3 | completed | Irinotecan Versus Only Best Supportive Care for Gastric Cancer |
Acinar Cell Adenocarcinoma of the Pancreas (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02047474 | — | P2 | completed | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer |
| NCT01835041 | — | P1 | completed | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer |
| NCT01643499 | — | P1 | completed | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies |
| NCT01821612 | — | Early P1 | completed | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer |
Metastatic Colorectal Cancer (CRC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07585279 | — | P2/P3 | not yet recruiting | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer |
| NCT07381764 | ROMANCE - GOIM | P2 | not yet recruiting | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" |
| NCT07395063 | — | P2 | not yet recruiting | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. |
Advanced Esophageal Squamous Cell Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07487896 | — | P3 | not yet recruiting | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy |
| NCT05818982 | — | P2 | unknown | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC |
| NCT06512428 | — | P2 | recruiting | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma |
Esophageal Squamous Cell Carcinoma (ESCC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07463573 | — | P3 | recruiting | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma |
| NCT05342636 | MK-3475 | P1/P2 | completed | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) |
| NCT03430843 | BGB-A317 | P3 | completed | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma |
Neuroblastoma (NB) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07318831 | — | P2 | recruiting | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children |
| NCT07375563 | NB-NK-2026 | P3 | recruiting | Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma |
| NCT03189706 | — | Early P1 | active not recruiting | Study of Chemoimmunotherapy for High-Risk Neuroblastoma |
Pancreatic Ductal Adenocarcinoma (PDAC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03977233 | — | P2 | recruiting | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer |
| NCT07235202 | PDAC | P1/P2 | recruiting | A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy |
| NCT02782182 | — | P1 | terminated | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study |
Neuroblastoma Recurrent (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07085338 | — | P2 | recruiting | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma |
| NCT04560166 | — | P2 | terminated | Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma |
| NCT01467986 | RIST-rNB-2011 | P2 | completed | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma |
Colorectal Cancer (CRC) (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07051785 | ARK | P2 | not yet recruiting | Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer |
| NCT07047560 | II | P2 | recruiting | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study |
| NCT00851045 | — | P2 | completed | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer |
Small Cell Lung Cancer Extensive Stage (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06954246 | — | P3 | recruiting | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
| NCT06749691 | LIAES | P2 | recruiting | Liposomal Irinotecan and Apatinib in ES-SCLC |
| NCT06739928 | II | P2 | recruiting | Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC |
Biliary Tract Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06463548 | — | N/A | not yet recruiting | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma |
| NCT06699459 | NICRRBTC | P2 | not yet recruiting | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC |
| NCT06430827 | — | P2 | unknown | Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma |
Advanced Gastric Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06486545 | — | N/A | not yet recruiting | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer |
| NCT01084330 | — | P2 | completed | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer |
| NCT01136031 | TI-2ndAGC | P1/P2 | completed | Paclitaxel and Irinotecan in Advanced Gastric Cancer |
Cervical Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06459180 | MK-2870 | P3 | active not recruiting | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) |
| NCT04697628 | innovaTV 301 | P3 | completed | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer |
| NCT00106262 | — | P2 | terminated | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer |
Colo-rectal Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06011772 | — | Early P1 | active not recruiting | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer |
| NCT03493061 | — | P2 | completed | A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM |
| NCT03545711 | — | P1/P2 | unknown | Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer |
Metastatic Colorectal Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05863195 | — | P3 | recruiting | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial |
| NCT02595931 | — | P1 | active not recruiting | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
| NCT03290937 | — | P1 | completed | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer |
Borderline Resectable Pancreatic Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05688215 | — | P1/P2 | recruiting | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
| NCT04481204 | — | P2 | withdrawn | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study |
| NCT03970252 | — | Early P1 | completed | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer |
Rectal Neoplasms (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06417476 | — | P2 | active not recruiting | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer |
| NCT01609231 | MK-0646-025 | P2 | terminated | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) |
| NCT00506844 | ERBIRIX | P2 | unknown | Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer |
Pancreas Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04141995 | — | P2 | terminated | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer |
| NCT05417386 | — | P1 | terminated | FOLFIRINOX + NIS793 in Pancreatic Cancer |
| NCT02021422 | — | P1 | completed | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy |
Stomach Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05427383 | — | P2/P3 | recruiting | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy |
| NCT04486651 | — | P3 | unknown | HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
| NCT04770623 | — | P2 | completed | Docetaxel and Irinotecan in Gastric Cancer |
Colon Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04920032 | — | P1 | recruiting | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas |
| NCT03365882 | S1613 | P2 | completed | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery |
| NCT02575508 | — | P1/P2 | withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer |
Advanced Pancreatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04796948 | — | P1 | completed | A Study of Irinotecan Liposome in Advanced Pancreatic Cancer |
| NCT03336216 | — | P2 | completed | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer |
| NCT04482257 | — | P1 | unknown | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. |
Metastatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04641871 | — | P1 | completed | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies |
| NCT02049593 | — | P1 | completed | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
| NCT03009058 | MODULATE | P1/P2 | terminated | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer |
Recurrent Colorectal Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03823079 | — | P2 | unknown | Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia |
| NCT02508077 | — | P2 | terminated | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer |
| NCT00545545 | — | P1/P2 | completed | Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma |
Neoplasm Metastasis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02677116 | — | P1 | completed | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer |
| NCT00433927 | FOLFIRI | P3 | unknown | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) |
| NCT00037180 | — | P2 | terminated | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy |
Mucinous Adenocarcinoma of the Colon (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01814501 | — | P2 | completed | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab |
| NCT01923337 | — | P1 | completed | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer |
| NCT00005036 | — | P3 | completed | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
Head and Neck Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00040807 | — | P2 | completed | Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer |
| NCT00100828 | — | P2 | terminated | Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer |
| NCT00639769 | — | P2 | completed | Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
Carcinoma of Unknown Primary (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00066781 | — | P2 | completed | Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary |
| NCT00004005 | — | P2 | completed | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin |
| NCT00004922 | — | P2 | completed | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors |
Bladder Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00066612 | S0306 | P2 | completed | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy |
| NCT00089128 | — | P2 | terminated | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer |
| NCT00004095 | — | P1 | completed | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors |
Neuroendocrine Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07595913 | — | P3 | not yet recruiting | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma |
| NCT03168594 | IP | P2 | terminated | Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma |
Biliary Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07062536 | — | P2 | not yet recruiting | mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line |
| NCT03464968 | — | P2 | completed | mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line |
Locally Advanced Pancreatic Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06998940 | — | P3 | recruiting | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations |
| NCT06381154 | — | P2 | recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer |
High-Risk Neuroblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04221035 | HR-NBL2 | P3 | recruiting | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) |
| NCT07549321 | SHINE | P2/P3 | recruiting | A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients |
Metastatic Ewing Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07194044 | METTSEO | P1 | recruiting | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes |
| NCT05042934 | — | P1/P2 | withdrawn | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma |
Intrahepatic Cholangiocarcinoma (Icc) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07328919 | — | P3 | not yet recruiting | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations |
| NCT06648525 | — | P2 | not yet recruiting | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC |
Desmoplastic Small Round Cell Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07328425 | ISG-TULIPS | P2 | recruiting | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS |
| NCT04095221 | — | P1/P2 | completed | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma |
Ewing's Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07092306 | NALIRI-VT | P2 | not yet recruiting | A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma |
| NCT02511132 | — | P2 | completed | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma |
Recurrent or Metastatic Nasopharyngeal Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07070479 | — | P2 | recruiting | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial |
| NCT06657690 | — | P2 | recruiting | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC |
Gastrointestinal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07056777 | — | P1/P2 | recruiting | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer |
| NCT00353015 | — | P2 | completed | Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract |
Locally Recurrent Rectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06928584 | — | P2 | recruiting | Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer |
| NCT07183865 | NOVELTY-R | P2 | recruiting | Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) |
Glioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06801730 | NALIRIBVRG | P2 | recruiting | Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma |
| NCT00404495 | — | P2 | completed | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. |
Recurrent Rectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06751394 | TRACER | P2 | not yet recruiting | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer |
| NCT05628038 | TORCH-R | P2 | recruiting | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer |
Relapsed Neuroblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07334301 | BEACON2 | P1/P2 | recruiting | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma |
| NCT04211675 | STING | P1/P2 | recruiting | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab |
Colorectal Neoplasms Malignant (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06643793 | II | P2 | recruiting | Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC |
| NCT05278351 | — | P2 | unknown | Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC |
Extensive-stage Small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06478043 | — | P2 | not yet recruiting | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC |
| NCT06332950 | II | P1/P2 | not yet recruiting | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy |
Cholangiocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06438822 | — | P2 | recruiting | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma |
| NCT04059562 | TRITICC | P2 | completed | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma |
Metastatic Adenocarcinoma of the Pancreas (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06225999 | — | P2 | completed | Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas |
| NCT04083235 | NAPOLI 3 | P3 | completed | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment |
Ganglioneuroblastoma, Nodular (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06172296 | — | P3 | recruiting | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma |
| NCT04385277 | GM-CSF | P2 | active not recruiting | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) |
Borderline Resectable Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06387810 | undetermined | P2 | recruiting | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer |
| NCT06345300 | — | P2 | unknown | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study |
Unresectable Metastatic Colorectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06107413 | IV | P2 | active not recruiting | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
| NCT04160416 | TRICAP | P2 | unknown | mXELOXIRI Combined With Molecular Targeted Drug in mCRC |
Refractory Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06006273 | — | P1 | recruiting | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors |
| NCT03810742 | — | P1 | completed | Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors |
Pediatric Solid Tumor (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06760117 | — | P1 | recruiting | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors |
| NCT05620862 | — | P1 | active not recruiting | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors |
Small Cell Lung Cancer (SCLC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05027100 | — | N/A | unknown | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC |
| NCT04727853 | SCLC | P2 | completed | Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) |
Advanced Biliary Tract Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04005339 | NAPOLI-2 | P2 | active not recruiting | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer |
| NCT05009953 | — | P2 | terminated | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer |
Advanced Colorectal Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04535401 | — | P1 | unknown | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines |
| NCT04109924 | TAS-102 | P2 | completed | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study |
Hepatoblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03017326 | PHITT | P3 | active not recruiting | Paediatric Hepatic International Tumour Trial |
| NCT04478292 | — | P3 | recruiting | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy |
Oncology (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03837977 | NET02 | P2 | completed | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma |
| NCT04299880 | — | P1 | completed | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols |
Treatment Related Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04034173 | — | P2 | not yet recruiting | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation |
| NCT05217069 | — | P2 | completed | FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC |
Adenocarcinoma of the Stomach (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03722108 | REGIRI | P1/P2 | terminated | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas |
| NCT01640782 | ITACA-S | P3 | completed | Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach |
Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03535727 | — | P1/P2 | completed | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer |
| NCT00183859 | — | P1 | completed | Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan |
Previously Treated Metastatic Colorectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03522649 | GB201 | P3 | unknown | A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer |
| NCT01896856 | — | P1/P2 | completed | Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer |
Breast Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03328884 | Phenomenal | P2 | completed | Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients |
| NCT00532714 | — | P2 | completed | Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC |
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03045770 | — | N/A | unknown | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA |
| NCT03030937 | — | P2 | unknown | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA |
Pediatric Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02747537 | — | P2 | withdrawn | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan |
| NCT00990912 | — | P1/P2 | completed | A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) |
Advanced Malignant Solid Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02419495 | KPT-330 | P1 | terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies |
| NCT00576654 | — | P1 | completed | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery |
Esophageal Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02319187 | — | P3 | unknown | Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial |
| NCT00213486 | — | P2 | completed | Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial |
Colorectal Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02244632 | — | P1/P2 | completed | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer |
| NCT00506207 | TIROX | P1 | unknown | A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy |
Biliary Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01859728 | GAMBIT | P2 | unknown | GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer |
| NCT00948935 | — | P2 | completed | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma |
Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01607554 | — | P1/P2 | terminated | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer |
| NCT00264134 | — | P1/P2 | terminated | Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer |
Stage IV Colorectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01271582 | — | P4 | unknown | Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients |
| NCT01550510 | — | P1/P2 | terminated | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA |
Metastatic Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00248287 | CA225200 | P2 | active not recruiting | PhII ICb With/Without Erbitux in MBC Pts |
| NCT01501669 | PROCEED | P3 | unknown | Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer |
Refractory Solid Tumors in Children (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00993044 | VIT-B | P1 | completed | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin |
| NCT01282697 | RAPIRI | P1 | completed | Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors |
Breast Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01042379 | I-SPY | P2 | recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
| NCT00072852 | — | P2 | completed | Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine |
Adult Rhabdomyosarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00354835 | — | P3 | completed | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma |
| NCT01055314 | — | P2 | completed | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma |
Advanced Solid Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00986843 | — | P1 | completed | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) |
| NCT00979563 | Oratecan-101 | P1 | completed | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies |
Anal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00654160 | — | P1 | completed | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer |
| NCT00003427 | — | P1 | completed | Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer |
Malignant Gliomas (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00671801 | — | P1 | terminated | Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I |
| NCT00463073 | — | P2 | completed | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas |
Carcinoma, Small Cell Lung (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00308529 | — | P2 | completed | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer |
| NCT00294931 | — | P2 | completed | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer |
Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00240097 | SCLC | P2 | completed | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) |
| NCT00319800 | — | P2 | unknown | Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC |
Extensive Stage Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00057837 | — | P2 | completed | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
| NCT00118235 | — | P2 | completed | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer |
Kidney Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00089102 | — | P2 | terminated | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer |
| NCT00401128 | — | P2 | completed | Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer |
Fallopian Tube Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00053833 | — | P2 | terminated | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00003345 | — | P2 | completed | Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
Carcinoma, Non-Small-Cell Lung (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00139711 | — | P2 | completed | Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer |
| NCT00819728 | CPT-11 | P2 | completed | Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer |
Upper Gastrointestinal Tumours (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00220064 | — | P2 | completed | A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours |
| NCT00220168 | — | P4 | completed | Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours |
Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00005626 | — | P2 | completed | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) |
| NCT00053144 | — | P1 | completed | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia |
Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00003368 | — | P1 | completed | Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis |
| NCT00003245 | — | P2 | completed | Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma |
Lung Cancer (SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07258147 | — | P2 | not yet recruiting | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases |
Advanced Microsatellite Stable Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07363408 | — | P1 | not yet recruiting | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer |
Metastatic Appendix Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07271355 | — | P3 | not yet recruiting | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial |
Colorectal Cancer Liver Metastases (CRLM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07570914 | — | P2 | not yet recruiting | Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases |
Platinum-resistant Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07591831 | — | P2 | not yet recruiting | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer |
Rectal Cancer Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07521605 | — | P2 | not yet recruiting | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer |
Liver Metastases From Colorectal Cancer (mCRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07441369 | — | P2 | enrolling by invitation | Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer |
Soft Tissue Sarcoma (Excluding GIST) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07457775 | — | P2 | not yet recruiting | Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS |
Locally Advanced/Metastatic/Recurrent ESCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07417735 | — | P3 | not yet recruiting | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma |
ESCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07524374 | II | P2 | not yet recruiting | SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy |
Osteosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07479732 | — | P1/P2 | recruiting | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma |
Borderline Resectable Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06821997 | — | P2 | recruiting | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial |
Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07346157 | PNOC044 | P1/P2 | not yet recruiting | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease |
Relapsed or Refractory Pediatric Malignant Solid Tumors (Including Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07444918 | — | P2 | not yet recruiting | Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors |
Gastric Cancer (GC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07364422 | — | P1/P2 | not yet recruiting | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer |
Pancreatic Adenocarcinoma Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07314385 | — | P1 | not yet recruiting | NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer |
Metastatic Colorectal Carcinoma (mCRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07150403 | — | P2 | not yet recruiting | Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer |
SCLC, Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07141771 | — | P1/P2 | not yet recruiting | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07284134 | — | P3 | recruiting | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. |
First-line Treatment of Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07238283 | II | P3 | recruiting | Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer |
Rectal Cancer, Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07474103 | — | N/A | recruiting | SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC |
Malignant Ascites (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07397819 | — | P1/P2 | recruiting | Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy |
Metastatic Esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06846346 | GRACIE | P2 | recruiting | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma |
CIC-Rearranged Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06820957 | — | P2/P3 | active not recruiting | Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body |
Advanced Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07281157 | — | P2 | recruiting | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer |
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06958328 | LAP100 | P3 | recruiting | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer |
GEP-NET (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05385861 | — | P1/P2 | enrolling by invitation | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET |
Biliary Tract Cancer (BTC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07099794 | II | P2 | not yet recruiting | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen |
Advanced Small Intestine Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07060014 | — | P1 | not yet recruiting | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers |
HER2 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07059338 | HERBIC | P2 | not yet recruiting | Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer |
Small Bowel Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06835387 | — | P2 | recruiting | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors |
Gastroesophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05733689 | — | P1 | recruiting | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) |
Neuroendocrine Carcinomas (NEC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07014540 | — | P4 | not yet recruiting | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma |
Childhood Fibrolamellar Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06620302 | — | P1/P2 | recruiting | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma |
BRAF V600 Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07150247 | — | P2 | recruiting | Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer |
CRC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07204574 | — | P1/P2 | recruiting | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer |
Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06769425 | HS-10502 | P1 | recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors |
Stage I Mixed Cell Type Kidney Wilms Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06401330 | FHWT | P3 | recruiting | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) |
Pancreatic Adenocarcinoma Advanced or Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06897644 | PANThEON | P3 | recruiting | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. |
Solid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06771622 | — | P1/P2 | active not recruiting | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors |
Metastatic Gastro-esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06680622 | — | P2 | active not recruiting | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06820762 | II | P2 | not yet recruiting | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study |
Metastatic Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04199026 | — | N/A | recruiting | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma |
Advanced Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06745193 | — | P2 | not yet recruiting | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer |
Non-Muscle Invasive Bladder Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06766266 | — | P1 | recruiting | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669339 | — | P2 | recruiting | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma |
Solid Tumor Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06710821 | — | P1 | not yet recruiting | Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors |
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06649292 | — | P3 | recruiting | SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
Advanced Oesophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06656091 | — | P3 | not yet recruiting | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma |
Colon Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06490536 | — | P3 | recruiting | The Sagittarius Trial |
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06577376 | — | P1/P2 | not yet recruiting | A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
High-risk Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06528496 | N10 | P2 | recruiting | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma |
Pancreatic Cancer Metastatic to Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06531278 | — | P2 | recruiting | Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety |
Childhood Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06208657 | — | P1/P2 | recruiting | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer |
Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06514313 | — | P2 | recruiting | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. |
Neuroendocrine Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06485739 | — | P4 | not yet recruiting | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma |
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06238843 | G-HOPE-001 | P3 | active not recruiting | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) |
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06351020 | — | P3 | active not recruiting | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. |
Advanced Pancreatic Cancer (Part 1) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06782685 | — | P1/P2 | recruiting | Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV |
Advanced Malignant Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06394713 | — | P1/P2 | not yet recruiting | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors |
Colorectal Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06509126 | IMPROVE-2 | P3 | recruiting | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer |
Nasopharyngeal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06414577 | — | P2 | active not recruiting | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy |
Gastroesophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06356311 | TroFuse-015 | P3 | active not recruiting | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) |
Small Cell Lung Cancer Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06258642 | — | N/A | recruiting | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC |
Nanoliposomal Irinotecan (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06405490 | — | P2 | recruiting | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC |
Unresectable/Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06365008 | — | P2 | recruiting | Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer |
Xiao Chai Hu Tang (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06055179 | — | N/A | recruiting | XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) |
RAS Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06321081 | — | P2 | recruiting | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC |
Neoadjuvant Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06172036 | CAPT-02 | P2 | not yet recruiting | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab |
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06123494 | — | P3 | recruiting | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen |
Previously AG Chemotherapy Treated Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06166589 | — | P2 | not yet recruiting | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer |
Metastatic Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06282120 | — | N/A | unknown | Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer |
Rhabdomyosarcoma, Child (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05457829 | — | P2 | recruiting | Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study |
Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05255666 | TNBC | P2 | withdrawn | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) |
Locally Advanced (Unresectable) or Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05978492 | — | P1 | recruiting | A Study of TXN10128 in Subjects With Solid Tumors |
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05945823 | — | P2 | active not recruiting | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors |
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05838768 | — | P1 | active not recruiting | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. |
Fruquintinib (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06169202 | — | N/A | unknown | A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients |
Metastatic Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05694715 | — | P1 | recruiting | Combination Therapy in Cancers With Mutations in DNA Repair Genes |
Stage II Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05062889 | ERASE-CRC | P2 | suspended | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients |
Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05732129 | HRD | P2 | unknown | The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. |
Esophageal Squamous Cell Carcinoma Abdominal Stage 0 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05737563 | Escape | P3 | unknown | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
Gastric Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05319639 | POFI | P1/P2 | recruiting | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab |
Advanced Esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05677490 | — | P3 | recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma |
Advanced Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05238831 | ACT | Early P1 | withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial |
Brain Tumor, Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04525014 | PIRATE | P1 | terminated | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors |
Second Line Treatment of Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669807 | — | P2 | unknown | Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer |
Locally Advanced Rectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05610163 | JANUS | P2 | active not recruiting | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation |
Sarcoma, Ewing (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05440786 | LY2835219 | P2 | active not recruiting | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma |
Wilms Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05384821 | MetroWilms | P1/P2 | recruiting | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) |
Advanced or Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05379595 | OrigAMI-1 | P1/P2 | recruiting | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer |
Advanced Malignant Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05235542 | — | P1/P2 | completed | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors |
Childhood CNS Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03554707 | — | Early P1 | withdrawn | SGT-53 in Children With Recurrent or Progressive CNS Malignancies |
Cancer of Rectum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05358704 | CRAFTER | P2 | suspended | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer |
Stage IV Esophagus Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05322499 | — | P2 | unknown | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer |
Recurrent Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04743661 | — | P2 | active not recruiting | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma |
Rectal Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05148767 | — | P4 | recruiting | UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer |
Recurrent Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05201326 | — | P1 | unknown | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma |
Esophageal Squamous Cell Carcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05022654 | — | P2 | active not recruiting | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. |
Locally Advanced Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04821284 | — | P1/P2 | active not recruiting | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer |
Advanced Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05160896 | — | P2 | unknown | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer |
Pancreatic Cancer Non-resectable (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05047991 | — | P2 | unknown | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma |
Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04808791 | GEJ | P2 | completed | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
Metastatic Lung Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04514497 | — | P1 | active not recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer |
Mismatch Repair-proficient (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05160727 | — | P2 | unknown | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer |
Advanced Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05015621 | — | P3 | unknown | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
Advanced Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04924192 | — | P2 | terminated | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer |
High-risk Locally Advanced Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05018182 | — | P2 | unknown | FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer |
Metastatic Colorectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05312398 | — | P2 | active not recruiting | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen |
Gastro-Oesophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04879368 | INTEGRATEIIb | P3 | completed | RegoNivo vs Standard of Care Chemotherapy in AGOC |
Advanced Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04728035 | — | P1 | completed | Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance |
Liver and Intrahepatic Bile Duct Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04251715 | — | P2 | active not recruiting | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma |
Refractory or Recurrent Neuroblastoma in Children (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04842526 | — | P2 | unknown | Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study |
Locally Advanced Cervical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04789941 | — | P2 | unknown | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix |
Platinum-Resistant Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04753216 | — | P2 | completed | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Clinical Stage III Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03641313 | — | P2 | active not recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer |
Relapsed Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04238819 | LY2835219 | P1/P2 | completed | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma |
Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04358354 | — | P3 | unknown | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer |
Anaplastic Kidney Wilms Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04322318 | — | P2 | recruiting | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT |
Pancreatic Adenosquamous Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04340141 | — | P3 | active not recruiting | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer |
Locally Advanced Pancreatic Carcinoma(LAPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03861702 | — | P2 | completed | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: |
Clinical Stage IV Gastric Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04329494 | — | P1 | recruiting | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer |
Carcinoma, Pancreatic Ductal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03403101 | — | P2 | unknown | The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer |
P1b: Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04492033 | ABL001 | P1/P2 | terminated | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients |
Refractory Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04239092 | — | P1 | terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. |
Metastatic Small Intestinal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04205968 | — | P2 | recruiting | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers |
Unresectable Metastatic Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04508452 | — | P2 | unknown | A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC |
Locally Advanced Unresectable Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03739801 | — | P1/P2 | withdrawn | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
BRAF V600E Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04117945 | — | P2 | active not recruiting | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer |
Glioblastoma, Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04267978 | — | P2 | recruiting | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas |
Cancer Colorectal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04189055 | CETIDYL | P2 | unknown | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. |
HER-2 Protein Overexpression (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04215159 | BIOs-Her | P2 | unknown | Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor |
Rectal Neoplasm Malignant Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04227886 | — | N/A | unknown | Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer |
Gastric Carcinoma Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04442984 | IRIGA | P2 | unknown | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) |
Peritoneal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04088786 | — | P1 | completed | Phase I Trial HIPEC With Nal-irinotecan |
Advanced Bile Duct Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04072445 | — | P2 | completed | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer |
High Risk Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03794349 | — | P2 | active not recruiting | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma |
Locally Advanced Digestive System Neuroendocrine Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03736720 | — | P2 | terminated | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin |
Gastrointestinal Neuroendocrine Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03963193 | — | P2 | unknown | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type |
Cancer of Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03607643 | — | P1/P2 | unknown | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
Recurrent Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04499586 | — | P2 | unknown | A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer |
Head & Neck Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03712397 | — | P2 | completed | Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy |
Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03773367 | INTENSE | P2 | active not recruiting | Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. |
Advanced Esophageal Squamous Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03732508 | — | P2 | unknown | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer |
Metastatic Biliary Tract Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03337087 | — | P1/P2 | unknown | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer |
Colorectal Neoplasms, Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03608046 | AVETUXIRI | P2 | unknown | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer |
Intrahepatic Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03771846 | — | P3 | unknown | HAIC Versus Systemic Chemotherapy for Unresectable ICC |
mCRC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03567629 | — | P2 | unknown | Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer |
Childhood Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03533582 | — | P3 | active not recruiting | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery |
Locally Advanced Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03468335 | PREDICT | P3 | completed | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy |
Locally Advanced or Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03443492 | Pancreas | P2 | completed | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer |
Refractory or Recurrent Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03245450 | — | P1/P2 | completed | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors |
Overall Survival (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03726021 | — | P2 | completed | Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer |
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05074589 | — | P3 | completed | Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer |
Ewing's Tumor Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03416517 | — | P1/P2 | unknown | Anlotinib and Irinotecan for Ewing Sarcoma |
Solid Tumor, Unspecified, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03318445 | — | P1 | completed | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair |
Recurrent Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03323034 | — | P1 | completed | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
Diffuse Intrinsic Pontine Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03086616 | DIPG | P1 | completed | CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009) |
GastroEsophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03279237 | — | P1 | completed | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers |
Childhood Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02975882 | — | P1 | completed | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
Colon Cancer Liver Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03175016 | DEBIRI-CRLM | P2/P3 | unknown | Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer |
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03136055 | — | P2 | completed | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas |
Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02631733 | — | P1 | completed | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors |
Metastatic Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03116555 | — | P2 | unknown | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA |
Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02967289 | IROCAS | P3 | completed | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting |
Colorectal Adenocarcinoma Metastatic to the Liver (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03069950 | — | P2 | withdrawn | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver |
ColoRectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03053167 | — | P2 | unknown | Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients |
Cancer, Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02937116 | — | P1 | completed | First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors |
BRAF V600E-mutant Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02928224 | BEACON CRC | P3 | completed | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer |
Malignant Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02801097 | PAYLOAD | P1 | terminated | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) |
Pediatric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02813135 | ESMART | P1/P2 | recruiting | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors |
High-grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02848794 | — | P1/P2 | unknown | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma |
Alveolar Rhabdomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02567435 | — | P3 | active not recruiting | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
Ductal Adenocarcinoma of Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02626520 | — | P2 | terminated | Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla |
Pineoblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02596828 | — | P2 | completed | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma |
Recurrent Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02192359 | — | P1 | active not recruiting | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02625623 | — | P3 | completed | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) |
Unresectable Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02640365 | DOUBLIRI | P1 | completed | A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer |
Advanced Solid Tumours (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02588105 | AToM | P1 | completed | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer |
Relapsed Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02596503 | — | P1 | completed | A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors |
Biliary Tract Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02558959 | — | P2 | completed | Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer |
Stage IV Non-small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02312622 | — | P2 | completed | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer |
Small Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02489903 | QUADRUPLE THREAT | P2 | completed | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) |
Stage IVA Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02573220 | — | P1 | withdrawn | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer |
Biliary Tract Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02527824 | — | P2 | unknown | Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer |
Childhood Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02392793 | — | P1 | completed | Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies |
Advanced Nonhematologic Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02327169 | — | P1 | completed | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies |
Adenocarcinoma of Unknown Primary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02333188 | — | P1 | completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer |
Inoperable Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03067792 | — | P3 | completed | FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer |
Esophageal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02366819 | — | P4 | suspended | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer |
Resectable Prancreas Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02172976 | — | P2/P3 | completed | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma |
Rectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02314182 | GRECCAR8 | P3 | completed | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis |
Lung Neoplasms, Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02275806 | — | P2 | terminated | Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC |
High Grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02022644 | — | P1 | completed | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma |
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02030678 | — | P2 | unknown | A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer |
Solid Tumor Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05177276 | — | P1/P2 | withdrawn | Selinexor Combination Ph 1 Study |
Pancreatic Metastatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02143219 | PAMELA70 | P2 | completed | Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer |
Medulloblastoma Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01356290 | MEMMAT | P2 | recruiting | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors |
Digestive Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02387138 | SIRINOX | P1 | completed | A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan |
Pediatric Oncology (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02085148 | — | P1 | completed | A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy |
Resectable Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01992705 | GCC 1324 | Early P1 | completed | Borderline Pancreas Study: FOLFIRINOX +SBRT |
Central Nervous System Embryonal Tumor With Rhabdoid Features (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02095132 | — | P1/P2 | completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
Recurrent Childhood Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02509234 | TrIPReSarc | N/A | unknown | Trabectedin and Irinotecan for Refractory Pediatric Sarcomas |
Advanced Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02024607 | — | P1/P2 | completed | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer |
Recurrent or Refractory Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02013336 | — | P1 | unknown | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors |
First Line Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01963182 | IriGen | P2 | completed | Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer |
Pilomyxoid Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01837862 | — | P1/P2 | completed | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas |
Neoplasm Malignant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01930552 | — | P1 | completed | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies |
High-risk Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02025881 | HR MB-5 | P1/P2 | terminated | Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma |
Recurrent Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01876446 | — | P2 | completed | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer |
Incurable Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02071069 | — | P2 | unknown | Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer |
Colorectal Cancer Liver Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02086656 | COI-B | P2 | completed | PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES |
Newly Diagnosed Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01864109 | — | P2 | active not recruiting | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma |
Recurrent Non-Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01935947 | — | P2 | terminated | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer |
Astrocytoma, Oligoastrocytoma, Mixed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01999270 | — | P1 | completed | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors |
Colonic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01826396 | — | P2 | unknown | Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer |
BRAF NP_004324.2:p.V600X (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01787500 | — | P1 | completed | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery |
Ganglioneuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01767194 | — | P2 | completed | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma |
Metastatic Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01773109 | NKTR-102 | P2 | completed | Etirinotecan Pegol (NKTR-102) in NSCLC |
Central Nervous System Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01939483 | — | N/A | withdrawn | A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases |
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01715441 | NEXIRI2 | P2 | completed | Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors |
Anaplastic Astrocytomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01663012 | — | P2 | completed | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma |
Small Cell Carcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01635400 | — | P2 | unknown | Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer |
Gastrointestinal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01693445 | — | P1 | completed | S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer |
Carcinoma of Esophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01608464 | — | P2 | terminated | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer |
Brain Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01535183 | — | P2 | unknown | Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents |
RHABDOMYOSARCOMA (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01355445 | VIT-0910 | P2 | completed | Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma |
Rhabdomyosarcoma and Other Soft Tissue Sarcomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01518413 | — | P1 | completed | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors |
Progression Free Survival of the Treatment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01480986 | — | P2 | completed | IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC |
Recurrent Colon Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01383343 | — | P1 | completed | Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer |
Bone Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01313884 | — | P2 | terminated | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma |
Adenocarcinoma of Pancreas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01359007 | — | P2 | terminated | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer |
Neoplasm Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01336985 | — | P1 | terminated | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads |
KRAS Mutant Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01274624 | — | P1 | completed | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer |
Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01239485 | — | P1 | unknown | Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents |
Central Nervous System Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01217437 | — | P2 | completed | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors |
Gastrointestinal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01129310 | IXOGoo1 | P2 | completed | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. |
Extensive-stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02323737 | — | P2 | completed | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer |
Estrogen Receptor Negative (ER-Negative) Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01173497 | — | P2 | completed | A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis |
Recurrent Malignant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01144988 | AVIRMA01-09 | P2 | unknown | Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma |
Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01091259 | — | P2 | completed | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer |
Malignant Glioma of Brain (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01017653 | — | P2 | terminated | Panitumumab and Irinotecan for Malignant Gliomas |
Gastro-Intestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01046864 | FOLFIRI | P1 | completed | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) |
Brain Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01014767 | — | P3 | terminated | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors |
Pediatric High Risk Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01574092 | — | P2 | completed | Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas |
PRETEXT I Hepatoblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00980460 | — | P3 | active not recruiting | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer |
Advanced Esophageal Squamous Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01051765 | — | P2 | unknown | Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial |
Newly Diagnosed High-Grade Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00890786 | — | Early P1 | completed | A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas |
Unresectable Metastatic Colo-rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00816777 | PARAGON | P1/P2 | terminated | Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer |
Advanced Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00874328 | IP | P1/P2 | unknown | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) |
Central Nervous System Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00876993 | CNS | P1 | completed | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors |
Hepatoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00861783 | — | P1 | completed | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma |
Metastatic Colorectal Cancer (MCRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00594984 | — | P1/P2 | completed | Phase I/II Combination With Irinotecan- Erbitux |
Unresectable or Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00668863 | — | P2 | completed | Study Of Sunitinib With FOLFIRI In Colorectal Cancer |
Colorectal, Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00569335 | SIRB | P2 | completed | Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer |
Colorecal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00506571 | TIROX2 | P2 | unknown | Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer |
Neoplasms, Colorectal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00540943 | — | P1 | completed | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer |
Small Intestine Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00433550 | — | P2 | completed | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer |
Brain Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00463203 | — | P2 | completed | Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy |
Adult Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00433381 | — | P2 | completed | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00614965 | — | P2 | completed | Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV |
High-Grade Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00393094 | — | P2 | terminated | Bevacizumab and Irinotecan to Treat Brain Tumors |
Childhood Cerebral Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00381797 | — | P2 | completed | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma |
Childhood Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00335556 | — | P2 | completed | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors |
Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00298675 | — | P1 | completed | Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors |
Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00360828 | — | P2 | terminated | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas |
Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00507091 | — | P1 | completed | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination |
Recurrent Squamous Cell Carcinoma of the Hypopharynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00103259 | — | P2 | completed | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Childhood Burkitt Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00101270 | — | P1 | completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
Non-Hodgkins Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00718757 | — | P1 | completed | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies |
Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00222443 | — | P1 | completed | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy |
Adenocarcinoma of Esophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00165490 | — | P2 | completed | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer |
Rectal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00506623 | — | P2 | unknown | Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer |
Uterine Cervical Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00136955 | — | P2 | completed | Irinotecan Study For Cervical Cancer |
Diarrhea (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00093353 | N2003-01 | P1 | completed | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma |
Gastrointestinal Carcinoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00416767 | — | P2 | completed | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery |
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00154102 | CRYSTAL | P3 | completed | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) |
Rectal Mucinous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00068692 | — | P3 | completed | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer |
Neoplasms, Unknown Primary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00193596 | — | P3 | completed | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site |
Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00143533 | — | P1 | completed | Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors |
Penile Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00066391 | — | P2 | completed | Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer |
Colon Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00180960 | — | P2 | terminated | Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia |
Carcinoma, Hepatocellular (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00635323 | — | P2 | completed | Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma |
Cervix Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00251888 | — | P1 | completed | CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto |
Rectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00682786 | — | P2 | completed | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma |
Small-Cell-Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00144989 | IP | P3 | completed | A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC |
Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00276003 | — | P2 | completed | INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. |
Adult Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00045201 | — | P1 | active not recruiting | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors |
Advanced Adult Primary Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00031681 | — | P1 | completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) |
Alveolar Childhood Rhabdomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00025363 | — | P2 | completed | Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma |
Malignant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00283556 | CPT-11 | P1/P2 | completed | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma |
Brain and Nervous System (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00251797 | — | P1 | completed | A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors |
Childhood Central Nervous System Germ Cell Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00004078 | — | P2 | completed | Irinotecan in Treating Children With Refractory Solid Tumors |
AIDS-related Peripheral/Systemic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00003970 | — | P1 | completed | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
Gallbladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00003276 | — | P2 | completed | Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer |
Drug/Agent Toxicity by Tissue/Organ (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00002759 | — | P1 | completed | Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma |
Unspecified Adult Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00037804 | — | P1 | completed | Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction |
Adult Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02055196 | — | P1 | withdrawn | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
Irinotecan pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ARIEL-ENGIC | NCT07094893 | P4 | not yet recruiting | Colorectal Cancer | 280 | — |
| ASCENT | NCT01588990 | P4 | completed | Colorectal Neoplasms | 128 | PMID 32142532 |
| CRC | NCT00138060 | P4 | completed | Metastatic Colorectal Cancer | 71 | PMID 11990381 |
| HR-NBL2 | NCT04221035 | P3 | recruiting | High-Risk Neuroblastoma | 800 | — |
| OrigAMI-2 | NCT06662786 | P3 | recruiting | Colorectal Neoplasms | 1,000 | — |
| IR RMS | NCT07466316 | P3 | not yet recruiting | Rhabdomyosarcoma | 342 | — |
| FHWT | NCT06401330 | P3 | recruiting | Stage I Mixed Cell Type Kidney Wilms Tumor | 1,656 | — |
| CAPRI-3 GOIM | NCT07389265 | P3 | recruiting | Metastatic Colorectal Cancer (mCRC) | 480 | — |
| LAP100 | NCT06958328 | P3 | recruiting | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma | 356 | — |
| PANThEON | NCT06897644 | P3 | recruiting | Pancreatic Adenocarcinoma Advanced or Metastatic | 340 | PMID 41318310 |
| CLDN | NCT07518147 | P3 | recruiting | Gastric Cancer | 438 | — |
| EFFIPEC | NCT04861558 | P3 | recruiting | Colorectal Cancer | 213 | — |
| ESCC | NCT06644781 | P3 | recruiting | Esophageal Squamous Cell Carcinoma | 510 | — |
| PREOPANC-3 | NCT04927780 | P3 | active not recruiting | Pancreatic Cancer | 378 | PMID 37550634 |
| OrigAMI-3 | NCT06750094 | P3 | recruiting | Colorectal Neoplasms | 700 | — |
| AtezoTRIBE2 | NCT06733038 | P3 | recruiting | Colorectal Cancer | 238 | — |
| PANKU-BTC01 | NCT07582315 | P3 | not yet recruiting | Biliary Tract Cancer | 538 | — |
| II | NCT07238283 | P3 | recruiting | First-line Treatment of Metastatic Pancreatic Cancer | 662 | — |
| NB-NK-2026 | NCT07375563 | P3 | recruiting | Neuroblastoma (NB) | 5 | — |
| OSCAR | NCT02885753 | P3 | recruiting | Colorectal Neoplasms | 348 | PMID 35027324 |
| MK-3475 | NCT05239741 | P3 | active not recruiting | Colorectal Neoplasms | 100 | — |
| IMPROVE-2 | NCT06509126 | P3 | recruiting | Colorectal Cancer Stage IV | 500 | — |
| MK-2870 | NCT06459180 | P3 | active not recruiting | Cervical Cancer | 686 | — |
| PTCA199-11 | NCT06250972 | P3 | recruiting | Pancreatic Adenocarcinoma | 210 | PMID 38050737 |
| RASolute 302 | NCT06625320 | P3 | active not recruiting | Pancreatic Cancer | 500 | — |
| G-HOPE-001 | NCT06238843 | P3 | active not recruiting | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 464 | — |
| PHITT | NCT03017326 | P3 | active not recruiting | Hepatoblastoma | 450 | — |
| TroFuse-015 | NCT06356311 | P3 | active not recruiting | Gastroesophageal Cancer | 450 | — |
| NEXT-REGIRI | NCT03829462 | P3 | active not recruiting | Metastatic Colorectal Cancer (mCRC) | 377 | PMID 14612495 |
| SOLARIS | NCT04094688 | P3 | active not recruiting | Colorectal Adenocarcinoma | 455 | — |
| CheckMate 8HW | NCT04008030 | P3 | active not recruiting | Metastatic Colorectal Cancer | 839 | PMID 39602630 |
| LIBImAb | NCT04776655 | P3 | recruiting | Colorectal Cancer | 280 | — |
| LAGOON | NCT05153239 | P3 | completed | Relapsed Small Cell Lung Cancer | 705 | — |
| Escape | NCT05737563 | P3 | unknown | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 380 | — |
| innovaTV 301 | NCT04697628 | P3 | completed | Cervical Cancer | 502 | PMID 38959480 |
| IROCAS | NCT02967289 | P3 | completed | Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2) | 792 | PMID 30415988 |
| INTEGRATEIIb | NCT04879368 | P3 | completed | Gastro-Oesophageal Cancer | 462 | PMID 36814222 |
| NAPOLI 3 | NCT04083235 | P3 | completed | Metastatic Adenocarcinoma of the Pancreas | 770 | PMID 37708904 |
| AIO-KRK-0114 | NCT02934529 | P3 | completed | Metastatic Colorectal Cancer | 673 | PMID 39903881 |
| STRATEGIC-1 | NCT01910610 | P3 | unknown | Colorectal Cancer Metastatic | 464 | PMID 26141683 |
| NEOPAN | NCT02539537 | P3 | completed | Pancreatic Cancer | 171 | PMID 40378359 |
| RESILIENT | NCT03088813 | P3 | completed | Small Cell Lung Cancer | 491 | PMID 38648575 |
| CinClare | NCT02605265 | P3 | completed | Locally Advanced Rectal Cancer | 356 | PMID 33119477 |
| BGB-A317 | NCT03430843 | P3 | completed | Esophageal Squamous Cell Carcinoma (ESCC) | 512 | PMID 35442766 |
| BEACON CRC | NCT02928224 | P3 | completed | BRAF V600E-mutant Metastatic Colorectal Cancer | 702 | PMID 30892987 |
| TRIPLETE | NCT03231722 | P3 | completed | Metastatic Colorectal Cancer | 435 | PMID 36822922 |
| PREDICT | NCT03468335 | P3 | completed | Locally Advanced Pancreatic Cancer | 151 | PMID 41087530 |
| MK-3475 | NCT03933449 | P3 | completed | Esophageal Carcinoma | 123 | PMID 34973513 |
| MK-3475 | NCT02564263 | P3 | completed | Esophageal Carcinoma | 628 | PMID 33026938 |
| VITA | NCT03495921 | P3 | terminated | Ewing Sarcoma | 32 | PMID 25917459 |
| Trybeca-1 | NCT03665441 | P3 | completed | Pancreatic Adenocarcinoma | 512 | PMID 41187298 |
| GB201 | NCT03522649 | P3 | unknown | Previously Treated Metastatic Colorectal Cancer | 668 | — |
| BRAVA | NCT04943627 | P3 | withdrawn | Advanced Cancer | 0 | — |
| CanStem303C | NCT02753127 | P3 | completed | Colorectal Cancer | 1,253 | — |
| TRIBE2 | NCT02339116 | P3 | unknown | Metastatic Colorectal Cancer | 654 | PMID 28599628 |
| AXEPT | NCT01996306 | P3 | completed | Colorectal Neoplasms | 650 | PMID 29555258 |
| GRECCAR8 | NCT02314182 | P3 | completed | Rectal Adenocarcinoma | 5 | PMID 25849254 |
| FOLFIRI | NCT00433927 | P3 | unknown | Neoplasm Metastasis | 568 | PMID 30293873 |
| FOLF(HA)iri | NCT01290783 | P3 | unknown | Metastatic Colorectal Cancer | 390 | PMID 20333384 |
| AFEQT | NCT01670721 | P3 | completed | Colorectal Cancer Metastatic | 175 | — |
| COMETS | NCT01030042 | P3 | completed | Metastatic Colorectal Cancer | 110 | — |
| BEBYP | NCT00720512 | P3 | terminated | Colorectal Cancer | 184 | PMID 25600568 |
| PROCEED | NCT01501669 | P3 | unknown | Metastatic Breast Cancer | 222 | — |
| ITACA-S | NCT01640782 | P3 | completed | Adenocarcinoma of the Stomach | 1,100 | PMID 24728035 |
| VELOUR | NCT00561470 | P3 | completed | Colorectal Neoplasms | 1,226 | PMID 39207600 |
| IP | NCT00144989 | P3 | completed | Small-Cell-Lung Cancer | 281 | PMID 24309370 |
| CRYSTAL | NCT00154102 | P3 | completed | Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer | 1,221 | PMID 19339720 |
| S0124 | NCT00045162 | P3 | completed | Lung Cancer | 671 | PMID 19349543 |
| PACCE | NCT00115765 | P3 | completed | Colorectal Cancer | 1,053 | PMID 30679026 |
| R | NCT00143455 | P3 | completed | Small Cell Lung Carcinoma | 485 | — |
| TRIBE | NCT00719797 | P3 | completed | Colorectal Cancer | 509 | PMID 35594613 |
| MIROX | NCT00268398 | P3 | completed | Colorectal Cancer | 284 | PMID 25403578 |
| JANUS | NCT05610163 | P2 | active not recruiting | Locally Advanced Rectal Carcinoma | 783 | PMID 39116386 |
| I-SPY | NCT01042379 | P2 | recruiting | Breast Neoplasms | 5,000 | PMID 21796368 |
| ROMANCE - GOIM | NCT07381764 | P2 | not yet recruiting | Metastatic Colorectal Cancer (CRC) | 150 | — |
| ISG-TULIPS | NCT07328425 | P2 | recruiting | Desmoplastic Small Round Cell Tumor | 20 | PMID 37158111 |
| MEMMAT | NCT01356290 | P2 | recruiting | Medulloblastoma Recurrent | 232 | PMID 36291912 |
| NOVELTY-R | NCT07183865 | P2 | recruiting | Locally Recurrent Rectal Cancer | 44 | — |
| TNBC | NCT05255666 | P2 | withdrawn | Triple Negative Breast Cancer | 0 | — |
| OPTICAL | NCT07356973 | P2 | not yet recruiting | Glioblastoma | 147 | — |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| ERASE-CRC | NCT05062889 | P2 | suspended | Stage II Colon Cancer | 477 | — |
| II | NCT07099794 | P2 | not yet recruiting | Biliary Tract Cancer (BTC) | 90 | — |
| N10 | NCT06528496 | P2 | recruiting | High-risk Neuroblastoma | 45 | — |
| RAD-NALIRIFOX | NCT07173387 | P2 | active not recruiting | Pancreatic Cancer | 42 | PMID 26615328 |
| TRACER | NCT06751394 | P2 | not yet recruiting | Recurrent Rectal Cancer | 44 | — |
| HERBIC | NCT07059338 | P2 | not yet recruiting | HER2 Positive | 34 | — |
| ShorTrip | NCT05253846 | P2 | active not recruiting | Locally Advanced Rectal Cancer | 63 | — |
| GRACIE | NCT06846346 | P2 | recruiting | Metastatic Esophageal Adenocarcinoma | 88 | — |
| II | NCT07123441 | P2 | not yet recruiting | Colorectal Cancer | 300 | — |
| ARK | NCT07051785 | P2 | not yet recruiting | Colorectal Cancer (CRC) | 68 | — |
| CANTOR | NCT06792695 | P2 | recruiting | Metastatic Colorectal Cancer | 120 | — |
| II | NCT07524374 | P2 | not yet recruiting | ESCC | 33 | — |
| QL1706 | NCT07229846 | P2 | not yet recruiting | Colorectal Cancer | 30 | — |
| II | NCT06827717 | P2 | recruiting | Ewing Sarcoma | 29 | — |
| CRAFTER | NCT05358704 | P2 | suspended | Cancer of Rectum | 38 | — |
| II | NCT06820762 | P2 | not yet recruiting | SCLC | 40 | PMID 36147357 |
| LIAES | NCT06749691 | P2 | recruiting | Small Cell Lung Cancer Extensive Stage | 30 | — |
| NALPAC | NCT05472259 | P2 | recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 134 | — |
| II | NCT06739928 | P2 | recruiting | Small Cell Lung Cancer Extensive Stage | 120 | — |
| II | NCT06766019 | P2 | active not recruiting | Pancreatic Cancer | 47 | — |
| GM-CSF | NCT04385277 | P2 | active not recruiting | Ganglioneuroblastoma, Nodular | 41 | — |
| II | NCT07047560 | P2 | recruiting | Colorectal Cancer (CRC) | 46 | — |
| II | NCT07044921 | P2 | recruiting | Colorectal Cancer Metastatic | 30 | — |
| FRUITFUL | NCT07011576 | P2 | recruiting | Colon Cancer | 60 | — |
| VICTORIA | NCT06714357 | P2 | recruiting | Colorectal Cancer Metastatic | 130 | — |
| CAMPFIRE | NCT05999994 | P2 | recruiting | Neoplasms | 105 | — |
| NALIRI-VT | NCT07092306 | P2 | not yet recruiting | Ewing's Sarcoma | 74 | — |
| SCOTI | NCT05806931 | P2 | recruiting | Colon Cancer | 50 | — |
| CAPT-02 | NCT06172036 | P2 | not yet recruiting | Neoadjuvant Chemotherapy | 180 | — |
| VICPROIRI | NCT06763029 | P2 | recruiting | Colorectal Cancer Metastatic | 36 | — |
| II | NCT06643793 | P2 | recruiting | Colorectal Neoplasms Malignant | 30 | — |
| IV | NCT06107413 | P2 | active not recruiting | Unresectable Metastatic Colorectal Cancer | 280 | — |
| LY2835219 | NCT05440786 | P2 | active not recruiting | Sarcoma, Ewing | 46 | — |
| NAPOLI-2 | NCT04005339 | P2 | active not recruiting | Advanced Biliary Tract Cancer | 48 | — |
| CA225200 | NCT00248287 | P2 | active not recruiting | Metastatic Breast Cancer | 154 | — |
| NALIRIBVRG | NCT06801730 | P2 | recruiting | Glioma | 38 | — |
| INTENSE | NCT03773367 | P2 | active not recruiting | Resectable Gastric and Gastroesophageal Junction Adenocarcinoma | 60 | — |
| NICRRBTC | NCT06699459 | P2 | not yet recruiting | Biliary Tract Carcinoma | 76 | — |
| LyRICX | NCT03764553 | P2 | active not recruiting | Esophageal Cancer | 320 | — |
| undetermined | NCT06387810 | P2 | recruiting | Borderline Resectable Pancreatic Cancer | 45 | — |
| NEO-IMPACT | NCT06094140 | P2 | active not recruiting | Pancreatic Cancer | 20 | — |
| BEACON | NCT02308527 | P2 | completed | Neuroblastoma | 225 | PMID 38190578 |
| LIVERPEARL | NCT04595266 | P2 | active not recruiting | Colorectal Cancer Metastatic | 48 | — |
| PANIRINOX | NCT02980510 | P2 | active not recruiting | Metastatic Colorectal Cancer | 219 | PMID 36443816 |
| HAIC | NCT06538623 | P2 | completed | Pancreatic Neoplasms | 40 | — |
| NaliCap | NCT04371224 | P2 | unknown | Pancreatic Cancer | 200 | — |
| TORCH-R | NCT05628038 | P2 | recruiting | Recurrent Rectal Cancer | 93 | PMID 38053659 |
| HOLIPANC | NCT04617457 | P2 | unknown | Pancreatic Cancer | 150 | PMID 34794396 |
| S1613 | NCT03365882 | P2 | completed | Colon Adenocarcinoma | 240 | PMID 39761503 |
| Phenomenal | NCT03328884 | P2 | completed | Breast Cancer Metastatic | 55 | — |
| POFI | NCT06197438 | P2 | unknown | Gastric Cancer | 36 | — |
| FUNGEMAX | NCT03693677 | P2 | completed | Metastatic Pancreatic Cancer | 288 | — |
| INTERACT-II | NCT06003998 | P2 | unknown | Colorectal Cancer | 85 | PMID 38238055 |
| SINAI | NCT05363007 | P2 | unknown | Metastatic Pancreatic Cancer | 60 | — |
| AVETRIC | NCT04513951 | P2 | completed | Metastatic Colorectal Cancer | 62 | — |
| NET02 | NCT03837977 | P2 | completed | Oncology | 58 | PMID 37287870 |
| IRIGA | NCT04442984 | P2 | unknown | Gastric Carcinoma Stage IV | 326 | — |
| NIVACOR | NCT04072198 | P2 | completed | Colorectal Cancer | 73 | PMID 32867715 |
| TAS-102 | NCT04109924 | P2 | completed | Advanced Colorectal Carcinoma | 42 | PMID 39244627 |
| CETIDYL | NCT04189055 | P2 | unknown | Cancer Colorectal | 72 | PMID 18281264 |
| ELEVATE CRC | NCT05330429 | P2 | terminated | Metastatic Colorectal Cancer | 77 | — |
| ERASE-TMZ | NCT05031975 | P2 | unknown | Colorectal Cancer | 35 | PMID 21859995 |
| TRITICC | NCT04059562 | P2 | completed | Cholangiocarcinoma | 28 | PMID 37217885 |
| HRD | NCT05732129 | P2 | unknown | Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer | 29 | — |
| AVETUXIRI | NCT03608046 | P2 | unknown | Colorectal Neoplasms, Malignant | 59 | PMID 40562041 |
| AIO-KRK-0116 | NCT04034459 | P2 | unknown | Metastatic Colorectal Cancer | 109 | — |
| AtezoTRIBE | NCT03721653 | P2 | completed | Metastatic Colorectal Cancer | 218 | PMID 38865678 |
| FOOTPATH | NCT03487016 | P2 | unknown | Metastatic Pancreatic Cancer | 270 | — |
| GEJ | NCT04808791 | P2 | completed | Gastroesophageal Junction Adenocarcinoma | 7 | — |
| LY01610 | NCT04381910 | P2 | completed | Small Cell Lung Cancer | 66 | — |
| AFEMA | NCT03279289 | P2 | completed | Metastatic Colorectal Cancer | 170 | — |
| BEYOND | NCT03751176 | P2 | unknown | Colorectal Cancer Metastatic | 31 | — |
| nITRo | NCT03528785 | P2 | unknown | Pancreatic Adenocarcinoma | 67 | PMID 33403007 |
| S1505 | NCT02562716 | P2 | completed | Pancreatic Adenocarcinoma | 147 | PMID 33475684 |
| QUATTRO-II | NCT04097444 | P2 | unknown | Metastatic Colorectal Cancer | 112 | PMID 32703200 |
| SCLC | NCT04727853 | P2 | completed | Small Cell Lung Cancer (SCLC) | 66 | — |
| TRICAP | NCT04160416 | P2 | unknown | Unresectable Metastatic Colorectal Cancer | 48 | — |
| QUADRUPLE THREAT | NCT02489903 | P2 | completed | Small Cell Carcinoma | 139 | PMID 33569311 |
| SULTAN | NCT03164655 | P2 | completed | Colorectal Cancer Metastatic | 20 | PMID 32000724 |
| N2011-01 | NCT02035137 | P2 | completed | Neuroblastoma | 114 | PMID 34270348 |
| OPALO | NCT03142516 | P2 | completed | Colorectal Neoplasms | 20 | — |
| CELIM2 | NCT01802645 | P2 | unknown | Colorectal Cancer | 91 | — |
| PAMELA70 | NCT02143219 | P2 | completed | Pancreatic Metastatic Cancer | 72 | — |
| HIGH-LIGHT | NCT02842580 | P2 | terminated | Colorectal Neoplasms | 21 | — |
| CBL | NCT03711240 | P2 | unknown | Colorectal Cancer | 40 | — |
| ROCKET | NCT02096354 | P2 | completed | Colorectal Neoplasms | 62 | PMID 36529613 |
| RIST-rNB-2011 | NCT01467986 | P2 | completed | Neuroblastoma Recurrent | 130 | PMID 38936379 |
| DEEPER | NCT02515734 | P2 | unknown | Colorectal Cancer | 360 | — |
| BIOs-Her | NCT04215159 | P2 | unknown | HER-2 Protein Overexpression | 42 | — |
| IriGen | NCT01963182 | P2 | completed | First Line Metastatic Colorectal Cancer | 47 | PMID 37932443 |
| Pancreas | NCT03443492 | P2 | completed | Locally Advanced or Metastatic Pancreatic Cancer | 130 | PMID 31765987 |
| FOLFIRINOX | NCT01928290 | P2 | completed | Stomach Neoplasms | 67 | PMID 32469386 |
| IP | NCT03168594 | P2 | terminated | Neuroendocrine Carcinoma | 66 | — |
| S1201 | NCT01498289 | P2 | completed | Adenocarcinoma of the Gastroesophageal Junction | 213 | — |
| BTC | NCT03110510 | P2 | withdrawn | Biliary Tract Cancer | 0 | — |
| PANTHER | NCT01862003 | P2 | completed | Metastatic Colorectal Cancer | 24 | PMID 36352028 |
| CAPTEM | NCT02414009 | P2 | completed | Metastatic Colorectal Cancer | 82 | — |
| BeTRI | NCT02497157 | P2 | completed | Metastatic Colorectal Cancer | 45 | — |
| BEV-ONCO2012 | NCT01858649 | P2 | completed | Metastatic Colorectal Cancer | 60 | PMID 10673991 |
| VIT-0910 | NCT01355445 | P2 | completed | RHABDOMYOSARCOMA | 120 | PMID 34343032 |
| MINOAS | NCT02624726 | P2 | unknown | Metastatic Colorectal Cancer | 31 | PMID 31203498 |
| BACCHUS | NCT01650428 | P2 | completed | Rectal Cancer | 20 | PMID 26493588 |
| GAMBIT | NCT01859728 | P2 | unknown | Biliary Cancer | 48 | — |
| FOLFIRI-AD | NCT01639326 | P2 | unknown | Metastatic Colorectal Cancer | 96 | — |
| RS CAMPTO | NCT01220063 | P2 | completed | Metastatic Colorectal Cancer | 48 | — |
| CHARTA | NCT01321957 | P2 | completed | Metastatic Colorectal Cancer | 250 | PMID 22897915 |
| NIEGA | NCT03400592 | P2 | unknown | Stomach Neoplasms | 55 | — |
| CRICKET | NCT02296203 | P2 | unknown | Metastatic Colorectal Cancer | 27 | PMID 36880426 |
| Folfirinox | NCT03167112 | P2 | unknown | Pancreatic Cancer | 20 | PMID 23532000 |
| IXOGoo1 | NCT01129310 | P2 | completed | Gastrointestinal Neoplasm | 47 | — |
| IMC-1121B | NCT01634555 | P2 | completed | Solid Tumors | 29 | — |
| LAPC | NCT01397019 | P2 | completed | Pancreatic Cancer | 56 | — |
| ML22774 | NCT01729481 | P2 | unknown | Metastatic Pancreatic Adenocarcinoma | 150 | PMID 37794220 |
| TDICC | NCT01977235 | P2 | unknown | Small Cell Lung Carcinoma | 110 | PMID 22983686 |
| AMALTHEA | NCT02129257 | P2 | completed | Metastatic Colorectal Cancer | 73 | — |
| PASSION | NCT02119026 | P2 | completed | Metastatic Colorectal Cancer | 120 | PMID 7535799 |
| COI-B | NCT02086656 | P2 | completed | Colorectal Cancer Liver Metastases | 46 | — |
| NKTR-102 | NCT01773109 | P2 | completed | Metastatic Non Small Cell Lung Cancer | 40 | — |
| QUATTRO | NCT02246049 | P2 | completed | Colorectal Neoplasms | 69 | — |
| REGAIN | NCT02316496 | P2 | terminated | Colorectal Cancer Metastatic | 2 | — |
| Chime | NCT02216487 | P2 | unknown | Metastatic Colorectal Cancer | 45 | — |
| TPCA | NCT00394433 | P2 | completed | Esophageal Cancer | 38 | — |
| STEAM | NCT01765582 | P2 | terminated | Colorectal Neoplasms | 280 | PMID 30552157 |
| BEVIAC | NCT01677884 | P2 | completed | Colorectal Neoplasms | 10 | — |
| NEXIRI2 | NCT01715441 | P2 | completed | Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors | 173 | PMID 32737004 |
| MAVERICC | NCT01374425 | P2 | completed | Colorectal Cancer | 376 | — |
| DEBIRITUX | NCT01060423 | P2 | terminated | Colorectal Cancer | 8 | — |
| SIM | NCT01479465 | P2 | terminated | Colorectal Cancer | 266 | PMID 28246207 |
| PEPCOL | NCT01375816 | P2 | terminated | Colorectal Cancer | 55 | — |
| DI | NCT01380275 | P2 | unknown | Sarcoma | 35 | PMID 25164234 |
| MK-0646-025 | NCT01609231 | P2 | terminated | Rectal Neoplasms | 11 | — |
| FL | NCT01269216 | P2 | completed | Rectal Cancer | 136 | — |
| SPECTRA | NCT00958386 | P2 | completed | Metastatic Colorectal Cancer | 61 | — |
| CRC | NCT01367275 | P2 | terminated | Colorectal Cancer | 8 | — |
| AGC | NCT01138904 | P2 | completed | Gastric Cancer | 80 | — |
| PCA | NCT00911820 | P2 | completed | Esophageal Cancer | 88 | — |
| eSCOUT | NCT01225744 | P2 | completed | Metastatic Colorectal Cancer | 47 | — |
| XRT | NCT00597402 | P2 | completed | Glioblastoma | 125 | — |
| AVIRMA01-09 | NCT01144988 | P2 | unknown | Recurrent Malignant Glioma | 35 | — |
| CRC | NCT01281761 | P2 | completed | Metastatic Colorectal Cancer | 52 | — |
| FOSCO | NCT00889343 | P2 | terminated | Colorectal Neoplasms | 101 | — |
| FOLFERA | NCT01205711 | P2 | completed | Colorectal Cancer | 111 | — |
| GEJ | NCT00848783 | P2 | terminated | Gastric Cancer | 8 | — |
| AZD6244 | NCT01116271 | P2 | completed | Colorectal Cancer | 32 | — |
| PIMABI | NCT00655499 | P2 | completed | Colorectal Cancer | 65 | PMID 23041588 |
| AVAXIRI | NCT00875771 | P2 | completed | Metastatic Colorectal Cancer | 80 | PMID 25925749 |
| MK-0646 | NCT00614393 | P2 | completed | Metastatic Colorectal Cancer | 558 | PMID 26405092 |
| OMEGA | NCT00467142 | P2 | completed | Colorectal Cancer | 62 | PMID 24758527 |
| GBM | NCT00817284 | P2 | completed | Glioblastoma Multiforme | 60 | — |
| EGFR | NCT00637091 | P2 | completed | Advanced Colorectal Cancer | 40 | PMID 21706149 |
| RNCLC | NCT00546130 | P2 | unknown | Small Cell Lung Cancer | 45 | PMID 14676791 |
| TIRASMUS | NCT00827684 | P2 | completed | Metastatic Colorectal Cancer | 50 | — |
| P-HDFL-DI | NCT00166881 | P2 | completed | Gastric Cancer | 29 | — |
| FC-4 | NCT00845039 | P2 | terminated | Colon Cancer | 4 | — |
| ERBIFORT | NCT00557102 | P2 | completed | Colorectal Cancer | 24 | — |
| TIROX2 | NCT00506571 | P2 | unknown | Colorecal Neoplasms | 42 | — |
| SCLC | NCT00240097 | P2 | completed | Non-Small Cell Lung Cancer | 30 | PMID 20934233 |
| ERBIRIX | NCT00506844 | P2 | unknown | Rectal Neoplasms | 40 | — |
| ED-SCLC | NCT00452634 | P2 | completed | Small Cell Lung Cancer | 62 | — |
| S0306 | NCT00066612 | P2 | completed | Bladder Cancer | 45 | PMID 18501081 |
| FOIB | NCT01163396 | P2 | completed | Colorectal Cancer Metastatic | 57 | PMID 20702138 |
| CEPAFIRI | NCT00210184 | P2 | completed | Gastric Cancer | 42 | PMID 21907007 |
| SIRB | NCT00569335 | P2 | completed | Colorectal, Cancer | 52 | — |
| TIROX2 | NCT00512681 | P2 | completed | Stomach Neoplasms | 44 | — |
| DCE-MRI | NCT00352521 | P2 | completed | Brain and Central Nervous System Tumors | 20 | — |
| CPT-11 | NCT00165464 | P2 | completed | Esophageal Cancer | 54 | PMID 19139178 |
| S0119 | NCT00030433 | P2 | completed | Lung Cancer | 85 | PMID 17545848 |
| ABX-EGF | NCT00111761 | P2 | completed | Colorectal Cancer | 43 | PMID 17531105 |
| STEPP | NCT00332163 | P2 | completed | Metastatic Colorectal Cancer | 95 | PMID 22070868 |
| BRAIN | NCT00345163 | P2 | completed | Glioblastoma | 167 | PMID 19720927 |
| GE | NCT00256269 | P2 | terminated | Esophageal Cancer | 4 | — |
| CPT-11 | NCT00819728 | P2 | completed | Carcinoma, Non-Small-Cell Lung | 35 | — |
| CC6 | NCT02118064 | P2 | completed | Colorectal Cancer | 161 | — |
Terminated and withdrawn Irinotecan trials (176)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05255666withdrawnCombination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
- NCT05062889suspendedExploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- NCT04543916withdrawnVenetoclax and Irinotecan in Relapsed/Refractory SCLC
- NCT05358704suspendedPreoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
- NCT02366819suspendedGenetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
- NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
- NCT05083481terminatedA Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT04481204withdrawnNew and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
- NCT06509906terminatedM9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- NCT04239092terminated9-ING-41 in Pediatric Patients With Refractory Malignancies.
- NCT04141995terminatedFOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
- NCT04492033terminatedA Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
- NCT05049863terminatedChemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
- NCT02419495terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- NCT05678257terminatedA Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- NCT03736720terminatedLiposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
- NCT04525014terminatedRRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- NCT05330429terminatedStudy of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- NCT05461794terminatedStudy To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- NCT05546411terminatedA Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
- NCT05824455terminatedA Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
- NCT05148195terminatedA Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
- NCT05417386terminatedFOLFIRINOX + NIS793 in Pancreatic Cancer
- NCT03879798terminatedDS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
- NCT03739801withdrawnMM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- NCT05251038withdrawnStudy of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
- NCT05009953terminatedStudy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
- NCT03678428terminatedFUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
- NCT04924192terminatedA Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
- NCT04560166terminatedNaxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
- NCT05042934withdrawnLurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
- NCT05039944terminatedSI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
- NCT03554707withdrawnSGT-53 in Children With Recurrent or Progressive CNS Malignancies
- NCT04173325terminatedFeasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
- NCT03722108terminatedRegorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
- NCT03495921terminatedA Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
- NCT01897454terminatedGemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
- NCT04943627withdrawnBalstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- NCT03119064terminatedBrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
- NCT03500874terminatedAdjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
- NCT03251417terminatedApatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
- NCT02842580terminatedDe-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
- NCT02025881terminatedStudy of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
- NCT03222089withdrawnPhase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- NCT02720601withdrawnIrinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
- NCT02747537withdrawnTreating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
- NCT03368859terminatedA Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
- NCT02801097terminatedRRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
- NCT03168594terminatedStudy to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
- NCT03110510withdrawnFOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
- NCT03069950withdrawnStudy of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
- NCT03380689withdrawnPhase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
- NCT01939483withdrawnA Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
- NCT02485834terminatedFDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
- NCT02782182terminatedPerioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
- NCT02046538withdrawnPhase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
- NCT01760252terminatedNeoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
- NCT01813253terminatedPhase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
- NCT02331251terminatedStudy of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
- NCT01847495withdrawnEvaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
- NCT02423954terminatedStudy of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- NCT02275806terminatedCisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC
- NCT02626520terminatedPhase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
- NCT02508077terminatedFOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
- NCT03009058terminatedStudy of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- NCT02110953terminatedIrinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
- NCT01935947terminatedAzacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
- NCT02316496terminatedRechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
- NCT02358863terminatedMolecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
- NCT02573220withdrawnIrinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
- NCT00524186terminatedSunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
- NCT01925274terminatedA Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
- NCT02345460terminatedPreoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
- NCT01765582terminatedSequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
- NCT02283359terminatedSelinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
- NCT01347866terminatedClinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
- NCT01858662terminatedStudy Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
- NCT02575508withdrawnPan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
- NCT05177276withdrawnSelinexor Combination Ph 1 Study
- NCT01608464terminatedPre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
- NCT02060955terminatedRandomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
- NCT01060423terminatedTACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
- NCT01550510terminatedResearch Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
- NCT01479465terminatedEfficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
- NCT01631539withdrawnChemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
- NCT01505608terminatedRandomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
- NCT01375816terminatedLiposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
- NCT01320683terminatedCombination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
- NCT01086345terminatedRadiosurgery Plus Bevacizumab in Glioblastoma
- NCT01609231terminatedA Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
- NCT01313884terminatedCyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
- NCT01654081withdrawnA Protocol of Irinotecan for Carcinoma of the Lung
- NCT01280643terminatedCombination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
- NCT00720512terminatedSecond-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
- NCT00671801terminatedIrinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
- NCT00465907terminatedStudy of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
- NCT02055196withdrawnGenetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
- NCT01941173withdrawnShort-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
- NCT01042028terminatedA Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer
- NCT01014767terminatedIntercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
- NCT01367275terminatedIrinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
- NCT00996346terminatedPhase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
- NCT01359007terminatedFOLFIRINOX in Patients With Inoperable Pancreatic Cancer
- NCT01016860terminatedOSI-906 and Irinotecan in Patients With Advanced Cancer
- NCT01607554terminatedIrinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
- NCT01285102terminatedChemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
- NCT00889343terminatedStudy to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
- NCT00811993terminatedA Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
- NCT00717990terminatedIrinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
- NCT00499369terminatedIrinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
- NCT00838578terminatedPhase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
- NCT00848783terminatedIrinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
- NCT01473303withdrawnCombination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
- NCT00755118terminatedLohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
- NCT00577109withdrawnA Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
- NCT01004159terminatedCetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
- NCT00109850terminatedS0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
- NCT01293942withdrawnIXO+A in mCRC With Liver-only Metastases
- NCT01167725terminatedStandard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
- NCT00766220withdrawnYttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
- NCT00969033terminatedCS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
- NCT00642746terminatedErlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
- NCT00588900terminatedIrinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
- NCT01017653terminatedPanitumumab and Irinotecan for Malignant Gliomas
- NCT00954512terminatedStudy of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- NCT00296062terminatedDose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
- NCT00816777terminatedChemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
- NCT01336985terminatedSafety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
- NCT00845039terminatedA Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
- NCT00473616terminatedPhase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
- NCT00960063terminatedA Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
- NCT00360828terminatedPhase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
- NCT00361244terminatedSU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
- NCT00177853terminatedCelecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
- NCT00984438withdrawnSurgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
- NCT00314353terminatedStudy of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
- NCT00077233terminatedFOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
- NCT00276744terminatedIndividualized Drug Treatment for Treating Patients With Pancreatic Cancer
- NCT00393094terminatedBevacizumab and Irinotecan to Treat Brain Tumors
- NCT00449163terminatedCombination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
- NCT00936832withdrawnSunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
- NCT00681876terminatedPhase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
- NCT01070290withdrawnA Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
- NCT00808899terminatedNeuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
- NCT00271011terminatedA Study of Mitomycin C, Irinotecan, and Cetuximab
- NCT00089102terminatedGemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
- NCT00642603terminatedA Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
- NCT00209664suspendedPhase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
- NCT00755534terminatedIrinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
- NCT00100828terminatedIrinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
- NCT00089128terminatedGemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
- NCT00290719terminatedGefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
- NCT00216086terminatedCapecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
- NCT00183807terminatedA Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
- NCT00396487terminatedTailored Treatment in Metastatic Colorectal Cancer
- NCT00323011terminatedFOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
- NCT00506168terminatedStudy of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
- NCT00320320terminatedIrinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer
- NCT00106262terminatedStudy of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
- NCT00256269terminatedOxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
- NCT00316433terminatedOxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer
- NCT00106054terminatedNeoadjuvant Colorectal Cancer With Unresectable Liver Metastases
- NCT00233623withdrawnIrinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
- NCT00264134terminatedDocetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
- NCT00033306terminatedBMS-247550 in Treating Patients With Metastatic Colorectal Cancer
- NCT00070434withdrawnS0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- NCT00053833terminatedS0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- NCT00180960terminatedTreatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
- NCT00037180terminatedFor Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
- NCT00052585terminatedGefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
- NCT00023868terminatedCombination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)
- NCT00040391terminatedA Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- NCT00006037terminatedChemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer
- NCT00544778terminatedCombination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
- NCT00003843terminatedIrinotecan in Treating Patients With Colorectal Cancer
- NCT00006269terminatedOctreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
All Irinotecan trials (1344)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | P2 | recruiting | 62 | New Approaches to Neuroblastoma Therapy Consortium | Dec 2024 | |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | P1/P2 | active not recruiting | 192 | CARsgen Therapeutics Co., Ltd. | Oct 2020 | |
| NCT06023641 | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease | P2 | recruiting | 135 | St. Jude Children's Research Hospital | Mar 2024 | |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | P1/P2 | recruiting | 90 | Australian & New Zealand Children's Haematology/Oncology Group | Jul 2024 | |
| NCT06541262 | CX-4945 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | P1/P2 | recruiting | 104 | Milton S. Hershey Medical Center | Oct 2024 |
| NCT07521605 | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer | P2 | not yet recruiting | 44 | Guangdong Provincial People's Hospital | May 2026 | |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | P3 | recruiting | 408 | ECOG-ACRIN Cancer Research Group | Oct 2023 | |
| NCT05610163 | JANUS | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | P2 | active not recruiting | 783 | Alliance for Clinical Trials in Oncology | Dec 2022 |
| NCT04221035 | HR-NBL2 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | P3 | recruiting | 800 | Gustave Roussy, Cancer Campus, Grand Paris | Nov 2019 |
| NCT07444918 | Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors | P2 | not yet recruiting | 33 | Tianjin Medical University Cancer Institute and Hospital | Mar 2026 | |
| NCT07570914 | Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | P2 | not yet recruiting | 28 | Tianjin Medical University Cancer Institute and Hospital | May 2026 | |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer | P2 | recruiting | 30 | Tianjin Medical University Cancer Institute and Hospital | Nov 2025 | |
| NCT07585279 | A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer | P2/P3 | not yet recruiting | 408 | Hebei Medical University Fourth Hospital | May 2026 | |
| NCT06662786 | OrigAMI-2 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | P3 | recruiting | 1,000 | Janssen Research & Development, LLC | Oct 2024 |
| NCT01042379 | I-SPY | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | P2 | recruiting | 5,000 | QuantumLeap Healthcare Collaborative | Mar 2010 |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | P1/P2 | recruiting | 81 | Children's Oncology Group | Jun 2025 | |
| NCT05314998 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | P3 | not yet recruiting | 394 | John Neoptolemos | Jan 2025 | |
| NCT07490301 | IV | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma | P2/P3 | recruiting | 900 | AbbVie | Apr 2026 |
| NCT07466316 | IR RMS | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | P3 | not yet recruiting | 342 | Children's Oncology Group | Jun 2026 |
| NCT07549321 | SHINE | A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients | P2/P3 | recruiting | 144 | Renaissance Pharma Ltd. | Apr 2026 |
| NCT07346157 | PNOC044 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease | P1/P2 | not yet recruiting | 69 | Sabine Mueller, MD, PhD | Jul 2026 |
| NCT07381764 | ROMANCE - GOIM | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" | P2 | not yet recruiting | 150 | Gruppo Oncologico Italia Meridionale | Mar 2026 |
| NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | P3 | not yet recruiting | 129 | City of Hope Medical Center | Jul 2026 | |
| NCT02813135 | ESMART | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | recruiting | 472 | Gustave Roussy, Cancer Campus, Grand Paris | Aug 2016 |
| NCT06401330 | FHWT | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | P3 | recruiting | 1,656 | Children's Oncology Group | Apr 2025 |
| NCT06998940 | Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | P3 | recruiting | 94 | SWOG Cancer Research Network | May 2026 | |
| NCT07328919 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | P3 | not yet recruiting | 138 | TransThera Sciences (Nanjing), Inc. | Jan 2026 | |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | P1/P2 | not yet recruiting | 100 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Dec 2025 | |
| NCT07334301 | BEACON2 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma | P1/P2 | recruiting | 160 | University of Birmingham | Nov 2024 |
| NCT04340141 | Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | P3 | active not recruiting | 358 | Alliance for Clinical Trials in Oncology | Oct 2020 | |
| NCT07194044 | METTSEO | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | P1 | recruiting | 15 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2026 |
| NCT07389265 | CAPRI-3 GOIM | Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | P3 | recruiting | 480 | University of Campania Luigi Vanvitelli | Oct 2025 |
| NCT05379595 | OrigAMI-1 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | P1/P2 | recruiting | 225 | Janssen Research & Development, LLC | Jul 2022 |
| NCT06958328 | LAP100 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | P3 | recruiting | 356 | NRG Oncology | Aug 2025 |
| NCT07328425 | ISG-TULIPS | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS | P2 | recruiting | 20 | Italian Sarcoma Group | Nov 2025 |
| NCT07096362 | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma | P2 | recruiting | 50 | University of Miami | Sep 2025 | |
| NCT04625907 | FaR-RMS | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | P1/P2 | recruiting | 1,672 | University of Birmingham | Sep 2020 |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | P2 | active not recruiting | 115 | St. Jude Children's Research Hospital | Dec 2013 | |
| NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | P2 | not yet recruiting | 30 | Tianjin Medical University Cancer Institute and Hospital | May 2026 | |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | P1 | not yet recruiting | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | May 2025 | |
| NCT01356290 | MEMMAT | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors | P2 | recruiting | 232 | Medical University of Vienna | Apr 2014 |
| NCT07094893 | ARIEL-ENGIC | Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status | P4 | not yet recruiting | 280 | Gruppo Oncologico del Nord-Ovest | Apr 2026 |
| NCT06928584 | Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer | P2 | recruiting | 221 | Fudan University | Mar 2025 | |
| NCT07183865 | NOVELTY-R | Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) | P2 | recruiting | 44 | Fudan University | Mar 2025 |
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | P1 | active not recruiting | 750 | Eli Lilly and Company | Oct 2024 | |
| NCT05255666 | TNBC | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | P2 | withdrawn | 0 | Washington University School of Medicine | Jul 2023 |
| NCT03977233 | Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | P2 | recruiting | 45 | UNC Lineberger Comprehensive Cancer Center | Jun 2019 | |
| NCT06897644 | PANThEON | Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. | P3 | recruiting | 340 | Gruppo Oncologico del Nord-Ovest | Mar 2025 |
| NCT07518147 | CLDN | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | P3 | recruiting | 438 | Sichuan Baili Pharmaceutical Co., Ltd. | May 2026 |
| NCT07356973 | OPTICAL | Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma | P2 | not yet recruiting | 147 | CRISM Therapeutics LTD | Mar 2026 |
| NCT07417735 | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma | P3 | not yet recruiting | 436 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Mar 2026 | |
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | P3 | recruiting | 478 | National Cancer Institute (NCI) | Apr 2024 | |
| NCT05062889 | ERASE-CRC | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | P2 | suspended | 477 | Gruppo Oncologico del Nord-Ovest | May 2023 |
| NCT04861558 | EFFIPEC | Efficacy of Hyperthermic Intraperitoneal Chemotherapy | P3 | recruiting | 213 | Uppsala University | May 2021 |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | P2 | recruiting | 25 | Mayo Clinic | Dec 2024 | |
| NCT07076212 | Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma | P2 | recruiting | 52 | Medical University of South Carolina | Apr 2026 | |
| NCT06644781 | ESCC | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | P3 | recruiting | 510 | Daiichi Sankyo | Mar 2025 |
| NCT04587128 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | P2 | active not recruiting | 34 | University of Wisconsin, Madison | Oct 2020 | |
| NCT07325214 | Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer | N/A | not yet recruiting | 136 | IMGT Co., Ltd. | Apr 2026 | |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | P3 | recruiting | 614 | Astellas Pharma Global Development, Inc. | Feb 2026 | |
| NCT07099794 | II | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | P2 | not yet recruiting | 90 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aug 2025 |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | P2 | recruiting | 280 | Fox Chase Cancer Center | Feb 2023 | |
| NCT04927780 | PREOPANC-3 | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | P3 | active not recruiting | 378 | Erasmus Medical Center | Sep 2021 |
| NCT06547203 | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study | P2 | recruiting | 34 | Sun Yat-sen University | Jul 2024 | |
| NCT06528496 | N10 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma | P2 | recruiting | 45 | Memorial Sloan Kettering Cancer Center | Jul 2024 |
| NCT07463573 | QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma | P3 | recruiting | 466 | Qilu Pharmaceutical Co., Ltd. | Apr 2026 | |
| NCT07397819 | Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy | P1/P2 | recruiting | 48 | Dong sheng Zhang | Nov 2025 | |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | P1 | recruiting | 411 | Inhibrx Biosciences, Inc | Oct 2018 | |
| NCT06995872 | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma | P1 | recruiting | 40 | National Cancer Institute (NCI) | Oct 2025 | |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | P2 | recruiting | 30 | The First Hospital of Jilin University | Nov 2025 | |
| NCT06750094 | OrigAMI-3 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | P3 | recruiting | 700 | Janssen Research & Development, LLC | Dec 2024 |
| NCT05319730 | MK-3475 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | P1/P2 | recruiting | 230 | Merck Sharp & Dohme LLC | May 2023 |
| NCT06733038 | AtezoTRIBE2 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | P3 | recruiting | 238 | Gruppo Oncologico del Nord-Ovest | Nov 2024 |
| NCT06571461 | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer | P3 | not yet recruiting | 408 | CSPC Ouyi Pharmaceutical Co., Ltd. | Sep 2024 | |
| NCT06586515 | MOONRAY-01 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | P1 | recruiting | 630 | Eli Lilly and Company | Sep 2024 |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | P2 | active not recruiting | 94 | Children's Oncology Group | Jul 2019 | |
| NCT07364422 | To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | P1/P2 | not yet recruiting | 49 | Onconic Therapeutics Inc. | Feb 2026 | |
| NCT07395063 | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | P2 | not yet recruiting | 68 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Feb 2026 | |
| NCT07085338 | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma | P2 | recruiting | 54 | St. Jude Children's Research Hospital | Nov 2025 | |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | P1/P2 | recruiting | 42 | Washington University School of Medicine | Dec 2025 | |
| NCT06951503 | AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | P3 | recruiting | 560 | Akeso | May 2025 | |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | P1/P2 | active not recruiting | 500 | FBD Biologics Limited | Mar 2025 | |
| NCT07595913 | A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma | P3 | not yet recruiting | 240 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Jul 2026 | |
| NCT07606599 | A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure | P3 | not yet recruiting | 398 | Sichuan Baili Pharmaceutical Co., Ltd. | May 2026 | |
| NCT07582315 | PANKU-BTC01 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) | P3 | not yet recruiting | 538 | Sichuan Baili Pharmaceutical Co., Ltd. | May 2026 |
| NCT07487896 | A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | P3 | not yet recruiting | 440 | MediLink Therapeutics (Suzhou) Co., Ltd. | Apr 2026 | |
| NCT07391566 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | P1/P2 | not yet recruiting | 99 | Luye Pharma Group Ltd. | Mar 2026 | |
| NCT07318831 | Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children | P2 | recruiting | 27 | Tianjin Medical University Cancer Institute and Hospital | Jan 2026 | |
| NCT07238283 | II | Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer | P3 | recruiting | 662 | Jiangsu HengRui Medicine Co., Ltd. | Dec 2025 |
| NCT07474103 | SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC | N/A | recruiting | 49 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 2025 | |
| NCT07173387 | RAD-NALIRIFOX | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer | P2 | active not recruiting | 42 | Shandong Cancer Hospital and Institute | Oct 2025 |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | P2 | recruiting | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2025 | |
| NCT04199026 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | N/A | recruiting | 20 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT06751394 | TRACER | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer | P2 | not yet recruiting | 44 | Sixth Affiliated Hospital, Sun Yat-sen University | Jan 2025 |
| NCT06006273 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | P1 | recruiting | 48 | M.D. Anderson Cancer Center | Aug 2023 | |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | P1 | recruiting | 681 | Astellas Pharma Inc | Jun 2022 | |
| NCT07258147 | Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases | P2 | not yet recruiting | 30 | Sichuan University | Oct 2026 | |
| NCT07059338 | HERBIC | Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer | P2 | not yet recruiting | 34 | Sun Yat-sen University | Jul 2025 |
| NCT07235202 | PDAC | A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy | P1/P2 | recruiting | 45 | Shenzhen Majory Biotechnology Co., Ltd. | Dec 2025 |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | P2 | not yet recruiting | 124 | Fudan University | Nov 2024 | |
| NCT07375563 | NB-NK-2026 | Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma | P3 | recruiting | 5 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Nov 2025 |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | P3 | recruiting | 382 | Alliance for Clinical Trials in Oncology | Jan 2023 | |
| NCT07150403 | Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer | P2 | not yet recruiting | 74 | Federation Francophone de Cancerologie Digestive | Dec 2025 | |
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | P3 | recruiting | 686 | Luye Pharma Group Ltd. | Mar 2024 | |
| NCT05412082 | SMART TNT | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | P1 | recruiting | 25 | University of Miami | Oct 2022 |
| NCT05384821 | MetroWilms | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) | P1/P2 | recruiting | 28 | Centre Oscar Lambret | Sep 2022 |
| NCT05253846 | ShorTrip | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | P2 | active not recruiting | 63 | Gruppo Oncologico del Nord-Ovest | Jan 2022 |
| NCT07284134 | JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. | P3 | recruiting | 560 | Shanghai Junshi Bioscience Co., Ltd. | Dec 2025 | |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | P1/P2 | recruiting | 35 | Roswell Park Cancer Institute | Feb 2026 | |
| NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | P3 | not yet recruiting | 252 | Shanghai JMT-Bio Inc. | Oct 2025 | |
| NCT06846346 | GRACIE | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | P2 | recruiting | 88 | UNICANCER | Nov 2025 |
| NCT02885753 | OSCAR | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | P3 | recruiting | 348 | Federation Francophone de Cancerologie Digestive | Dec 2016 |
| NCT05239741 | MK-3475 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | P3 | active not recruiting | 100 | Merck Sharp & Dohme LLC | Apr 2022 |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | P4 | recruiting | 24 | Tang-Du Hospital | Mar 2024 | |
| NCT07123441 | II | A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer | P2 | not yet recruiting | 300 | Sanjun Cai | Sep 2025 |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | P2 | not yet recruiting | 46 | Peking University Cancer Hospital & Institute | Jun 2025 | |
| NCT06490536 | The Sagittarius Trial | P3 | recruiting | 700 | IFOM ETS - The AIRC Institute of Molecular Oncology | Oct 2024 | |
| NCT06485739 | Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma | P4 | not yet recruiting | 20 | First Affiliated Hospital Xi'an Jiaotong University | Jul 2024 | |
| NCT06835387 | Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | P2 | recruiting | 36 | Tiago Biachi de Castria | Jun 2025 | |
| NCT07543744 | A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI | P1 | recruiting | 180 | R-Pharm | Apr 2025 | |
| NCT05004116 | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer | P1/P2 | recruiting | 77 | Memorial Sloan Kettering Cancer Center | Aug 2021 | |
| NCT05382442 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | P2 | active not recruiting | 254 | Akeso | Jun 2022 | |
| NCT07309185 | Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy | P2 | recruiting | 66 | Shandong Tumor Hospital | Jul 2024 | |
| NCT06361316 | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer | N/A | recruiting | 53 | Kuirong Jiang | Apr 2024 | |
| NCT05854498 | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | P2 | recruiting | 50 | University of Wisconsin, Madison | Oct 2023 | |
| NCT07051785 | ARK | Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | P2 | not yet recruiting | 68 | Liu Huang | Jul 2025 |
| NCT06210971 | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | P2 | recruiting | 60 | Hebei Medical University Fourth Hospital | Feb 2024 | |
| NCT07150247 | Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer | P2 | recruiting | 20 | Sun Yat-sen University | Jun 2025 | |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | P3 | recruiting | 180 | Luye Pharma Group Ltd. | Sep 2024 | |
| NCT06509126 | IMPROVE-2 | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer | P3 | recruiting | 500 | National Cancer Institute, Naples | Jun 2024 |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | P1/P2 | withdrawn | 0 | Virginia Commonwealth University | Jun 2021 | |
| NCT06459180 | MK-2870 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | P3 | active not recruiting | 686 | Merck Sharp & Dohme LLC | Jul 2024 |
| NCT06967155 | A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer | P2 | active not recruiting | 23 | Blokhin's Russian Cancer Research Center | Mar 2025 | |
| NCT06792695 | CANTOR | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | P2 | recruiting | 120 | AstraZeneca | Mar 2025 |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | P1 | recruiting | 132 | MOMA Therapeutics | Jul 2025 | |
| NCT05365581 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | P1 | recruiting | 398 | Astellas Pharma Global Development, Inc. | Jun 2022 | |
| NCT06250972 | PTCA199-11 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer | P3 | recruiting | 210 | Fudan University | May 2024 |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | P3 | recruiting | 450 | Qilu Pharmaceutical Co., Ltd. | Jun 2025 | |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | P2 | not yet recruiting | 68 | Harbin Medical University | Oct 2024 | |
| NCT07062536 | mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line | P2 | not yet recruiting | 130 | Seoul National University Bundang Hospital | Jun 2026 | |
| NCT06680622 | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | P2 | active not recruiting | 126 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Mar 2025 | |
| NCT07524374 | II | SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy | P2 | not yet recruiting | 33 | Zhigang Li | Mar 2026 |
| NCT06649292 | SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | P3 | recruiting | 524 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Nov 2024 | |
| NCT07229846 | QL1706 | A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | P2 | not yet recruiting | 30 | Yanqiao Zhang | Feb 2026 |
| NCT06827717 | II | Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma | P2 | recruiting | 29 | Sun Yat-sen University | Apr 2025 |
| NCT07474727 | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | P2 | not yet recruiting | 180 | Multitude Therapeutics Inc. | Apr 2026 | |
| NCT06491134 | Liposomal Irinotecan With Cisplatin and Concurrent Radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma | P1 | not yet recruiting | 12 | Hebei Medical University Fourth Hospital | Jun 2024 | |
| NCT07415031 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | P2 | recruiting | 170 | Mirati Therapeutics Inc. | May 2026 | |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | not yet recruiting | 63 | Peking University | Feb 2025 | |
| NCT07457775 | Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS | P2 | not yet recruiting | 24 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Mar 2026 | |
| NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | P1 | recruiting | 25 | Astellas Pharma Global Development, Inc. | Oct 2025 | |
| NCT05694715 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | P1 | recruiting | 24 | University of California, San Francisco | May 2023 | |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | P2 | recruiting | 208 | Ming-Yuan Chen | Jun 2025 | |
| NCT05358704 | CRAFTER | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | P2 | suspended | 38 | Rutgers, The State University of New Jersey | May 2022 |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | P1 | recruiting | 22 | University of California, Irvine | Aug 2021 | |
| NCT04329494 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | P1 | recruiting | 49 | City of Hope Medical Center | Aug 2020 | |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | P1/P2 | recruiting | 56 | Peking University People's Hospital | Mar 2026 | |
| NCT07314385 | NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer | P1 | not yet recruiting | 24 | National Taiwan University Hospital | Jan 2026 | |
| NCT06820957 | Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body | P2/P3 | active not recruiting | 437 | Children's Oncology Group | Nov 2025 | |
| NCT07014540 | A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma | P4 | not yet recruiting | 45 | Beijing GoBroad Hospital | Jun 2025 | |
| NCT06820762 | II | Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | P2 | not yet recruiting | 40 | The Second Affiliated Hospital of Dalian Medical University | Feb 2025 |
| NCT06749691 | LIAES | Liposomal Irinotecan and Apatinib in ES-SCLC | P2 | recruiting | 30 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2024 |
| NCT06625320 | RASolute 302 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | P3 | active not recruiting | 500 | Revolution Medicines, Inc. | Oct 2024 |
| NCT06513455 | Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer | P1/P2 | not yet recruiting | 132 | Harbin Medical University | Sep 2024 | |
| NCT06578052 | Irinotecan Liposome in Combination With Capecitabine | N/A | recruiting | 20 | Junjie Hang | Aug 2024 | |
| NCT06238843 | G-HOPE-001 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) | P3 | active not recruiting | 464 | Innovent Biologics (Suzhou) Co. Ltd. | Jun 2024 |
| NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | P2 | recruiting | 120 | Sun Yat-Sen University Cancer Center | Jun 2023 | |
| NCT04211675 | STING | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | P1/P2 | recruiting | 31 | Nationwide Children's Hospital | Sep 2022 |
| NCT05472259 | NALPAC | A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) | P2 | recruiting | 134 | Belgian Group of Digestive Oncology | May 2022 |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | P1/P2 | recruiting | 442 | Artios Pharma Ltd | Jan 2021 | |
| NCT03017326 | PHITT | Paediatric Hepatic International Tumour Trial | P3 | active not recruiting | 450 | University of Birmingham | Aug 2017 |
| NCT06739928 | II | Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | P2 | recruiting | 120 | Guangzhou Institute of Respiratory Disease | Jan 2025 |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | P3 | recruiting | 490 | Beijing Konruns Pharmaceutical Co., Ltd. | Feb 2024 | |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | P3 | active not recruiting | 841 | Pfizer | Dec 2020 | |
| NCT07027748 | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma | P1 | recruiting | 18 | Steven DuBois, MD | Jun 2025 | |
| NCT06259058 | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer | P1/P2 | not yet recruiting | 96 | Tianjin Medical University Cancer Institute and Hospital | Apr 2024 | |
| NCT06501664 | Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC | P3 | not yet recruiting | 360 | Rui-hua Xu, MD, PhD | Aug 2024 | |
| NCT06894797 | Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. | N/A | recruiting | 68 | Peking University Cancer Hospital & Institute | Apr 2025 | |
| NCT06540326 | Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab | P2 | recruiting | 100 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Nov 2024 | |
| NCT06657690 | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC | P2 | recruiting | 56 | Sun Yat-sen University | Nov 2024 | |
| NCT00077285 | Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma | P2 | active not recruiting | 65 | Memorial Sloan Kettering Cancer Center | Oct 2003 | |
| NCT06499610 | Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer | P4 | not yet recruiting | 44 | First Affiliated Hospital Xi'an Jiaotong University | Jul 2024 | |
| NCT06766019 | II | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | P2 | active not recruiting | 47 | The First Affiliated Hospital with Nanjing Medical University | Oct 2024 |
| NCT06365008 | Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer | P2 | recruiting | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2024 | |
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | P2 | recruiting | 224 | AstraZeneca | Dec 2023 | |
| NCT05722327 | MRTX849 | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | P1 | active not recruiting | 24 | M.D. Anderson Cancer Center | Dec 2023 |
| NCT04743661 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | P2 | active not recruiting | 62 | Pediatric Brain Tumor Consortium | Apr 2022 | |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | P3 | recruiting | 330 | Shanghai Children's Medical Center | Mar 2021 | |
| NCT04385277 | GM-CSF | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | P2 | active not recruiting | 41 | Children's Oncology Group | Dec 2020 |
| NCT06478043 | A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC | P2 | not yet recruiting | 54 | Zhejiang Cancer Hospital | Sep 2024 | |
| NCT05424692 | PTC | Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer | N/A | recruiting | 200 | Peking Union Medical College Hospital | Sep 2021 |
| NCT05838768 | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | P1 | active not recruiting | 123 | Novartis Pharmaceuticals | Jun 2023 | |
| NCT06577376 | A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma | P1/P2 | not yet recruiting | 252 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Aug 2024 | |
| NCT07047560 | II | Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study | P2 | recruiting | 46 | Tianjin Medical University Cancer Institute and Hospital | Sep 2024 |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | P2 | recruiting | 94 | SWOG Cancer Research Network | Jun 2020 | |
| NCT07044921 | II | Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. | P2 | recruiting | 30 | Chinese PLA General Hospital | Sep 2024 |
| NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer | P1 | not yet recruiting | 30 | City of Hope Medical Center | Jul 2026 | |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | P2 | recruiting | 256 | Children's Oncology Group | Oct 2020 | |
| NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | P2 | not yet recruiting | 31 | China Medical University, China | Jan 2026 | |
| NCT07011576 | FRUITFUL | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) | P2 | recruiting | 60 | SCRI Development Innovations, LLC | Sep 2025 |
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | P2 | not yet recruiting | 33 | The First Affiliated Hospital of Zhengzhou University | Aug 2025 | |
| NCT07104604 | Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement | P1 | recruiting | 59 | Affiliated Cancer Hospital of Shantou University Medical College | Aug 2025 | |
| NCT05733689 | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | P1 | recruiting | 20 | University of California, Irvine | Jun 2025 | |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | P4 | not yet recruiting | 31 | China Medical University, China | Apr 2025 | |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | N/A | not yet recruiting | 60 | Zhou Chengzhi | Jul 2024 | |
| NCT06123494 | SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen | P3 | recruiting | 360 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2024 | |
| NCT06714357 | VICTORIA | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer | P2 | recruiting | 130 | National Cancer Institute, Naples | Mar 2025 |
| NCT05391126 | GENOCARE | GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | N/A | recruiting | 178 | Reema A. Patel | Sep 2022 |
| NCT04361708 | I-FLOAT | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | P1 | recruiting | 54 | University of Chicago | May 2020 |
| NCT05999994 | CAMPFIRE | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | P2 | recruiting | 105 | Eli Lilly and Company | Jan 2020 |
| NCT01864109 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | P2 | active not recruiting | 83 | Memorial Sloan Kettering Cancer Center | May 2013 | |
| NCT00492999 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | P2 | active not recruiting | 64 | Memorial Sloan Kettering Cancer Center | May 2007 | |
| NCT06356311 | TroFuse-015 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | P3 | active not recruiting | 450 | Merck Sharp & Dohme LLC | May 2024 |
| NCT07092306 | NALIRI-VT | A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma | P2 | not yet recruiting | 74 | Tang Xiaodong | Aug 2025 |
| NCT05806931 | SCOTI | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | P2 | recruiting | 50 | Rutgers, The State University of New Jersey | May 2023 |
| NCT07441369 | Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer | P2 | enrolling by invitation | 16 | Fudan University | May 2026 | |
| NCT05669339 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | P2 | recruiting | 12 | University of Florida | Dec 2024 | |
| NCT06405139 | Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer | P2 | recruiting | 36 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | May 2024 | |
| NCT06370754 | FD-IMPACT | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment | P1/P2 | not yet recruiting | 117 | Fudan University | Apr 2024 |
| NCT06375473 | MA-PC-RWS-011 | Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients | — | recruiting | 3,000 | Peking Union Medical College Hospital | Apr 2024 |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | P1/P2 | recruiting | 10 | National University Hospital, Singapore | Feb 2023 | |
| NCT06332950 | II | Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | P1/P2 | not yet recruiting | 80 | Baohui Han | Apr 2024 |
| NCT06210360 | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX | P2 | not yet recruiting | 134 | Changhai Hospital | Feb 2024 | |
| NCT06782685 | Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV | P1/P2 | recruiting | 138 | Dai, Guanghai | Jun 2024 | |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | P1/P2 | active not recruiting | 87 | Idience Co., Ltd. | Jun 2021 | |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | P3 | active not recruiting | 236 | National Cancer Institute (NCI) | Sep 2009 | |
| NCT02595931 | M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | P1 | active not recruiting | 66 | National Cancer Institute (NCI) | Jul 2016 | |
| NCT04514497 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | P1 | active not recruiting | 29 | National Cancer Institute (NCI) | Oct 2021 | |
| NCT05688215 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | P1/P2 | recruiting | 56 | Jonsson Comprehensive Cancer Center | Mar 2023 | |
| NCT06821997 | NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial | P2 | recruiting | 20 | Roswell Park Cancer Institute | Mar 2026 | |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | P2 | recruiting | 173 | Hebei Medical University Fourth Hospital | Jan 2024 | |
| NCT05062317 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | P2 | recruiting | 120 | M.D. Anderson Cancer Center | Apr 2022 | |
| NCT05945823 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | P2 | active not recruiting | 53 | Taiho Oncology, Inc. | Jul 2023 | |
| NCT04796012 | VITAS | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | P1/P2 | recruiting | 23 | University of Texas Southwestern Medical Center | Apr 2023 |
| NCT04689347 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | P1/P2 | recruiting | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Jan 2021 | |
| NCT06656091 | A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | P3 | not yet recruiting | 450 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Oct 2024 | |
| NCT03641313 | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | P2 | active not recruiting | 17 | National Cancer Institute (NCI) | Nov 2020 | |
| NCT06172036 | CAPT-02 | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab | P2 | not yet recruiting | 180 | Zhejiang University | Jan 2024 |
| NCT04539808 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | P2 | active not recruiting | 42 | OHSU Knight Cancer Institute | May 2021 | |
| NCT06166589 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | P2 | not yet recruiting | 19 | Shanghai Zhongshan Hospital | Jan 2024 | |
| NCT07060014 | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | P1 | not yet recruiting | 22 | The Methodist Hospital Research Institute | Jul 2025 | |
| NCT06763029 | VICPROIRI | Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer | P2 | recruiting | 36 | Fudan University | Feb 2025 |
| NCT06710821 | Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors | P1 | not yet recruiting | 40 | Yizhuo Zhang | Dec 2024 | |
| NCT06700603 | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | P2 | not yet recruiting | 48 | Rui-hua Xu, MD, PhD | Nov 2024 | |
| NCT06643793 | II | Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC | P2 | recruiting | 30 | Affiliated Hospital of Nantong University | Nov 2024 |
| NCT06531278 | Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety | P2 | recruiting | 40 | Jiang Long | Jul 2024 | |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | N/A | not yet recruiting | 30 | Yunpeng Liu | Jul 2024 | |
| NCT06341296 | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | P2 | recruiting | 86 | West China Hospital | Jun 2024 | |
| NCT06258642 | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | N/A | recruiting | 39 | Fudan University | Apr 2024 | |
| NCT06107413 | IV | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | P2 | active not recruiting | 280 | AbbVie | Nov 2023 |
| NCT05400603 | Aflac-NBL-2002 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma | P1 | recruiting | 24 | Emory University | Nov 2023 |
| NCT05440786 | LY2835219 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | P2 | active not recruiting | 46 | Eli Lilly and Company | Sep 2022 |
| NCT05727163 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | P2 | recruiting | 194 | Sun Yat-sen University | Jul 2022 | |
| NCT06532344 | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer | P1 | active not recruiting | 32 | Ono Pharmaceutical Co., Ltd. | Jul 2021 | |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | P2 | active not recruiting | 176 | ECOG-ACRIN Cancer Research Group | Aug 2020 | |
| NCT04443543 | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer | P2 | not yet recruiting | 222 | Fudan University | Jun 2020 | |
| NCT04005339 | NAPOLI-2 | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | P2 | active not recruiting | 48 | Georgetown University | Jul 2019 |
| NCT03483038 | A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | P2 | active not recruiting | 45 | University of Florida | Dec 2018 | |
| NCT03533582 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | P3 | active not recruiting | 537 | Children's Oncology Group | May 2018 | |
| NCT00248287 | CA225200 | PhII ICb With/Without Erbitux in MBC Pts | P2 | active not recruiting | 154 | US Oncology Research | Jul 2005 |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | P2 | recruiting | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Apr 2024 | |
| NCT05962502 | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | P2 | recruiting | 54 | Sun Yat-sen University | Aug 2023 | |
| NCT06417476 | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | P2 | active not recruiting | 66 | Pei-Rong Ding | Dec 2022 | |
| NCT05148767 | UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer | P4 | recruiting | 606 | Zhejiang Cancer Hospital | Jan 2022 | |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | P3 | recruiting | 416 | Sunshine Lake Pharma Co., Ltd. | Jan 2021 | |
| NCT06340204 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | P1 | recruiting | 44 | Peking University People's Hospital | Mar 2024 | |
| NCT06801730 | NALIRIBVRG | Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma | P2 | recruiting | 38 | Zhifeng Tian,MD | Jan 2025 |
| NCT06351020 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | P3 | active not recruiting | 387 | LaNova Medicines Zhejiang Co., Ltd. | Jun 2024 | |
| NCT06394713 | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | P1/P2 | not yet recruiting | 60 | Qilu Pharmaceutical Co., Ltd. | Jun 2024 | |
| NCT06011772 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | Early P1 | active not recruiting | 2 | Roswell Park Cancer Institute | Dec 2023 | |
| NCT06514313 | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. | P2 | recruiting | 110 | Yizhuo Zhang | Jul 2024 | |
| NCT06055179 | XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) | N/A | recruiting | 98 | Guangzhou University of Traditional Chinese Medicine | Mar 2024 | |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | P2 | recruiting | 51 | West China Hospital | Aug 2024 | |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | P2/P3 | recruiting | 286 | Shanghai JMT-Bio Inc. | Apr 2022 | |
| NCT03773367 | INTENSE | Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | P2 | active not recruiting | 60 | Lund University Hospital | Dec 2018 |
| NCT06697366 | Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer | P2 | not yet recruiting | 27 | Ruijin Hospital | Nov 2024 | |
| NCT06699459 | NICRRBTC | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC | P2 | not yet recruiting | 76 | Sir Run Run Shaw Hospital | Nov 2024 |
| NCT02567435 | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | P3 | active not recruiting | 325 | National Cancer Institute (NCI) | Jun 2016 | |
| NCT05843188 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | P2 | active not recruiting | 155 | University Health Network, Toronto | Aug 2023 | |
| NCT05462236 | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | P2 | recruiting | 120 | AUM Biosciences Pte Ltd | Apr 2023 | |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | P3 | active not recruiting | 592 | AstraZeneca | Mar 2024 | |
| NCT06192680 | Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | P2 | not yet recruiting | 63 | Harbin Medical University | Apr 2024 | |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | P1/P2 | recruiting | 70 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Oct 2022 | |
| NCT03829462 | NEXT-REGIRI | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients | P3 | active not recruiting | 377 | Institut du Cancer de Montpellier - Val d'Aurelle | Mar 2019 |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | P1 | active not recruiting | 18 | City of Hope Medical Center | Apr 2016 | |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | recruiting | 550 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2020 | |
| NCT06769425 | HS-10502 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | P1 | recruiting | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | May 2025 |
| NCT01189643 | Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | Early P1 | active not recruiting | 15 | Memorial Sloan Kettering Cancer Center | Aug 2010 | |
| NCT00045201 | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | P1 | active not recruiting | 60 | National Cancer Institute (NCI) | Jun 2002 | |
| NCT05312398 | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | P2 | active not recruiting | 219 | University of Campania Luigi Vanvitelli | Jul 2021 | |
| NCT06321081 | ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | P2 | recruiting | 60 | Beijing Hospital | Mar 2024 | |
| NCT05846867 | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | P1/P2 | active not recruiting | 170 | Akeso | May 2023 | |
| NCT06341309 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | P1/P2 | not yet recruiting | 20 | West China Hospital | Aug 2024 | |
| NCT06443307 | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | — | recruiting | 933 | Peking University | Jul 2024 | |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | P2 | active not recruiting | 35 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aug 2022 | |
| NCT04034173 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | P2 | not yet recruiting | 120 | Ludwig-Maximilians - University of Munich | Aug 2019 | |
| NCT05457829 | Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study | P2 | recruiting | 88 | Sun Yat-sen University | Dec 2023 | |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | P1/P2 | not yet recruiting | 74 | Sun Yat-sen University | Jun 2024 | |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | P2 | active not recruiting | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2021 | |
| NCT04094688 | SOLARIS | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | P3 | active not recruiting | 455 | Alliance for Clinical Trials in Oncology | Oct 2019 |
| NCT03764553 | LyRICX | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | P2 | active not recruiting | 320 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | May 2019 |
| NCT07056777 | Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer | P1/P2 | recruiting | 186 | Zhejiang Doer Biologics Co., Ltd. | Mar 2025 | |
| NCT06387810 | undetermined | Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer | P2 | recruiting | 45 | Peking Union Medical College Hospital | Apr 2024 |
| NCT05978492 | A Study of TXN10128 in Subjects With Solid Tumors | P1 | recruiting | 96 | Txinno Bioscience Inc. | Jul 2023 | |
| NCT06094140 | NEO-IMPACT | NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer | P2 | active not recruiting | 20 | Australasian Gastro-Intestinal Trials Group | May 2022 |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | P1 | active not recruiting | 138 | Toray Industries, Inc | Apr 2019 | |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | P2 | active not recruiting | 350 | Actuate Therapeutics Inc. | Jan 2019 | |
| NCT03493048 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | P2 | active not recruiting | 146 | Sun Yat-sen University | Apr 2018 | |
| NCT03189706 | Study of Chemoimmunotherapy for High-Risk Neuroblastoma | Early P1 | active not recruiting | 48 | Memorial Sloan Kettering Cancer Center | Jun 2017 | |
| NCT04008030 | CheckMate 8HW | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | P3 | active not recruiting | 839 | Bristol-Myers Squibb | Aug 2019 |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer | P4 | suspended | 36 | University of Chicago | Dec 2014 | |
| NCT07542002 | Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory Study | P2 | recruiting | 37 | Ningbo Medical Center Lihuili Hospital | Mar 2025 | |
| NCT06304974 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) | P3 | active not recruiting | 497 | Sichuan Baili Pharmaceutical Co., Ltd. | Mar 2024 | |
| NCT05238831 | ACT | SMMART Adaptive Clinical Treatment (ACT) Trial | Early P1 | withdrawn | 0 | OHSU Knight Cancer Institute | Jan 2023 |
| NCT04390399 | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | P2 | active not recruiting | 328 | ImmunityBio, Inc. | Jul 2020 | |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | P1/P2 | terminated | 226 | Astellas Pharma Global Development, Inc. | Oct 2021 | |
| NCT05235542 | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | P1/P2 | completed | 128 | Akeso | Mar 2022 | |
| NCT04776655 | LIBImAb | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | P3 | recruiting | 280 | Azienda USL Reggio Emilia - IRCCS | Apr 2021 |
| NCT06225622 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | P1 | unknown | 78 | Shanghai Zhongshan Hospital | Mar 2024 | |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | P2/P3 | active not recruiting | 140 | Oslo University Hospital | Sep 2016 | |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Apr 2023 | |
| NCT05153239 | LAGOON | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | P3 | completed | 705 | PharmaMar | Jul 2022 |
| NCT03279237 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | P1 | completed | 25 | Massachusetts General Hospital | Oct 2017 | |
| NCT06437678 | Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | P2 | unknown | 50 | Zhejiang Cancer Hospital | May 2024 | |
| NCT05731518 | ES-SCLC | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | P1/P2 | unknown | 67 | Biocity Biopharmaceutics Co., Ltd. | Feb 2023 |
| NCT05818982 | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | P2 | unknown | 72 | Peking University | Feb 2023 | |
| NCT04821284 | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer | P1/P2 | active not recruiting | 120 | Flemming Forsberg | Dec 2021 | |
| NCT02308527 | BEACON | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | P2 | completed | 225 | University of Birmingham | Jul 2013 |
| NCT05737563 | Escape | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC | P3 | unknown | 380 | Sun Yat-sen University | Feb 2023 |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II,Multi-center, Clinical Study. | P1/P2 | recruiting | 125 | Sun Yat-sen University | Aug 2021 | |
| NCT04595266 | LIVERPEARL | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | P2 | active not recruiting | 48 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Jun 2021 |
| NCT02980510 | PANIRINOX | Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients | P2 | active not recruiting | 219 | UNICANCER | Dec 2016 |
| NCT06486545 | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer | N/A | not yet recruiting | 18 | Hunan Cancer Hospital | Aug 2024 | |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | P2 | recruiting | 138 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Mar 2024 | |
| NCT06139211 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | P1/P2 | recruiting | 186 | Shanghai Junshi Bioscience Co., Ltd. | Jan 2024 | |
| NCT04697628 | innovaTV 301 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | P3 | completed | 502 | Seagen, a wholly owned subsidiary of Pfizer | Feb 2021 |
| NCT06282120 | Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer | — | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Jan 2024 | |
| NCT04393584 | RusGCG-01 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma | P2/P3 | unknown | 538 | Blokhin's Russian Cancer Research Center | Jan 2019 |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | P1/P2 | enrolling by invitation | 52 | National Health Research Institutes, Taiwan | Aug 2025 | |
| NCT07204574 | The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer | P1/P2 | recruiting | 40 | Chang Gung Memorial Hospital | May 2025 | |
| NCT06538623 | HAIC | Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer | P2 | completed | 40 | Ruijin Hospital | Aug 2024 |
| NCT06430827 | Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma | P2 | unknown | 20 | Ba Yi | Jun 2024 | |
| NCT06475326 | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer | P2 | recruiting | 87 | Fudan University | Jun 2024 | |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | P2 | recruiting | 20 | The First Affiliated Hospital with Nanjing Medical University | Dec 2023 | |
| NCT05859750 | A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer | P2 | recruiting | 78 | Akeso | May 2023 | |
| NCT05319639 | POFI | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | P1/P2 | recruiting | 51 | Fujian Cancer Hospital | Feb 2023 |
| NCT05750290 | CKD-702 Plus Irinotecan in Gastric Cancer | P2 | unknown | 40 | National Cancer Center, Korea | Dec 2022 | |
| NCT05229003 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | P2 | recruiting | 44 | Fudan University | Mar 2022 | |
| NCT06760117 | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors | P1 | recruiting | 39 | Sun Yat-sen University | Jan 2022 | |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | P2 | active not recruiting | 22 | Sichuan Baili Pharmaceutical Co., Ltd. | Dec 2021 | |
| NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | P2 | unknown | 77 | Seoul National University Hospital | Jul 2020 | |
| NCT04371224 | NaliCap | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer | P2 | unknown | 200 | Seoul National University Hospital | Jun 2020 |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | P2 | recruiting | 109 | Beijing Sanbo Brain Hospital | Feb 2020 | |
| NCT03290937 | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | P1 | completed | 34 | M.D. Anderson Cancer Center | Dec 2017 | |
| NCT06766266 | Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment | P1 | recruiting | 18 | First Affiliated Hospital of Chongqing Medical University | Jan 2025 | |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | P2 | unknown | 40 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Mar 2024 | |
| NCT01858168 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | P1 | completed | 49 | Massachusetts General Hospital | Jul 2013 | |
| NCT05342636 | MK-3475 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | P1/P2 | completed | 90 | Merck Sharp & Dohme LLC | Jul 2022 |
| NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | P1 | terminated | 3 | EMD Serono Research & Development Institute, Inc. | Oct 2024 | |
| NCT05628038 | TORCH-R | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer | P2 | recruiting | 93 | Fudan University | Nov 2022 |
| NCT05278351 | Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC | P2 | unknown | 87 | Shanghai Zhongshan Hospital | Jul 2022 | |
| NCT05643677 | Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | P2 | unknown | 47 | Fujian Medical University | Dec 2022 | |
| NCT05669807 | Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | P2 | unknown | 184 | Zhejiang Cancer Hospital | Dec 2022 | |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | P2 | active not recruiting | 5 | OHSU Knight Cancer Institute | Apr 2021 | |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | P1/P2 | active not recruiting | 64 | Emory University | Jan 2018 | |
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | P2 | completed | 24 | National Cancer Institute (NCI) | Jun 2019 | |
| NCT06300489 | Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | P1 | unknown | 30 | Zhejiang Cancer Hospital | Mar 2024 | |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | P2 | active not recruiting | 128 | Pfizer | May 2019 | |
| NCT05595889 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | P2 | unknown | 40 | Fujian Cancer Hospital | Dec 2022 | |
| NCT04617457 | HOLIPANC | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas | P2 | unknown | 150 | University of Cologne | Oct 2021 |
| NCT06225999 | Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas | P2 | completed | 41 | Institut de Recherches Internationales Servier | Apr 2024 | |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | P1/P2 | recruiting | 300 | Binhui Biopharmaceutical Co., Ltd. | Apr 2019 | |
| NCT04238819 | LY2835219 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | P1/P2 | completed | 47 | Eli Lilly and Company | Nov 2020 |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | P1/P2 | unknown | 18 | Academic and Community Cancer Research United | Nov 2018 | |
| NCT02967289 | IROCAS | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | P3 | completed | 792 | UNICANCER | Mar 2017 |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | P1 | terminated | 40 | Actuate Therapeutics Inc. | Jun 2020 | |
| NCT03365882 | S1613 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | P2 | completed | 240 | SWOG Cancer Research Network | Nov 2017 |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | P1/P2 | completed | 316 | PharmaMar | May 2016 | |
| NCT06169202 | A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients | — | unknown | 50 | China Medical University, China | Jun 2023 | |
| NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | P3 | unknown | 351 | RemeGen Co., Ltd. | Mar 2021 | |
| NCT05546853 | LAP-NET1 | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | P1 | completed | 43 | University Hospital, Grenoble | Mar 2023 |
| NCT05620862 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | P1 | active not recruiting | 68 | Sun Yat-sen University | Oct 2022 | |
| NCT05015621 | A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma | P3 | unknown | 194 | Hutchison Medipharma Limited | Sep 2021 | |
| NCT04934618 | A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer | P2 | unknown | 85 | Nanfang Hospital, Southern Medical University | May 2020 | |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | P2 | terminated | 11 | University of Nebraska | Feb 2021 | |
| NCT04879368 | INTEGRATEIIb | RegoNivo vs Standard of Care Chemotherapy in AGOC | P3 | completed | 462 | Australasian Gastro-Intestinal Trials Group | May 2021 |
| NCT04535401 | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | P1 | unknown | 10 | National Cancer Institute (NCI) | Aug 2021 | |
| NCT04067115 | U01CA236220 | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients | P1/P2 | completed | 37 | Sarcoma Alliance for Research through Collaboration | Jan 2021 |
| NCT05383352 | SIRACUSA | A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas | P1 | completed | 177 | Ipsen | May 2022 |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | P2 | unknown | 80 | Zhejiang Cancer Hospital | Apr 2022 | |
| NCT05799443 | Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | P2 | unknown | 23 | Fujian Cancer Hospital | Apr 2023 | |
| NCT03328884 | Phenomenal | Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients | P2 | completed | 55 | MedSIR | May 2017 |
| NCT06197438 | POFI | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | P2 | unknown | 36 | Fujian Cancer Hospital | Jan 2024 |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | P2 | active not recruiting | 22 | Academic and Community Cancer Research United | Mar 2020 | |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | P2 | active not recruiting | 38 | XIANG YANQUN | May 2024 | |
| NCT05839470 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | P2 | unknown | 20 | Fujian Cancer Hospital | Nov 2023 | |
| NCT04083235 | NAPOLI 3 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment | P3 | completed | 770 | Ipsen | Feb 2020 |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | P1/P2 | completed | 21 | Memorial Sloan Kettering Cancer Center | Sep 2019 | |
| NCT05379790 | Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin | P1 | completed | 20 | Erasmus Medical Center | May 2022 | |
| NCT06538207 | An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer | P1 | completed | 46 | Ono Pharmaceutical Co., Ltd. | Jan 2021 | |
| NCT02934529 | AIO-KRK-0114 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | P3 | completed | 673 | Ludwig-Maximilians - University of Munich | Mar 2015 |
| NCT03693677 | FUNGEMAX | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI | P2 | completed | 288 | Federation Francophone de Cancerologie Digestive | Nov 2018 |
| NCT04492033 | ABL001 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | P1/P2 | terminated | 41 | Handok Inc. | Jun 2020 |
| NCT06003998 | INTERACT-II | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab | P2 | unknown | 85 | Catharina Ziekenhuis Eindhoven | Dec 2022 |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | P2 | unknown | 102 | Shanghai JMT-Bio Inc. | Jan 2024 | |
| NCT05363007 | SINAI | Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma | P2 | unknown | 60 | National Taiwan University Hospital | May 2022 |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | P2 | unknown | 100 | Benaroya Research Institute | Nov 2020 | |
| NCT04358354 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | P3 | unknown | 388 | Sixth Affiliated Hospital, Sun Yat-sen University | Oct 2020 | |
| NCT04513951 | AVETRIC | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | P2 | completed | 62 | Gruppo Oncologico del Nord-Ovest | Apr 2020 |
| NCT02975882 | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | P1 | completed | 33 | Children's Oncology Group | Aug 2017 | |
| NCT01910610 | STRATEGIC-1 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | P3 | unknown | 464 | GERCOR - Multidisciplinary Oncology Cooperative Group | Oct 2013 |
| NCT02087475 | Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin | P3 | unknown | 360 | Sixth Affiliated Hospital, Sun Yat-sen University | Jan 2011 | |
| NCT04757779 | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | P2 | unknown | 40 | First People's Hospital of Hangzhou | Dec 2019 | |
| NCT04752696 | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | P2 | completed | 41 | Cardiff Oncology | May 2021 | |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | P1 | unknown | 20 | Ruijin Hospital | Dec 2021 | |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | P2 | unknown | 180 | OncXerna Theraputics, Inc. | Aug 2022 | |
| NCT05047991 | Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | P2 | unknown | 153 | CSPC Ouyi Pharmaceutical Co., Ltd. | Oct 2021 | |
| NCT03837977 | NET02 | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma | P2 | completed | 58 | The Christie NHS Foundation Trust | Nov 2018 |
| NCT05049863 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | P1 | terminated | 17 | Washington University School of Medicine | Feb 2023 | |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | P1/P2 | completed | 34 | University of Michigan Rogel Cancer Center | May 2019 | |
| NCT04442984 | IRIGA | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) | P2 | unknown | 326 | Blokhin's Russian Cancer Research Center | Nov 2019 |
| NCT05160727 | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | P2 | unknown | 44 | Zhejiang Cancer Hospital | Oct 2021 | |
| NCT04072198 | NIVACOR | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | P2 | completed | 73 | Gruppo Oncologico Italiano di Ricerca Clinica | Sep 2019 |
| NCT03323034 | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | P1 | completed | 30 | Children's Oncology Group | Jan 2018 | |
| NCT03861702 | Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: | P2 | completed | 28 | Nelson Yee | Sep 2020 | |
| NCT03699319 | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | P1/P2 | completed | 49 | David Bajor, MD | Dec 2018 | |
| NCT02419495 | KPT-330 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | P1 | terminated | 221 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT04109924 | TAS-102 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | P2 | completed | 42 | Roswell Park Cancer Institute | Dec 2019 |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | P2 | terminated | 180 | NuCana plc | Apr 2023 | |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | P2 | terminated | 11 | Roswell Park Cancer Institute | Jun 2019 | |
| NCT02138617 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | P2 | completed | 100 | UNC Lineberger Comprehensive Cancer Center | May 2014 | |
| NCT04189055 | CETIDYL | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. | P2 | unknown | 72 | Hôpital Franco-Britannique-Fondation Cognacq-Jay | Jan 2020 |
| NCT04525014 | PIRATE | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors | P1 | terminated | 2 | EpicentRx, Inc. | Jan 2023 |
| NCT03403101 | The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer | P2 | unknown | 65 | Fudan University | Jul 2020 | |
| NCT04929652 | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer | P1/P2 | unknown | 48 | Jiangsu Cancer Institute & Hospital | Jun 2021 | |
| NCT04796948 | A Study of Irinotecan Liposome in Advanced Pancreatic Cancer | P1 | completed | 41 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2021 | |
| NCT03693807 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | P2 | completed | 35 | Memorial Sloan Kettering Cancer Center | Oct 2018 | |
| NCT05330429 | ELEVATE CRC | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | P2 | terminated | 77 | Gilead Sciences | Jul 2022 |
| NCT04728035 | Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance | P1 | completed | 119 | CSPC Ouyi Pharmaceutical Co., Ltd. | May 2021 | |
| NCT04641871 | Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies | P1 | completed | 78 | Symphogen A/S | Oct 2020 | |
| NCT05031975 | ERASE-TMZ | Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | P2 | unknown | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | May 2022 |
| NCT03970252 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | Early P1 | completed | 28 | Jonsson Comprehensive Cancer Center | Jul 2019 | |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | P1/P2 | completed | 36 | Julie Krystal | Oct 2013 | |
| NCT02705300 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | P2 | completed | 70 | Vejle Hospital | May 2016 | |
| NCT02720068 | MK-4280 | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | P1 | completed | 481 | Merck Sharp & Dohme LLC | May 2016 |
| NCT02085148 | A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy | P1 | completed | 62 | Bayer | Apr 2014 | |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | P2 | unknown | 39 | Fudan University | Jul 2022 | |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | P2 | terminated | 96 | BeiGene | Oct 2022 | |
| NCT02047474 | Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | P2 | completed | 46 | Yale University | Mar 2014 | |
| NCT04059562 | TRITICC | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma | P2 | completed | 28 | Heinrich-Heine University, Duesseldorf | Oct 2021 |
| NCT05732129 | HRD | The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | P2 | unknown | 29 | Fudan University | Mar 2023 |
| NCT04842526 | Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study | P2 | unknown | 27 | Tianjin Medical University Cancer Institute and Hospital | Apr 2021 | |
| NCT03608046 | AVETUXIRI | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | P2 | unknown | 59 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Oct 2018 |
| NCT04034459 | AIO-KRK-0116 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | P2 | unknown | 109 | Ludwig-Maximilians - University of Munich | Nov 2016 |
| NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | P1 | unknown | 30 | South Plains Oncology Consortium | Dec 2013 | |
| NCT03567629 | Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer | P2 | unknown | 130 | Peking University | May 2018 | |
| NCT04988191 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | P1/P2 | unknown | 44 | Peking University | Dec 2020 | |
| NCT03263429 | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | P1/P2 | completed | 29 | Vanderbilt-Ingram Cancer Center | Aug 2017 | |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | P2 | unknown | 70 | Salah Azaïz Cancer Institute | Nov 2020 | |
| NCT01959139 | S1313 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | P1/P2 | completed | 126 | SWOG Cancer Research Network | Jan 2014 |
| NCT03810742 | Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors | P1 | completed | 44 | PharmaEngine | Mar 2019 | |
| NCT05217069 | FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC | P2 | completed | 57 | Ludwig-Maximilians - University of Munich | Sep 2019 | |
| NCT05546411 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | P2 | terminated | 8 | Kimberly Perez, MD | Jan 2023 | |
| NCT04915807 | RWD | Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | — | unknown | 222 | Hallym University Medical Center | Jun 2021 |
| NCT05824455 | JS109 | A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors | P1/P2 | terminated | 4 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. | Mar 2023 |
| NCT02539537 | NEOPAN | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | P3 | completed | 171 | UNICANCER | Oct 2015 |
| NCT03721653 | AtezoTRIBE | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | P2 | completed | 218 | Gruppo Oncologico del Nord-Ovest | Nov 2018 |
| NCT04486651 | HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer | P3 | unknown | 560 | Taizhou Hanzhong biomedical co. LTD | Sep 2020 | |
| NCT04985201 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | P2 | unknown | 40 | Shanghai Pulmonary Hospital, Shanghai, China | Nov 2021 | |
| NCT03487016 | FOOTPATH | First-line Therapy in Metastatic PDAC | P2 | unknown | 270 | Ludwig-Maximilians - University of Munich | Feb 2019 |
| NCT03088813 | RESILIENT | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | P3 | completed | 491 | Ipsen | Apr 2018 |
| NCT05148195 | A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors | P2 | terminated | 86 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Dec 2021 | |
| NCT04808791 | GEJ | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | P2 | completed | 7 | AHS Cancer Control Alberta | Oct 2021 |
| NCT03374254 | MK-3475 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) | P1 | completed | 116 | Merck Sharp & Dohme LLC | Feb 2018 |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | P1 | terminated | 4 | Colin D. Weekes, M.D., PhD | Aug 2022 | |
| NCT05160896 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | P2 | unknown | 90 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Nov 2021 | |
| NCT05027100 | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | N/A | unknown | 33 | Haibo Zhang | Sep 2021 | |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy(Irinotecan Plus Platinum)and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer(SCLC) | P2 | unknown | 60 | Peking Union Medical College Hospital | Jun 2020 | |
| NCT04324476 | A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer | P2 | unknown | 50 | Jiangsu Cancer Institute & Hospital | Sep 2019 | |
| NCT02605265 | CinClare | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 | P3 | completed | 356 | Fudan University | Oct 2015 |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | P1/P2 | completed | 76 | National Cancer Institute (NCI) | Mar 2014 | |
| NCT03184870 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | P1/P2 | completed | 332 | Bristol-Myers Squibb | Aug 2017 | |
| NCT04912258 | Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis | P3 | unknown | 80 | Fudan University | Aug 2021 | |
| NCT04508452 | A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC | P2 | unknown | 91 | First Affiliated Hospital of Zhejiang University | May 2020 | |
| NCT03336216 | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | P2 | completed | 205 | Bristol-Myers Squibb | Dec 2017 | |
| NCT04569916 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | P2 | unknown | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Sep 2020 | |
| NCT02022644 | Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma | P1 | completed | 18 | University of California, San Francisco | Oct 2014 | |
| NCT02631733 | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | P1 | completed | 18 | National Cancer Institute (NCI) | May 2017 | |
| NCT03879798 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | P1/P2 | terminated | 22 | Memorial Sloan Kettering Cancer Center | Mar 2019 | |
| NCT03141034 | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | P2 | completed | 40 | Washington University School of Medicine | Nov 2017 | |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | P1/P2 | withdrawn | 0 | University of Southern California | Apr 2020 | |
| NCT01835041 | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | P1 | completed | 21 | Wake Forest University Health Sciences | Apr 2013 | |
| NCT04381910 | LY01610 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | P2 | completed | 66 | Luye Pharma Group Ltd. | Sep 2020 |
| NCT03726021 | Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer | P2 | completed | 47 | Qingdao Central Hospital | Jan 2018 | |
| NCT03126071 | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | P2 | unknown | 100 | Jiangsu Cancer Institute & Hospital | Feb 2017 | |
| NCT03279289 | AFEMA | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen | P2 | completed | 170 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Oct 2017 |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | P1/P2 | withdrawn | 0 | Devalingam Mahalingam | Sep 2022 | |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | P2 | terminated | 17 | CSPC Ouyi Pharmaceutical Co., Ltd. | Sep 2021 | |
| NCT04770623 | Docetaxel and Irinotecan in Gastric Cancer | P2 | completed | 32 | Menoufia University | Mar 2021 | |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | P3 | terminated | 92 | Sun Yat-sen University | Dec 2021 | |
| NCT04411537 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer | P2 | unknown | 50 | Fudan University | Jul 2020 | |
| NCT04411524 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer | P2 | unknown | 50 | Fudan University | Jul 2020 | |
| NCT03712397 | Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy | P2 | completed | 59 | National Health Research Institutes, Taiwan | Dec 2018 | |
| NCT00354835 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma | P3 | completed | 481 | Children's Oncology Group | Dec 2006 | |
| NCT03493061 | A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | P2 | completed | 60 | Sun Yat-sen University | Feb 2018 | |
| NCT03430843 | BGB-A317 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | P3 | completed | 512 | BeiGene | Jan 2018 |
| NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | P2 | unknown | 136 | Sixth Affiliated Hospital, Sun Yat-sen University | Jun 2020 | |
| NCT04394598 | A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer | P2 | unknown | 210 | Fudan University | Mar 2020 | |
| NCT03387904 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | P2 | unknown | 120 | The First Affiliated Hospital of Zhengzhou University | Jan 2019 | |
| NCT04833036 | c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | P2 | unknown | 120 | Fudan University | Oct 2019 | |
| NCT03751176 | BEYOND | Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal | P2 | unknown | 31 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Nov 2018 |
| NCT02928224 | BEACON CRC | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | P3 | completed | 702 | Pfizer | Oct 2016 |
| NCT03528785 | nITRo | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer | P2 | unknown | 67 | Centro Ricerche Cliniche di Verona | Mar 2018 |
| NCT03369041 | Study of the Practice of Debiri in France | — | unknown | 70 | Federation Francophone de Cancerologie Digestive | Feb 2016 | |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer | P2 | terminated | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Aug 2021 | |
| NCT03535727 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | P1/P2 | completed | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2018 | |
| NCT01926197 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | P3 | completed | 27 | Stanford University | Aug 2013 | |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | P2 | completed | 73 | National Cancer Institute (NCI) | Feb 2013 | |
| NCT02562716 | S1505 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | P2 | completed | 147 | SWOG Cancer Research Network | Jan 2016 |
| NCT04560166 | Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma | P2 | terminated | 2 | Y-mAbs Therapeutics | Nov 2021 | |
| NCT04097444 | QUATTRO-II | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | P2 | unknown | 112 | Chugai Pharmaceutical | Oct 2019 |
| NCT05042934 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | P1/P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Sep 2021 | |
| NCT05018182 | FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer | P2 | unknown | 69 | West China Hospital | Aug 2021 | |
| NCT03771846 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | P3 | unknown | 188 | Shi Ming | Aug 2018 | |
| NCT02588105 | AToM | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | P1 | completed | 84 | AstraZeneca | Nov 2015 |
| NCT04074343 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | P1 | completed | 20 | University of California, Irvine | Aug 2019 | |
| NCT03883919 | Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy | P1 | completed | 20 | Washington University School of Medicine | Jul 2019 | |
| NCT04446091 | MAC | A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) | P1/P2 | unknown | 40 | Zhejiang Cancer Hospital | Jul 2020 |
| NCT03231722 | TRIPLETE | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS | P3 | completed | 435 | Gruppo Oncologico del Nord-Ovest | Sep 2017 |
| NCT05039944 | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | P2 | terminated | 7 | Sichuan Baili Pharmaceutical Co., Ltd. | Nov 2021 | |
| NCT03554707 | SGT-53 in Children With Recurrent or Progressive CNS Malignancies | Early P1 | withdrawn | 0 | SynerGene Therapeutics, Inc. | Jun 2022 | |
| NCT03668418 | xenoZ | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | — | unknown | 120 | University of Pisa | Jun 2018 |
| NCT03468335 | PREDICT | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy | P3 | completed | 151 | AIO-Studien-gGmbH | Mar 2018 |
| NCT05178745 | Resection Observatory | — | completed | 140 | Sanofi | Sep 2016 | |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | P1 | terminated | 10 | Augusta University | Jan 2020 | |
| NCT03722108 | REGIRI | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | P1/P2 | terminated | 89 | UNICANCER | Feb 2019 |
| NCT03206151 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | P3 | completed | 520 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Dec 2017 | |
| NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | P2 | completed | 30 | Tianjin Medical University Cancer Institute and Hospital | May 2019 | |
| NCT04727853 | SCLC | Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | P2 | completed | 66 | CSPC Ouyi Pharmaceutical Co., Ltd. | Mar 2021 |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | P1 | completed | 18 | Stony Brook University | Oct 2019 | |
| NCT03329183 | High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 | P2 | unknown | 90 | Shanghai Changzheng Hospital | Mar 2019 | |
| NCT03933449 | MK-3475 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | P3 | completed | 123 | Merck Sharp & Dohme LLC | Dec 2016 |
| NCT02564263 | MK-3475 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | P3 | completed | 628 | Merck Sharp & Dohme LLC | Dec 2015 |
| NCT05074589 | Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer | P3 | completed | 298 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2018 | |
| NCT04247984 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | P2 | completed | 264 | Chinese Academy of Medical Sciences | May 2018 | |
| NCT03495921 | VITA | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | P3 | terminated | 32 | Gradalis, Inc. | Aug 2018 |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | P1 | completed | 47 | M.D. Anderson Cancer Center | Feb 2013 | |
| NCT03665441 | Trybeca-1 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | P3 | completed | 512 | ERYtech Pharma | Sep 2018 |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | P1/P2 | completed | 53 | Green Cross Corporation | Apr 2018 | |
| NCT04160416 | TRICAP | mXELOXIRI Combined With Molecular Targeted Drug in mCRC | P2 | unknown | 48 | First Affiliated Hospital of Zhejiang University | Jul 2019 |
| NCT04790448 | Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer | P1/P2 | completed | 37 | Sun Yat-sen University | Jul 2020 | |
| NCT04227886 | Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer | — | unknown | 250 | Fudan University | Dec 2019 | |
| NCT04101929 | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen | P2 | unknown | 126 | Fudan University | Oct 2019 | |
| NCT03316326 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | P2 | unknown | 35 | National Taiwan University Hospital | Nov 2017 | |
| NCT03797625 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | P2 | completed | 52 | Fudan University | May 2017 | |
| NCT03562390 | Irinotecan for Advanced and Metastatic Breast Cancer | P2 | unknown | 124 | Liaoning Cancer Hospital & Institute | Apr 2017 | |
| NCT04789941 | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix | P2 | unknown | 50 | Assiut University | Apr 2021 | |
| NCT04088604 | LY01610 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | P1 | completed | 38 | Luye Pharma Group Ltd. | Feb 2019 |
| NCT02489903 | QUADRUPLE THREAT | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | P2 | completed | 139 | EpicentRx, Inc. | Jun 2015 |
| NCT03522649 | GB201 | A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | P3 | unknown | 668 | 1Globe Health Institute LLC | Apr 2018 |
| NCT03164655 | SULTAN | Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network | P2 | completed | 20 | UNICANCER | Jul 2018 |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | P2 | terminated | 23 | Albert Einstein College of Medicine | Jan 2012 | |
| NCT03136055 | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | P2 | completed | 36 | University of California, San Francisco | Jun 2017 | |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P2 | completed | 3 | Northwestern University | Mar 2021 | |
| NCT04943627 | BRAVA | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | P3 | withdrawn | 0 | Agenus Inc. | Aug 2021 |
| NCT02890355 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | P2 | completed | 123 | National Cancer Institute (NCI) | Oct 2016 | |
| NCT03119064 | 329 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma | P1/P2 | terminated | 12 | Brown University | Nov 2017 |
| NCT03086616 | DIPG | CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009) | P1 | completed | 6 | Sabine Mueller, MD, PhD | Oct 2017 |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | P3 | terminated | 92 | Sun Yat-sen University | May 2018 | |
| NCT01079780 | Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | P2 | completed | 136 | Eastern Cooperative Oncology Group | Jan 2011 | |
| NCT04072445 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | P2 | completed | 28 | Mayo Clinic | Oct 2019 | |
| NCT02171325 | Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment | P2 | unknown | 54 | Guangdong Association of Clinical Trials | Jun 2014 | |
| NCT02021422 | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | P1 | completed | 13 | Baylor Research Institute | Dec 2013 | |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | P2 | completed | 108 | National Cancer Institute (NCI) | Nov 2010 | |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | P1/P2 | completed | 2 | Barbara Ann Karmanos Cancer Institute | Dec 2015 | |
| NCT03963193 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | P2 | unknown | 112 | Henan Cancer Hospital | Jun 2019 | |
| NCT03613753 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | P2 | unknown | 72 | ShengFa Su | Jun 2018 | |
| NCT04299880 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | P1 | completed | 7 | Sumitomo Pharma America, Inc. | Feb 2020 | |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | P1/P2 | completed | 40 | Eisai Inc. | Mar 2018 | |
| NCT02753127 | CanStem303C | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | P3 | completed | 1,253 | Sumitomo Pharma America, Inc. | Jun 2016 |
| NCT02596828 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | P2 | completed | 4 | University of Regensburg | Apr 2016 | |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | P2 | terminated | 11 | Peking University | Sep 2017 | |
| NCT04482257 | Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. | P1 | unknown | 48 | CSPC Ouyi Pharmaceutical Co., Ltd. | Jul 2020 | |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | P2 | unknown | 45 | Chinese Academy of Medical Sciences | Jul 2018 | |
| NCT03318445 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | P1 | completed | 22 | Pamela Munster | Jan 2018 | |
| NCT02339116 | TRIBE2 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | P3 | unknown | 654 | Gruppo Oncologico del Nord-Ovest | Feb 2015 |
| NCT02035137 | N2011-01 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | P2 | completed | 114 | New Approaches to Neuroblastoma Therapy Consortium | Jul 2014 |
| NCT02044120 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | P1 | completed | 34 | Sarcoma Alliance for Research through Collaboration | May 2014 | |
| NCT01442935 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | P2 | completed | 256 | UNICANCER | Feb 2011 | |
| NCT03142516 | OPALO | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status | P2 | completed | 20 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Oct 2017 |
| NCT03778593 | FOLFIRINOX for 2nd-line Treatment of BTC | P2 | completed | 34 | Dong-A University Hospital | Mar 2019 | |
| NCT04337879 | A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | P1/P2 | unknown | 56 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Jul 2020 | |
| NCT03416517 | Anlotinib and Irinotecan for Ewing Sarcoma | P1/P2 | unknown | 47 | Peking University People's Hospital | Jan 2018 | |
| NCT03053167 | Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | P2 | unknown | 100 | China Medical University, China | Dec 2016 | |
| NCT03792269 | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | P2 | unknown | 100 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Jan 2016 | |
| NCT02030678 | A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer | P2 | unknown | 124 | Liaoning Cancer Hospital & Institute | Sep 2014 | |
| NCT01802645 | CELIM2 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | P2 | unknown | 91 | Technische Universität Dresden | Mar 2013 |
| NCT02511132 | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma | P2 | completed | 22 | Gradalis, Inc. | Feb 2016 | |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | P1/P2 | unknown | 160 | Leaf Vertical Inc. | Jan 2019 | |
| NCT04499586 | A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer | P2 | unknown | 30 | Fudan University | Jan 2019 | |
| NCT01930864 | Metformin Plus Irinotecan for Refractory Colorectal Cancer | P2 | unknown | 41 | Barretos Cancer Hospital | Sep 2015 | |
| NCT02143219 | PAMELA70 | Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer | P2 | completed | 72 | Institut Cancerologie de l'Ouest | Jul 2014 |
| NCT03545711 | Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer | P1/P2 | unknown | 42 | Chinese Academy of Medical Sciences | May 2018 | |
| NCT02164916 | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | P2 | completed | 106 | SWOG Cancer Research Network | Nov 2014 | |
| NCT03732508 | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | P2 | unknown | 30 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2018 | |
| NCT02842580 | HIGH-LIGHT | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | P2 | terminated | 21 | Federation Francophone de Cancerologie Digestive | Sep 2016 |
| NCT03711240 | CBL | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | P2 | unknown | 40 | National Cheng-Kung University Hospital | Jan 2019 |
| NCT02025881 | HR MB-5 | Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma | P1/P2 | terminated | 29 | Gustave Roussy, Cancer Campus, Grand Paris | Sep 2013 |
| NCT02096354 | ROCKET | A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer | P2 | completed | 62 | EpicentRx, Inc. | May 2014 |
| NCT03139331 | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | P1 | completed | 16 | University of California, San Francisco | Jun 2017 | |
| NCT03116555 | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA | P2 | unknown | 37 | China Medical University, China | Apr 2017 | |
| NCT02937116 | First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors | P1 | completed | 233 | Innovent Biologics (Suzhou) Co. Ltd. | Oct 2016 | |
| NCT01467986 | RIST-rNB-2011 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | P2 | completed | 130 | University of Regensburg | Aug 2013 |
| NCT03651219 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | P3 | unknown | 90 | Beijing Chest Hospital | Sep 2018 | |
| NCT03464968 | mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line | P2 | completed | 120 | Seoul National University Bundang Hospital | Jul 2015 | |
| NCT03222089 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | P2 | withdrawn | 0 | Fujian Cancer Hospital | Jul 2017 | |
| NCT02515734 | DEEPER | A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | P2 | unknown | 360 | Japan Clinical Cancer Research Organization | Aug 2015 |
| NCT02231723 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | P1 | completed | 139 | Sumitomo Pharma America, Inc. | Aug 2014 | |
| NCT00952003 | Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | P2 | completed | 40 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Jul 2009 | |
| NCT02172976 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | P2/P3 | completed | 40 | Krankenhaus Nordwest | Nov 2014 | |
| NCT02368860 | OXIRI | OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma | P1 | completed | 33 | National Cancer Centre, Singapore | Sep 2013 |
| NCT02720601 | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers | P2 | withdrawn | 0 | New Mexico Cancer Research Alliance | Nov 2015 | |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | P2/P3 | completed | 483 | United Therapeutics | Jun 2017 | |
| NCT02906059 | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | P1 | completed | 7 | NYU Langone Health | Sep 2016 | |
| NCT02157792 | M6620 First in Human Study | P1 | completed | 200 | EMD Serono Research & Development Institute, Inc. | Dec 2012 | |
| NCT03702985 | Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer | P2 | unknown | 160 | Fudan University | May 2018 | |
| NCT02747537 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | P2 | withdrawn | 0 | Washington University School of Medicine | Jun 2016 | |
| NCT02324543 | GTX | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | P1/P2 | completed | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Feb 2015 |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | P2 | completed | 38 | Roswell Park Cancer Institute | Aug 2013 | |
| NCT01528046 | Metformin in Children With Relapsed or Refractory Solid Tumors | P1 | completed | 26 | H. Lee Moffitt Cancer Center and Research Institute | Sep 2012 | |
| NCT03823079 | Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia | P2 | unknown | 50 | Fudan University | Feb 2019 | |
| NCT02244632 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | P1/P2 | completed | 105 | Isofol Medical AB | Sep 2014 | |
| NCT02596503 | A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors | P1 | completed | 2 | University of Colorado, Denver | Oct 2015 | |
| NCT00576654 | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | P1 | completed | 73 | National Cancer Institute (NCI) | Mar 2008 | |
| NCT03175016 | DEBIRI-CRLM | Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer | P2/P3 | unknown | 200 | Tianjin Medical University Cancer Institute and Hospital | Jun 2017 |
| NCT02688023 | Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer | P2 | unknown | 50 | Chinese Academy of Medical Sciences | Mar 2014 | |
| NCT03061058 | Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC | P3 | unknown | 240 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Apr 2013 | |
| NCT01271582 | Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients | P4 | unknown | 1,500 | Asan Medical Center | Jan 2009 | |
| NCT04215159 | BIOs-Her | Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor | P2 | unknown | 42 | Jin-Hee Ahn | Dec 2019 |
| NCT03045770 | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA | N/A | unknown | 150 | Fujian Cancer Hospital | Feb 2017 | |
| NCT03368859 | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | P2 | terminated | 70 | AbbVie | Mar 2018 | |
| NCT02801097 | PAYLOAD | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) | P1 | terminated | 28 | EpicentRx, Inc. | Aug 2016 |
| NCT01963182 | IriGen | Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer | P2 | completed | 47 | Centre Jean Perrin | Oct 2013 |
| NCT03443492 | Pancreas | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer | P2 | completed | 130 | National Health Research Institutes, Taiwan | Mar 2018 |
| NCT02024607 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | P1/P2 | completed | 495 | Sumitomo Pharma America, Inc. | Jan 2014 | |
| NCT01485744 | LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer | P1 | completed | 39 | Massachusetts General Hospital | Dec 2011 | |
| NCT02625623 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | P3 | completed | 371 | EMD Serono Research & Development Institute, Inc. | Dec 2015 | |
| NCT01928290 | FOLFIRINOX | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | P2 | completed | 67 | Washington University School of Medicine | Nov 2013 |
| NCT02049593 | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 44 | Jonsson Comprehensive Cancer Center | Jun 2014 | |
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | P2 | completed | 190 | Innovent Biologics (Suzhou) Co. Ltd. | May 2017 | |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | P2 | completed | 36 | Academic and Community Cancer Research United | Dec 2014 | |
| NCT03168594 | IP | Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma | P2 | terminated | 66 | Peking University | Apr 2017 |
| NCT01498289 | S1201 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | P2 | completed | 213 | SWOG Cancer Research Network | Feb 2012 |
| NCT03110510 | BTC | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | P2 | withdrawn | 0 | Samsung Medical Center | Sep 2019 |
| NCT02392793 | Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies | P1 | completed | 43 | St. Jude Children's Research Hospital | Mar 2015 | |
| NCT01896856 | Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer | P1/P2 | completed | 118 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 2013 | |
| NCT01862003 | PANTHER | Phase I/II Trial of Antagonism of HER in GI Cancer | P2 | completed | 24 | University College, London | May 2014 |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | P2 | completed | 27 | Joel Neal | Aug 2015 | |
| NCT01643499 | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | P1 | completed | 79 | University of Chicago | Mar 2012 | |
| NCT02414009 | CAPTEM | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients | P2 | completed | 82 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Sep 2014 |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | P1/P2 | completed | 78 | Cancer Research and Biostatistics Clinical Trials Consortium | Nov 2013 | |
| NCT02497157 | BeTRI | Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | P2 | completed | 45 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | May 2015 |
| NCT00354744 | High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma | P3 | completed | 109 | Children's Oncology Group | Jul 2006 | |
| NCT01867892 | A Phase II Study of Locally Advanced Pancreatic Cancer | P2 | unknown | 86 | National Health Research Institutes, Taiwan | Jun 2013 | |
| NCT01858649 | BEV-ONCO2012 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. | P2 | completed | 60 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | May 2013 |
| NCT01355445 | VIT-0910 | Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma | P2 | completed | 120 | Centre Oscar Lambret | Jan 2012 |
| NCT03069950 | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | P2 | withdrawn | 0 | Memorial Sloan Kettering Cancer Center | Feb 2017 | |
| NCT03099382 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | P3 | completed | 457 | Jiangsu HengRui Medicine Co., Ltd. | May 2017 | |
| NCT01803282 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | P1 | completed | 236 | Gilead Sciences | Mar 2013 | |
| NCT02677116 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | P1 | completed | 68 | Eli Lilly and Company | Aug 2016 | |
| NCT02896907 | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | Early P1 | completed | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Oct 2016 | |
| NCT02624726 | MINOAS | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | P2 | unknown | 31 | Hellenic Oncology Research Group | Jan 2016 |
| NCT01867697 | Nordic 8 - A Phase II Trial | P2 | completed | 173 | Per Pfeiffer | May 2012 | |
| NCT03503604 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | P1 | unknown | 18 | SuZhou Stainwei Biotech Inc. | May 2018 | |
| NCT01560949 | Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | P2 | completed | 34 | M.D. Anderson Cancer Center | Jun 2012 | |
| NCT01650428 | BACCHUS | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | P2 | completed | 20 | University College, London | Apr 2013 |
| NCT03380689 | SIRB2 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer | P1 | withdrawn | 0 | Fujian Cancer Hospital | Jan 2018 |
| NCT02645864 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | P1 | completed | 12 | Peking University | Jan 2016 | |
| NCT02348450 | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer | P4 | unknown | 308 | Guangdong Association of Clinical Trials | Feb 2015 | |
| NCT01859728 | GAMBIT | GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer | P2 | unknown | 48 | Hospital de Cancer de Barretos - Fundacao Pio XII | Jan 2013 |
| NCT03030937 | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA | P2 | unknown | 74 | Fujian Cancer Hospital | Feb 2017 | |
| NCT01274624 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | P1 | completed | 36 | Oncolytics Biotech | Dec 2010 | |
| NCT01114555 | Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma | P2 | completed | 34 | Memorial Sloan Kettering Cancer Center | Apr 2010 | |
| NCT03295084 | Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | P1 | completed | 39 | Dorte Nielsen | Jul 2015 | |
| NCT02387138 | SIRINOX | A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan | P1 | completed | 24 | Institut du Cancer de Montpellier - Val d'Aurelle | Apr 2014 |
| NCT01639326 | FOLFIRI-AD | Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 | P2 | unknown | 96 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Jul 2012 |
| NCT01992705 | GCC 1324 | Borderline Pancreas Study: FOLFIRINOX +SBRT | Early P1 | completed | 8 | University of Maryland, Baltimore | Mar 2014 |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | P1 | completed | 11 | Oncolytics Biotech | Dec 2015 | |
| NCT01939483 | A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases | N/A | withdrawn | 0 | University of California, Irvine | Dec 2012 | |
| NCT01220063 | RS CAMPTO | RSHF in Colorectal Cancer | P2 | completed | 48 | Institut Cancerologie de l'Ouest | Oct 2007 |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | P2 | completed | 22 | Endeavor Health | Jul 2012 | |
| NCT01321957 | CHARTA | Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer | P2 | completed | 250 | Martin-Luther-Universität Halle-Wittenberg | May 2011 |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | P2 | completed | 16 | John Hays | Feb 2013 | |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | P2 | terminated | 5 | Alliance for Clinical Trials in Oncology | Nov 2015 | |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | P1/P2 | unknown | 40 | The First People's Hospital of Lianyungang | Jul 2016 | |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | P1/P2 | completed | 54 | New Approaches to Neuroblastoma Therapy Consortium | May 2012 | |
| NCT02327169 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | P1 | completed | 81 | Millennium Pharmaceuticals, Inc. | Jan 2015 | |
| NCT03400592 | NIEGA | Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma | P2 | unknown | 55 | Peking University | Jun 2015 |
| NCT01996306 | AXEPT | A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC | P3 | completed | 650 | Epidemiological and Clinical Research Information Network | Dec 2013 |
| NCT00730158 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | P2 | completed | 33 | Edward Chu, MD | Dec 2008 | |
| NCT02296203 | CRICKET | Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | P2 | unknown | 27 | Gruppo Oncologico del Nord-Ovest | Oct 2014 |
| NCT01821612 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer | Early P1 | completed | 23 | Alliance for Clinical Trials in Oncology | May 2013 | |
| NCT05086848 | A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors | P1 | completed | 15 | Jiangsu HengRui Medicine Co., Ltd. | May 2016 | |
| NCT03167112 | Folfirinox | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer | P2 | unknown | 20 | Petr Kavan | Jul 2017 |
| NCT01129310 | IXOGoo1 | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. | P2 | completed | 47 | AHS Cancer Control Alberta | Jul 2010 |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study | P1 | terminated | 1 | University of Chicago | Jun 2016 | |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | P2 | withdrawn | 0 | Weill Medical College of Cornell University | Feb 2014 | |
| NCT01634555 | IMC-1121B | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI | P2 | completed | 29 | Eli Lilly and Company | Oct 2012 |
| NCT01397019 | LAPC | Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours | P2 | completed | 56 | Per Pfeiffer | Apr 2011 |
| NCT02314182 | GRECCAR8 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis | P3 | completed | 5 | Hospices Civils de Lyon | Nov 2014 |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | P2 | terminated | 17 | Beth Israel Medical Center | Dec 2011 | |
| NCT01813253 | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | P3 | terminated | 400 | Kuhnil Pharmaceutical Co., Ltd. | May 2013 | |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | P1/P2 | terminated | 81 | Western Regional Medical Center | Dec 2014 | |
| NCT00952029 | Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer | P2/P3 | completed | 492 | Federation Francophone de Cancerologie Digestive | Mar 2010 | |
| NCT02558868 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | P2 | completed | 80 | Zhejiang University | Sep 2015 | |
| NCT02558959 | Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer | P2 | completed | 64 | Zhejiang University | Sep 2015 | |
| NCT02333188 | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | P1 | completed | 50 | University of Chicago | Dec 2014 | |
| NCT01729481 | ML22774 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | P2 | unknown | 150 | Ludwig-Maximilians - University of Munich | Jul 2012 |
| NCT01442649 | Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | P2 | completed | 133 | UNICANCER | Dec 2010 | |
| NCT00890786 | A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas | Early P1 | completed | 27 | Children's Hospital Medical Center, Cincinnati | May 2009 | |
| NCT02256800 | Escalated Dose of Irinotecan in mCRC | N/A | completed | 213 | Jaw-Yuan Wang, MD, PhD | Aug 2014 | |
| NCT01847495 | Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis | N/A | withdrawn | 0 | Wake Forest University Health Sciences | Oct 2013 | |
| NCT02423954 | NivoPlus | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | P1/P2 | terminated | 33 | Western Regional Medical Center | Apr 2015 |
| NCT02527824 | Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer | P2 | unknown | 31 | Hallym University Medical Center | Mar 2015 | |
| NCT01977235 | TDICC | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer | P2 | unknown | 110 | Third Military Medical University | Sep 2013 |
| NCT00137852 | Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer | P2 | completed | 35 | Dana-Farber Cancer Institute | Jan 2002 | |
| NCT02275806 | Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC | P2 | terminated | 4 | Leo W. Jenkins Cancer Center | Oct 2014 | |
| NCT02129257 | AMALTHEA | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer | P2 | completed | 73 | Hellenic Cooperative Oncology Group | May 2014 |
| NCT02626520 | Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla | P2 | terminated | 11 | Essentia Health | May 2016 | |
| NCT02508077 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | P2 | terminated | 1 | City of Hope Medical Center | Feb 2016 | |
| NCT02119026 | PASSION | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer | P2 | completed | 120 | Prof. Dr. Werner Scheithauer | Feb 2011 |
| NCT03009058 | MODULATE | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | P1/P2 | terminated | 2 | Immodulon Therapeutics Ltd | May 2017 |
| NCT05086822 | A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors | P1 | completed | 32 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2014 | |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver | P1 | terminated | 2 | Fox Chase Cancer Center | Jan 2016 | |
| NCT02509234 | TrIPReSarc | Trabectedin and Irinotecan for Refractory Pediatric Sarcomas | — | unknown | 30 | Technical University of Munich | Feb 2014 |
| NCT02319187 | Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial | P3 | unknown | 240 | Chinese Academy of Medical Sciences | Dec 2014 | |
| NCT01566942 | FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer | P3 | unknown | 200 | Sun Yat-sen University | Jun 2012 | |
| NCT01139138 | PIE | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer | P1/P2 | completed | 49 | The Queen Elizabeth Hospital | Jun 2010 |
| NCT01183494 | FOLFIRI | A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients | P1 | completed | 17 | University of Chicago | Dec 2009 |
| NCT01653470 | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | P1 | completed | 141 | Bristol-Myers Squibb | Oct 2012 | |
| NCT02527785 | Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer | P2 | completed | 44 | Hallym University Medical Center | Feb 2015 | |
| NCT01935947 | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer | P2 | terminated | 17 | National Cancer Institute (NCI) | May 2013 | |
| NCT02086656 | COI-B | PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES | P2 | completed | 46 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Jun 2013 |
| NCT01773109 | NKTR-102 | Etirinotecan Pegol (NKTR-102) in NSCLC | P2 | completed | 40 | Abramson Cancer Center at Penn Medicine | Jan 2013 |
| NCT01506167 | ACORN | An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | — | completed | 719 | Hoffmann-La Roche | Jul 2012 |
| NCT02246049 | QUATTRO | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC | P2 | completed | 69 | EPS Corporation | May 2014 |
| NCT01383343 | Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer | P1 | completed | 17 | National Cancer Institute (NCI) | Aug 2011 | |
| NCT02641873 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | P1 | completed | 4 | Sumitomo Pharma Co., Ltd. | Dec 2015 | |
| NCT02316496 | REGAIN | Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study | P2 | terminated | 2 | GERCOR - Multidisciplinary Oncology Cooperative Group | Sep 2015 |
| NCT02376452 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | P2 | unknown | 100 | Fudan University | Sep 2014 | |
| NCT03146377 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | P2 | completed | 32 | The University of Hong Kong | Apr 2014 | |
| NCT01558869 | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | P2 | completed | 37 | The University of Hong Kong | Apr 2012 | |
| NCT01535183 | Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents | P2 | unknown | 40 | Seoul National University Hospital | Jan 2012 | |
| NCT01249638 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | P3 | unknown | 516 | Ludwig-Maximilians - University of Munich | Dec 2010 | |
| NCT00972881 | EXCITE | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | P1/P2 | completed | 82 | University College, London | Apr 2009 |
| NCT00433927 | FOLFIRI | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | P3 | unknown | 568 | PD Dr. med. Volker Heinemann | Jan 2007 |
| NCT00081289 | Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer | P2 | completed | 146 | Radiation Therapy Oncology Group | Mar 2004 | |
| NCT02640365 | DOUBLIRI | A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer | P1 | completed | 10 | GERCOR - Multidisciplinary Oncology Cooperative Group | Nov 2015 |
| NCT02358863 | mEGA | Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach | N/A | terminated | 13 | Georgetown University | Feb 2015 |
| NCT02216487 | Chime | Trial of FOLF(HA)Iri With Cetuximab in mCRC | P2 | unknown | 45 | Western General Hospital, Australia | Jun 2014 |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | P3 | completed | 225 | National Cancer Institute (NCI) | Oct 2003 | |
| NCT02935764 | FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients | P3 | unknown | 164 | Fudan University | Oct 2016 | |
| NCT00394433 | TPCA | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | P2 | completed | 38 | Dana-Farber Cancer Institute | Sep 2006 |
| NCT03067792 | FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer | P3 | completed | 52 | Yonsei University | Dec 2014 | |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | P1 | completed | 17 | University of California, Davis | Aug 2013 | |
| NCT01859858 | Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors | P1 | completed | 23 | UNC Lineberger Comprehensive Cancer Center | Jun 2013 | |
| NCT01588990 | ASCENT | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | P4 | completed | 128 | Hoffmann-La Roche | Jun 2012 |
| NCT01593228 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | P3 | completed | 37 | Sanofi | May 2012 | |
| NCT01413022 | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | P1 | completed | 44 | Washington University School of Medicine | Apr 2012 | |
| NCT00400114 | Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer | P2 | completed | 36 | University Health Network, Toronto | Sep 2006 | |
| NCT02573220 | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | P1 | withdrawn | 0 | University of Chicago | Jun 2015 | |
| NCT00708773 | Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors | P1 | completed | 68 | University of Chicago | Feb 2006 | |
| NCT02071069 | Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer | P2 | unknown | 54 | Tianshu Liu | Jul 2013 | |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | P2 | completed | 175 | National Cancer Institute (NCI) | Jan 2010 | |
| NCT01183780 | A Study in Second Line Metastatic Colorectal Cancer | P3 | completed | 1,072 | Eli Lilly and Company | Dec 2010 | |
| NCT01822613 | ESCC | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | P1 | completed | 48 | Novartis Pharmaceuticals | Jul 2013 |
| NCT01999270 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | P1 | completed | 6 | Washington University School of Medicine | Apr 2013 | |
| NCT00433550 | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer | P2 | completed | 33 | Alliance for Clinical Trials in Oncology | May 2007 | |
| NCT00731276 | Irinotecan in Treating Asian Patients With Solid Tumors | P1 | completed | 18 | National Cancer Centre, Singapore | Apr 2008 | |
| NCT00524186 | Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer | P1 | terminated | 23 | Roswell Park Cancer Institute | May 2007 | |
| NCT01523431 | CPT-11 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | P2/P3 | completed | 583 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Mar 2012 |
| NCT01925274 | A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | P2 | terminated | 19 | Pfizer | Nov 2013 | |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | P2 | terminated | 1 | Case Comprehensive Cancer Center | Sep 2015 | |
| NCT01765582 | STEAM | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | P2 | terminated | 280 | Hoffmann-La Roche | Jan 2013 |
| NCT01677884 | BEVIAC | Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy | P2 | completed | 10 | Gustave Roussy, Cancer Campus, Grand Paris | Nov 2012 |
| NCT01296763 | Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer | P1 | completed | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2011 | |
| NCT02283359 | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | P1 | terminated | 3 | H. Lee Moffitt Cancer Center and Research Institute | Dec 2014 | |
| NCT01520389 | Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment | P1 | completed | 112 | Merrimack Pharmaceuticals | Jan 2012 | |
| NCT02395068 | Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | P1 | unknown | 40 | Biotech Pharmaceutical Co., Ltd. | Nov 2012 | |
| NCT01675128 | ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | P1/P2 | completed | 24 | National Cancer Institute (NCI) | Aug 2012 | |
| NCT01290783 | FOLF(HA)iri | Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC | P3 | unknown | 390 | Alchemia Oncology | Dec 2011 |
| NCT01347866 | Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | P1 | terminated | 105 | Pfizer | Oct 2011 | |
| NCT01858662 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | P2 | terminated | 4 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Jan 2014 | |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | P1/P2 | completed | 52 | Jennerex Biotherapeutics | Jan 2012 | |
| NCT01304602 | A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer | P1 | completed | 20 | University of Kansas Medical Center | Feb 2011 | |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | P2 | completed | 97 | National Cancer Institute (NCI) | Aug 2006 | |
| NCT00857246 | Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | P2 | completed | 30 | NYU Langone Health | Jul 2005 | |
| NCT00183872 | Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | completed | 40 | University of Southern California | Apr 2005 | |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | P1/P2 | withdrawn | 0 | Roswell Park Cancer Institute | — | |
| NCT05177276 | Selinexor Combination Ph 1 Study | P1/P2 | withdrawn | 0 | Martin Gutierrez | Sep 2014 | |
| NCT01715441 | NEXIRI2 | Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors | P2 | completed | 173 | Institut du Cancer de Montpellier - Val d'Aurelle | Sep 2012 |
| NCT01608464 | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer | P2 | terminated | 170 | King Faisal Specialist Hospital & Research Center | May 2012 | |
| NCT00876993 | CNS | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | P1 | completed | 26 | Johns Hopkins All Children's Hospital | Sep 2008 |
| NCT02453464 | A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer | P1 | unknown | 36 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Aug 2015 | |
| NCT01882868 | A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | P2 | completed | 62 | Sanofi | Jul 2013 | |
| NCT00980239 | HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | P1 | completed | 115 | M.D. Anderson Cancer Center | Sep 2009 | |
| NCT00836277 | Phase II Study of Irinotecan and Panitumumab | P2 | completed | 24 | Weijing Sun, MD, FACP | May 2009 | |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan | P2 | terminated | 25 | CytoVac A/S | Feb 2014 | |
| NCT01374425 | MAVERICC | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | P2 | completed | 376 | Genentech, Inc. | Aug 2011 |
| NCT01550055 | CRC009 | Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer | P2/P3 | completed | 512 | Shanghai Zhangjiang Biotechnology Limited Company | May 2009 |
| NCT01670721 | AFEQT | Colorectal Cancer Metastatic | P3 | completed | 175 | Sanofi | Aug 2012 |
| NCT01030042 | COMETS | Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients | P3 | completed | 110 | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Sep 2009 |
| NCT00354679 | Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer | P2 | completed | 34 | Memorial Sloan Kettering Cancer Center | Apr 2006 | |
| NCT01091259 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | P2 | completed | 29 | NYU Langone Health | Mar 2010 | |
| NCT01060423 | DEBIRITUX | TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | P2 | terminated | 8 | Hans-Joachim Schmoll, MD | Feb 2010 |
| NCT02662959 | Irinotecan as 3rd Line Therapy in Gastric Cancer | P2 | unknown | 93 | Fudan University | Apr 2015 | |
| NCT01008475 | POSEIDON | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | P1/P2 | completed | 232 | Merck KGaA, Darmstadt, Germany | Oct 2009 |
| NCT00871169 | Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | P2 | completed | 61 | New Mexico Cancer Research Alliance | Oct 2008 | |
| NCT00098787 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | P2 | completed | 247 | Eastern Cooperative Oncology Group | Sep 2005 | |
| NCT01574092 | Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas | P2 | completed | 39 | Hospital Sant Joan de Deu | Nov 2009 | |
| NCT00620269 | Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III | P2 | unknown | 212 | National Cancer Center, Korea | Feb 2008 | |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | P2 | completed | 20 | Lawrence Recht | Jul 2012 | |
| NCT01550510 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | P1/P2 | terminated | 4 | Thomas Jefferson University | Dec 2011 | |
| NCT01479465 | SIM | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | P2 | terminated | 266 | Gilead Sciences | Dec 2011 |
| NCT00737438 | Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma | P2 | completed | 22 | Memorial Sloan Kettering Cancer Center | Aug 2008 | |
| NCT00522665 | Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | P1/P2 | completed | 41 | Hoosier Cancer Research Network | Aug 2007 | |
| NCT01075048 | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | P1/P2 | completed | 131 | Daiichi Sankyo | Jan 2010 | |
| NCT00535353 | AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | P1 | completed | 26 | NCIC Clinical Trials Group | Jan 2008 | |
| NCT01518413 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | P1 | completed | 17 | HMeany | Dec 2011 | |
| NCT00940316 | Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | P2 | completed | 28 | Northwestern University | Jan 2010 | |
| NCT01930552 | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | P1 | completed | 20 | Sanofi | Sep 2013 | |
| NCT01826396 | Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer | P2 | unknown | 100 | Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences | Apr 2013 | |
| NCT01631539 | Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC | N/A | withdrawn | 0 | Universitaire Ziekenhuizen KU Leuven | Sep 2012 | |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | P1/P2 | terminated | 14 | Giselle Sholler | Dec 2011 | |
| NCT01375816 | PEPCOL | Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | P2 | terminated | 55 | GERCOR - Multidisciplinary Oncology Cooperative Group | May 2011 |
| NCT01320683 | Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer | P2 | terminated | 1 | City of Hope Medical Center | Mar 2011 | |
| NCT01086345 | Radiosurgery Plus Bevacizumab in Glioblastoma | Early P1 | terminated | 9 | Case Comprehensive Cancer Center | Feb 2010 | |
| NCT00856375 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | P2 | completed | 83 | Nektar Therapeutics | Dec 2008 | |
| NCT01380275 | DI | Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. | P2 | unknown | 35 | National Cancer Center, Korea | Apr 2008 |
| NCT01609231 | MK-0646-025 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | P2 | terminated | 11 | Merck Sharp & Dohme LLC | Jul 2012 |
| NCT01652482 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | P2 | completed | 135 | Genentech, Inc. | Oct 2012 | |
| NCT00165490 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | P2 | completed | 19 | Dana-Farber Cancer Institute | Aug 2004 | |
| NCT00316862 | Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery | P2 | completed | 82 | Alliance for Clinical Trials in Oncology | Feb 2006 | |
| NCT00967330 | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma | P2 | completed | 182 | Hoffmann-La Roche | Jun 2010 | |
| NCT01269216 | FL | A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer | P2 | completed | 136 | Yonsei University | Oct 2008 |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | P2 | completed | 35 | Abramson Cancer Center at Penn Medicine | Apr 2009 | |
| NCT01693445 | S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer | P1 | completed | 22 | Hallym University Medical Center | Jun 2012 | |
| NCT01313884 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | P2 | terminated | 3 | Stanford University | May 2011 | |
| NCT00958386 | SPECTRA | Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) | P2 | completed | 61 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Aug 2009 |
| NCT01635400 | Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer | P2 | unknown | 50 | Zhejiang Cancer Hospital | Jun 2012 | |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | P1 | completed | 48 | Merrimack Pharmaceuticals | Oct 2011 | |
| NCT01046864 | FOLFIRI | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) | P1 | completed | 49 | Bristol-Myers Squibb | Feb 2010 |
| NCT01654081 | A Protocol of Irinotecan for Carcinoma of the Lung | P2 | withdrawn | 0 | Susanne Arnold | Oct 2013 | |
| NCT01444521 | Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer | P2 | completed | 50 | Chinese Academy of Medical Sciences | Apr 2011 | |
| NCT01280643 | Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | N/A | terminated | 3 | Fox Chase Cancer Center | Mar 2010 | |
| NCT00991952 | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery | P2 | completed | 19 | National Cancer Institute (NCI) | Sep 2009 | |
| NCT01226719 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | P2 | completed | 15 | SCRI Development Innovations, LLC | Dec 2010 | |
| NCT00720512 | BEBYP | Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab | P3 | terminated | 184 | Gruppo Oncologico del Nord-Ovest | Jun 2008 |
| NCT01533740 | Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients | — | completed | 31 | University of Rome Tor Vergata | Mar 2012 | |
| NCT01501669 | PROCEED | Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer | P3 | unknown | 222 | National Cancer Center, Korea | Jun 2011 |
| NCT00940303 | OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | P2 | completed | 97 | Hoffmann-La Roche | Jun 2009 | |
| NCT00671801 | Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | P1 | terminated | 24 | M.D. Anderson Cancer Center | Apr 2008 | |
| NCT00465907 | Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer | P2 | terminated | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2003 | |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | P1 | withdrawn | 0 | City of Hope Medical Center | — | |
| NCT01941173 | Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy | N/A | withdrawn | 0 | City of Hope Medical Center | Jan 2014 | |
| NCT01205022 | Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | P1 | completed | 3 | City of Hope Medical Center | Apr 2011 | |
| NCT01042028 | ICE | A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer | P1/P2 | terminated | 39 | Per Pfeiffer | Jan 2010 |
| NCT01014767 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | P3 | terminated | 27 | Tufts Medical Center | Nov 2009 | |
| NCT00617539 | Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases | P2 | completed | 30 | University of California, San Francisco | Feb 2005 | |
| NCT01494363 | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer | P2 | unknown | 53 | Soon Chun Hyang University | Oct 2011 | |
| NCT01480986 | IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC | P2 | completed | 40 | Peking University | Sep 2011 | |
| NCT01239485 | Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents | P1 | unknown | 18 | Seoul National University Hospital | Nov 2010 | |
| NCT05278728 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | P1/P2 | completed | 31 | Biotech Pharmaceutical Co., Ltd. | Jul 2009 | |
| NCT00921167 | A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas | P2 | completed | 32 | Clinical Research Center for Solid Tumor, Korea | Jun 2009 | |
| NCT00541125 | G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer | P2 | completed | 20 | Federation Francophone de Cancerologie Digestive | Nov 2007 | |
| NCT00311584 | Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma | P2 | completed | 59 | Children's Oncology Group | Apr 2006 | |
| NCT01367275 | CRC | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | P2 | terminated | 8 | M.D. Anderson Cancer Center | Aug 2011 |
| NCT00996346 | Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas | P1 | terminated | 17 | New Mexico Cancer Research Alliance | Oct 2009 | |
| NCT00099125 | Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | P2 | completed | 170 | Radiation Therapy Oncology Group | Nov 2004 | |
| NCT00061932 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | P2 | completed | 41 | National Cancer Institute (NCI) | Apr 2003 | |
| NCT00059761 | Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | P1 | completed | 36 | Radiation Therapy Oncology Group | Mar 2003 | |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | P2 | terminated | 5 | University of Oklahoma | May 2011 | |
| NCT00778102 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | P2 | completed | 80 | Hoffmann-La Roche | Oct 2008 | |
| NCT01138904 | AGC | FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC) | P2 | completed | 80 | Dong-A University Hospital | Sep 2009 |
| NCT00911820 | PCA | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | P2 | completed | 88 | Dana-Farber Cancer Institute | Jul 2009 |
| NCT01173497 | A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis | P2 | completed | 44 | Sanofi | Jul 2010 | |
| NCT00762255 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | P1 | completed | 19 | H. Lee Moffitt Cancer Center and Research Institute | Sep 2008 | |
| NCT00891930 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | P2 | completed | 74 | NantBioScience, Inc. | May 2009 | |
| NCT01322152 | Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer | P2 | completed | 52 | Fudan University | Mar 2011 | |
| NCT01009073 | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects | P1 | completed | 51 | AbbVie (prior sponsor, Abbott) | Oct 2009 | |
| NCT00537121 | Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer | P1 | completed | 23 | Roswell Park Cancer Institute | Nov 2006 | |
| NCT01225744 | eSCOUT | Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | P2 | completed | 47 | The Christie NHS Foundation Trust | Apr 2009 |
| NCT00693719 | Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer | P2 | completed | 31 | University of Arizona | Aug 2007 | |
| NCT00597402 | XRT | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | P2 | completed | 125 | Duke University | Jul 2007 |
| NCT01016860 | OSI-906 and Irinotecan in Patients With Advanced Cancer | P1 | terminated | 16 | University of Colorado, Denver | Dec 2009 | |
| NCT00967616 | Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy | P2 | completed | 100 | Daiichi Sankyo | Sep 2009 | |
| NCT00418938 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | P2 | completed | 266 | Amgen | Nov 2006 | |
| NCT01607554 | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer | P1/P2 | terminated | 2 | New Mexico Cancer Research Alliance | Apr 2012 | |
| NCT01144988 | AVIRMA01-09 | Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma | P2 | unknown | 35 | Medical University Innsbruck | Mar 2010 |
| NCT00060567 | Dose-Finding Study of E7070 in Combination With Irinotecan | P1 | completed | 88 | Eisai Inc. | Mar 2003 | |
| NCT00993044 | VIT-B | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | P1 | completed | 13 | Children's Hospital Los Angeles | Sep 2009 |
| NCT01282697 | RAPIRI | Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors | P1 | completed | 42 | University Hospital, Strasbourg, France | Apr 2011 |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer | P1 | terminated | 4 | Fox Chase Cancer Center | Oct 2010 | |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | P2 | completed | 41 | Katy Peters | Nov 2009 | |
| NCT01640782 | ITACA-S | Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach | P3 | completed | 1,100 | Mario Negri Institute for Pharmacological Research | Feb 2005 |
| NCT00303992 | Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | P2 | completed | 9 | University of California, San Francisco | May 2004 | |
| NCT00072527 | Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | P2 | completed | 78 | Alliance for Clinical Trials in Oncology | Nov 2003 | |
| NCT01474187 | Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer | P1 | unknown | 60 | Fudan University | Nov 2011 | |
| NCT01281761 | CRC | Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) | P2 | completed | 52 | Samsung Medical Center | Nov 2010 |
| NCT00975897 | Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | P2/P3 | completed | 3,240 | Medical Research Council | Jul 2009 | |
| NCT00889343 | FOSCO | Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer | P2 | terminated | 101 | AIO-Studien-gGmbH | Mar 2009 |
| NCT00811993 | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | P1 | terminated | 104 | Hoffmann-La Roche | Feb 2009 | |
| NCT00874328 | IP | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | P1/P2 | unknown | 74 | National Cancer Center, Korea | Oct 2008 |
| NCT00594984 | Phase I/II Combination With Irinotecan- Erbitux | P1/P2 | completed | 38 | Bristol-Myers Squibb | May 2008 | |
| NCT00717990 | Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment | P2 | terminated | 15 | University Hospital of Crete | Apr 2008 | |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | P1 | completed | 7 | Mayo Clinic | Jun 2008 | |
| NCT00786669 | VITAC | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | P1 | completed | 13 | Children's Hospital Medical Center, Cincinnati | Oct 2008 |
| NCT00499369 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy | P3 | terminated | 72 | National Cancer Institute (NCI) | Jun 2007 | |
| NCT01131078 | A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | P2 | completed | 306 | Hoffmann-La Roche | Jun 2005 | |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | P3 | completed | 3,397 | National Cancer Institute (NCI) | Feb 2004 | |
| NCT00838578 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | P1/P2 | terminated | 65 | Kyowa Kirin Co., Ltd. | Mar 2009 | |
| NCT01205711 | FOLFERA | Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 111 | Cardiff University | Apr 2010 |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | P2 | completed | 37 | SCRI Development Innovations, LLC | Jun 2008 | |
| NCT00986843 | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) | P1 | completed | 14 | Hanmi Pharmaceutical Company Limited | Jun 2008 | |
| NCT00848783 | GEJ | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | P2 | terminated | 8 | NYU Langone Health | May 2008 |
| NCT01473303 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | P1/P2 | withdrawn | 0 | Alliance for Clinical Trials in Oncology | Aug 2012 | |
| NCT01051765 | Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial | P2 | unknown | 60 | Peking University | Aug 2009 | |
| NCT00755118 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | P2 | terminated | 24 | University Hospital of Crete | Oct 2008 | |
| NCT00436072 | ZD6474 | ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | P1 | completed | 46 | Dana-Farber Cancer Institute | Feb 2007 |
| NCT00547547 | High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer | P1 | completed | 22 | City of Hope Medical Center | Apr 2006 | |
| NCT00057837 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P2 | completed | 140 | Eastern Cooperative Oncology Group | Jul 2004 | |
| NCT01116271 | AZD6244 | Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | P2 | completed | 32 | AstraZeneca | Apr 2010 |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma | P1 | completed | 18 | University of Michigan Rogel Cancer Center | Apr 2008 | |
| NCT02323737 | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer | P2 | completed | 62 | Chinese Academy of Medical Sciences | Jul 2010 | |
| NCT00655499 | PIMABI | Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 65 | GERCOR - Multidisciplinary Oncology Cooperative Group | Jun 2008 |
| NCT00577109 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. | P2 | withdrawn | 0 | Hoffmann-La Roche | Dec 2007 | |
| NCT01308632 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | P2/P3 | unknown | 30 | Grupo Español de Investigación en Neurooncología | Nov 2007 | |
| NCT00561470 | VELOUR | Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen | P3 | completed | 1,226 | Sanofi | Nov 2007 |
| NCT00551421 | Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | P1/P2 | completed | 17 | National Cancer Institute (NCI) | Oct 2007 | |
| NCT00941655 | Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial | P3 | completed | 15 | National Cancer Institute (NCI) | Jul 2009 | |
| NCT01084330 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | P2 | completed | 68 | Novartis Pharmaceuticals | Apr 2010 | |
| NCT01004159 | Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan | P2 | terminated | 20 | Roswell Park Cancer Institute | Sep 2009 | |
| NCT00875771 | AVAXIRI | Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients | P2 | completed | 80 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Apr 2009 |
| NCT00509353 | N2004-06 | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | P1 | completed | 26 | New Approaches to Neuroblastoma Therapy Consortium | Jan 2007 |
| NCT00109850 | S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer | P2 | terminated | 22 | SWOG Cancer Research Network | May 2005 | |
| NCT00615056 | A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen | P2 | completed | 171 | Pfizer | Mar 2008 | |
| NCT01286818 | FOLFIRI | A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) | P1 | completed | 6 | Eli Lilly and Company | Feb 2011 |
| NCT00671372 | A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | P1 | completed | 42 | Genentech, Inc. | Jul 2006 | |
| NCT00614393 | MK-0646 | Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | P2 | completed | 558 | Merck Sharp & Dohme LLC | Dec 2007 |
| NCT01293942 | IXO+A in mCRC With Liver-only Metastases | P2 | withdrawn | 0 | Ottawa Hospital Research Institute | Mar 2011 | |
| NCT00989469 | NEXIRI | Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation | P1/P2 | completed | 64 | Institut du Cancer de Montpellier - Val d'Aurelle | Feb 2009 |
| NCT01167725 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | P3 | terminated | 340 | Alliance for Clinical Trials in Oncology | Aug 2010 | |
| NCT00766220 | Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2009 | |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | P2 | unknown | 220 | Enzon Pharmaceuticals, Inc. | Jun 2009 | |
| NCT00509860 | Irinotecan (Camptosar) in Patients With Advanced Sarcomas | P2 | completed | 38 | M.D. Anderson Cancer Center | Mar 2003 | |
| NCT00969033 | CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin | P2 | terminated | 8 | Daiichi Sankyo | Jul 2009 | |
| NCT00642746 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | P2 | terminated | 16 | OHSU Knight Cancer Institute | Mar 2008 | |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | P2 | unknown | 72 | Adnexus, A Bristol-Myers Squibb R&D Company | Oct 2007 | |
| NCT00404495 | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | P2 | completed | 83 | Pfizer | Apr 2007 | |
| NCT00467142 | OMEGA | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | P2 | completed | 62 | Institut Bergonié | Jan 2007 |
| NCT00532714 | Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC | P2 | completed | 36 | National Cancer Center, Korea | Aug 2006 | |
| NCT00134069 | Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | P1 | completed | 48 | National Cancer Institute (NCI) | Jun 2005 | |
| NCT00817284 | GBM | Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) | P2 | completed | 60 | Ulrik Lassen | Nov 2008 |
| NCT00588900 | Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab | P2 | terminated | 5 | Alliance for Clinical Trials in Oncology | Mar 2008 | |
| NCT00103259 | Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | P2 | completed | 71 | National Cancer Institute (NCI) | Jul 2005 | |
| NCT00556413 | Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 42 | Institut du Cancer de Montpellier - Val d'Aurelle | Sep 2005 | |
| NCT01017653 | Panitumumab and Irinotecan for Malignant Gliomas | P2 | terminated | 16 | Annick Desjardins | Feb 2010 | |
| NCT00851045 | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | P2 | completed | 17 | Bristol-Myers Squibb | Oct 2009 | |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | P1 | completed | 19 | St. Jude Children's Research Hospital | Sep 2005 | |
| NCT00217711 | Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | P1/P2 | completed | 23 | Swiss Cancer Institute | May 2005 | |
| NCT00637091 | EGFR | Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions | P2 | completed | 40 | Asan Medical Center | Mar 2008 |
| NCT00546130 | RNCLC | Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer | P2 | unknown | 45 | University of Toyama | Nov 2007 |
| NCT00144989 | IP | A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC | P3 | completed | 281 | Haruhiko Fukuda | Sep 2002 |
| NCT00792363 | Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations | P2 | completed | 32 | Vejle Hospital | Nov 2008 | |
| NCT01136031 | TI-2ndAGC | Paclitaxel and Irinotecan in Advanced Gastric Cancer | P1/P2 | completed | 42 | Seoul National University Hospital | Jan 2008 |
| NCT00423696 | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | P2 | completed | 145 | UNICANCER | Mar 2006 | |
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | P1 | completed | 16 | Traws Pharma, Inc. | Jun 2008 | |
| NCT00861328 | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | P1 | completed | 18 | Traws Pharma, Inc. | Feb 2008 | |
| NCT00483834 | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | P2 | completed | 50 | University Health Network, Toronto | Dec 2006 | |
| NCT00118235 | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer | P2 | completed | 72 | National Cancer Institute (NCI) | Dec 2004 | |
| NCT00827684 | TIRASMUS | Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations | P2 | completed | 50 | Vejle Hospital | Mar 2009 |
| NCT00639327 | Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer | P2/P3 | completed | 300 | Japan Clinical Cancer Research Organization | Mar 2008 | |
| NCT00463203 | Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | P2 | completed | 54 | Rigshospitalet, Denmark | Mar 2007 | |
| NCT00364143 | Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors | P1 | completed | 40 | Yakult Honsha Co., LTD | Sep 2006 | |
| NCT00336856 | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy | P2 | completed | 35 | University of Pittsburgh | Jun 2006 | |
| NCT00502567 | A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors | P1 | completed | 104 | AstraZeneca | Jan 2005 | |
| NCT00143533 | Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors | P1 | completed | 20 | St. Jude Children's Research Hospital | Sep 2003 | |
| NCT00062374 | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction | P2 | completed | 55 | National Cancer Institute (NCI) | Jun 2003 | |
| NCT00166881 | P-HDFL-DI | Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin | P2 | completed | 29 | National Taiwan University Hospital | Jun 2000 |
| NCT00954512 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | P1/P2 | terminated | 15 | Merck Sharp & Dohme LLC | Sep 2009 | |
| NCT00298675 | Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors | P1 | completed | 59 | Sanofi | Mar 2006 | |
| NCT00296062 | Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer | P1 | terminated | 12 | Case Comprehensive Cancer Center | Mar 2006 | |
| NCT00160875 | Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer | P2/P3 | completed | 54 | University Health Network, Toronto | Apr 2009 | |
| NCT00816777 | PARAGON | Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer | P1/P2 | terminated | 4 | Generic Devices Consulting, Inc. | Dec 2008 |
| NCT00354978 | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | P2 | completed | 49 | M.D. Anderson Cancer Center | Jan 2005 | |
| NCT00154102 | CRYSTAL | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) | P3 | completed | 1,221 | Merck KGaA, Darmstadt, Germany | May 2004 |
| NCT01336985 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | P1 | terminated | 5 | National Institutes of Health Clinical Center (CC) | Mar 2011 | |
| NCT00845039 | FC-4 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab | P2 | terminated | 4 | Eli Lilly and Company | May 2009 |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | P2 | completed | 123 | National Cancer Institute (NCI) | Mar 2007 | |
| NCT00473616 | Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | P1 | terminated | 60 | AstraZeneca | May 2007 | |
| NCT00138216 | Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors | P1 | completed | 42 | Children's Oncology Group | Oct 2005 | |
| NCT00303771 | Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | P3 | completed | 282 | Federation Francophone de Cancerologie Digestive | Jun 2003 | |
| NCT00813072 | Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | completed | 135 | PharmaEngine | Nov 2007 | |
| NCT00557102 | ERBIFORT | Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung | P2 | completed | 24 | National Cancer Institute, France | Sep 2007 |
| NCT00689624 | Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | P2 | completed | 30 | University Hospital of Crete | Jul 2007 | |
| NCT00642577 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | P3 | completed | 214 | Hoffmann-La Roche | Jul 2007 | |
| NCT00079118 | Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer | P2 | completed | 70 | Alliance for Clinical Trials in Oncology | Apr 2004 | |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | P1 | terminated | 4 | Merck Sharp & Dohme LLC | Nov 2009 | |
| NCT00925015 | MK-0646 | Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | P1 | completed | 20 | Merck Sharp & Dohme LLC | Jun 2009 |
| NCT00979563 | Oratecan-101 | Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies | P1 | completed | 15 | Hanmi Pharmaceutical Company Limited | Jul 2008 |
| NCT00360828 | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | P2 | terminated | 10 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2006 | |
| NCT01224652 | Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | P3 | unknown | 518 | Korean Cancer Study Group | — | |
| NCT00668863 | Study Of Sunitinib With FOLFIRI In Colorectal Cancer | P2 | completed | 71 | Pfizer | May 2008 | |
| NCT00611728 | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | P1 | completed | 25 | Duke University | Mar 2008 | |
| NCT00497497 | A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | P1 | completed | 20 | Genentech, Inc. | Oct 2007 | |
| NCT00397904 | Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin | P2 | completed | 16 | Memorial Sloan Kettering Cancer Center | Oct 2006 | |
| NCT00192712 | Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer | P2/P3 | completed | 20 | Rambam Health Care Campus | Nov 2002 | |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | P1/P2 | terminated | 6 | Massachusetts General Hospital | Jul 2006 | |
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | P2 | completed | 135 | Washington University School of Medicine | Oct 2002 | |
| NCT00177853 | Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer | P1 | terminated | 23 | University of Pittsburgh | Dec 2006 | |
| NCT00469898 | Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P2 | completed | 50 | Vanderbilt-Ingram Cancer Center | Dec 2003 | |
| NCT01141244 | Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors | P1 | completed | 72 | National Cancer Institute (NCI) | Jun 2010 | |
| NCT00984438 | BCNU | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | P1/P2 | withdrawn | 0 | University of Cincinnati | Jun 2009 |
| NCT00563316 | Effect of Panitumumab on the Pharmacokinetics of Irinotecan | P1 | completed | 28 | Amgen | Mar 2008 | |
| NCT00506571 | TIROX2 | Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer | P2 | unknown | 42 | National Cancer Center, Korea | Jul 2007 |
| NCT00314353 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | P2 | terminated | 7 | NSABP Foundation Inc | Mar 2006 | |
| NCT00240097 | SCLC | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | P2 | completed | 30 | University of Alabama at Birmingham | Jun 2005 |
| NCT00112658 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | P2/P3 | completed | 342 | UNICANCER | Nov 2004 | |
| NCT00077233 | FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | P3 | terminated | 238 | Alliance for Clinical Trials in Oncology | Dec 2003 | |
| NCT00506844 | ERBIRIX | Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer | P2 | unknown | 40 | National Cancer Center, Korea | May 2006 |
| NCT00452634 | ED-SCLC | Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | P2 | completed | 62 | National Cancer Center, Korea | Apr 2006 |
| NCT00066612 | S0306 | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | P2 | completed | 45 | SWOG Cancer Research Network | Jul 2003 |
| NCT00540943 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer | P1 | completed | 25 | GlaxoSmithKline | Jul 2007 | |
| NCT01163396 | FOIB | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer | P2 | completed | 57 | Gruppo Oncologico del Nord-Ovest | Jul 2007 |
| NCT00276744 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | P2 | terminated | 249 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 2005 | |
| NCT00210184 | CEPAFIRI | Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer | P2 | completed | 42 | Institut Bergonié | Jul 2004 |
| NCT00832689 | Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer | P2 | completed | 39 | Yonsei University | Jun 2008 | |
| NCT00569335 | SIRB | Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer | P2 | completed | 52 | Taiho Pharmaceutical Co., Ltd. | Oct 2007 |
| NCT00569790 | Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer | P2 | completed | 53 | Taiho Pharmaceutical Co., Ltd. | Oct 2007 | |
| NCT00457691 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | P3 | completed | 768 | Pfizer | Jun 2007 | |
| NCT00614965 | Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV | P2 | completed | 124 | Hellenic Oncology Research Group | Nov 2006 | |
| NCT00393094 | Bevacizumab and Irinotecan to Treat Brain Tumors | P2 | terminated | 31 | National Cancer Institute (NCI) | Sep 2006 | |
| NCT00449163 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | P2 | terminated | 25 | University of Miami | Mar 2006 | |
| NCT00186979 | Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors | P1 | completed | 34 | St. Jude Children's Research Hospital | May 2003 | |
| NCT00003484 | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors | P1 | completed | 21 | Darell D. Bigner, MD, PhD | Sep 1997 | |
| NCT00936832 | Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery | P2 | withdrawn | 0 | Federation Francophone de Cancerologie Digestive | Apr 2009 | |
| NCT00681876 | Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | P2 | terminated | 16 | Hellenic Oncology Research Group | Apr 2008 | |
| NCT00469443 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | P3 | completed | 330 | Hellenic Oncology Research Group | Dec 2006 | |
| NCT01070290 | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen | P2 | withdrawn | 0 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | — | |
| NCT00545545 | Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | P1/P2 | completed | 32 | HiberCell, Inc. | Oct 2007 | |
| NCT00506207 | TIROX | A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy | P1 | unknown | 23 | National Cancer Center, Korea | Sep 2006 |
| NCT00601692 | Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer | P1 | completed | 27 | Memorial Sloan Kettering Cancer Center | Apr 2003 | |
| NCT00590031 | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | P2 | completed | 61 | Memorial Sloan Kettering Cancer Center | Nov 2002 | |
| NCT00045162 | S0124 | S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer | P3 | completed | 671 | SWOG Cancer Research Network | Nov 2002 |
| NCT00005791 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Oct 1999 | |
| NCT00004051 | Irinotecan in Treating Patients With Advanced Solid Tumors | P1 | completed | 40 | Memorial Sloan Kettering Cancer Center | Aug 1998 | |
| NCT00268359 | Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas | P2 | completed | 68 | Duke University | May 2005 | |
| NCT00062322 | Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer | P1 | completed | 0 | Fox Chase Cancer Center | Feb 2003 | |
| NCT00033657 | Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer | P2 | completed | 97 | Eastern Cooperative Oncology Group | Aug 2002 | |
| NCT00016952 | Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer | P2 | completed | 19 | Alliance for Clinical Trials in Oncology | Apr 2001 | |
| NCT00003955 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma | P2 | completed | 77 | Children's Oncology Group | Sep 1999 | |
| NCT00478634 | A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | P1 | completed | 19 | Novartis Pharmaceuticals | May 2007 | |
| NCT00143403 | Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer | P3 | completed | 321 | Pfizer | Dec 2001 | |
| NCT00042939 | Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | P2 | completed | 94 | Eastern Cooperative Oncology Group | Dec 2003 | |
| NCT00967655 | Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer | P2 | unknown | 54 | Loma Linda Oncology Medical Group, Inc. | Jul 2009 | |
| NCT00808899 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | P2 | terminated | 4 | St. Jude Children's Research Hospital | Dec 2008 | |
| NCT00512681 | TIROX2 | A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer | P2 | completed | 44 | National Cancer Center, Korea | Jul 2007 |
| NCT00352521 | DCE-MRI | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma | P2 | completed | 20 | Duke University | Apr 2006 |
| NCT00271011 | A Study of Mitomycin C, Irinotecan, and Cetuximab | P2 | terminated | 13 | University of Michigan Rogel Cancer Center | Dec 2005 | |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer | P2 | terminated | 9 | Medical University of South Carolina | Sep 2003 | |
| NCT00276692 | Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma | P2 | completed | 35 | Children's Cancer and Leukaemia Group | Aug 2003 | |
| NCT00353015 | Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract | P2 | completed | 21 | M.D. Anderson Cancer Center | Mar 2003 | |
| NCT00027612 | Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme | P1/P2 | completed | 58 | Alliance for Clinical Trials in Oncology | Jul 2002 | |
| NCT00183846 | Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers | P1 | completed | 22 | University of Southern California | Dec 2000 | |
| NCT00616005 | Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | P2 | completed | 41 | Duke University | Nov 2005 | |
| NCT00193596 | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | P3 | completed | 198 | SCRI Development Innovations, LLC | Sep 2003 | |
| NCT00054288 | Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors | P1 | completed | 0 | Roswell Park Cancer Institute | Aug 2001 | |
| NCT00004103 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer | P2 | completed | 0 | NYU Langone Health | Jul 1998 | |
| NCT00551213 | A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | P2 | completed | 67 | Merck Sharp & Dohme LLC | Nov 2007 | |
| NCT00437268 | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | P2 | completed | 26 | Eli Lilly and Company | Mar 2007 | |
| NCT00115765 | PACCE | PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | P3 | completed | 1,053 | Amgen | Jun 2005 |
| NCT00040807 | Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer | P2 | completed | 0 | Eastern Cooperative Oncology Group | Nov 2002 | |
| NCT00165464 | CPT-11 | Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer | P2 | completed | 54 | Dana-Farber Cancer Institute | Aug 2001 |
| NCT00012220 | Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas | P2 | completed | 259 | Alliance for Clinical Trials in Oncology | Jan 2001 | |
| NCT00183859 | Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan | P1 | completed | 42 | University of Southern California | Sep 1999 | |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | P2 | terminated | 41 | Hoffmann-La Roche | May 2008 | |
| NCT00066781 | Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary | P2 | completed | 31 | Alliance for Clinical Trials in Oncology | Feb 2004 | |
| NCT00275041 | Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer | P2 | completed | 21 | Alliance for Clinical Trials in Oncology | Feb 2006 | |
| NCT01311050 | A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer | — | unknown | 46 | King Faisal Specialist Hospital & Research Center | Jan 2009 | |
| NCT00308529 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | P2 | completed | 55 | SCRI Development Innovations, LLC | Mar 2006 | |
| NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | P2 | completed | 50 | SCRI Development Innovations, LLC | Feb 2006 | |
| NCT00718757 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | P1 | completed | 4 | St. Jude Children's Research Hospital | Jan 2005 | |
| NCT00249977 | Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan | P1 | completed | 21 | University of New Mexico | Apr 2003 | |
| NCT00387660 | Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer | P2 | completed | 80 | University of California, Davis | Oct 2001 | |
| NCT00003134 | Irinotecan in Treating Patients With Recurrent Glioma | P2 | completed | 64 | Alliance for Clinical Trials in Oncology | Jan 1998 | |
| NCT00628810 | Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 86 | Federation Francophone de Cancerologie Digestive | Jan 2007 | |
| NCT00463073 | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | P2 | completed | 32 | Rigshospitalet, Denmark | Aug 2006 | |
| NCT00507143 | Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | N/A | unknown | 100 | National Cancer Center, Korea | Aug 2006 | |
| NCT00361842 | Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer | P2 | completed | 65 | Jazz Pharmaceuticals | Jul 2006 | |
| NCT00138060 | CRC | Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants | P4 | completed | 71 | Institut de Recherche Clinique sur les Cancers et le Sang | Jun 2005 |
| NCT00506623 | Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer | P2 | unknown | 48 | National Cancer Center, Korea | Jul 2004 | |
| NCT00084617 | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma | P2 | completed | 39 | National Cancer Institute (NCI) | Mar 2004 | |
| NCT00209664 | Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer | P2 | suspended | 40 | Hokkaido Gastrointestinal Cancer Study Group | Jan 2004 | |
| NCT00143455 | R | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer | P3 | completed | 485 | Pfizer | Jun 2002 |
| NCT00283556 | CPT-11 | High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma | P1/P2 | completed | 30 | Kentuckiana Cancer Institute | Aug 2001 |
| NCT00755534 | Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | P2 | terminated | 68 | Hellenic Oncology Research Group | Nov 2008 | |
| NCT00100828 | Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer | P2 | terminated | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Nov 2004 | |
| NCT00132054 | Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer | P1 | completed | 30 | Japan Multinational Trial Organization | May 2004 | |
| NCT00104793 | Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer | P2 | completed | 55 | Japan Multinational Trial Organization | Jun 2003 | |
| NCT00030433 | S0119 | S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P2 | completed | 85 | SWOG Cancer Research Network | Jan 2002 |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | P2 | terminated | 16 | Medical University of South Carolina | Nov 2001 | |
| NCT00101686 | Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine. | P3 | completed | 547 | Pfizer | Feb 2003 | |
| NCT00111761 | ABX-EGF | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer | P2 | completed | 43 | Amgen | Jul 2002 |
| NCT00012389 | Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | P3 | completed | 0 | Sanofi | Dec 2000 | |
| NCT00004095 | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors | P1 | completed | 38 | Northwestern University | Aug 1999 | |
| NCT00332163 | STEPP | Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | P2 | completed | 95 | Amgen | Apr 2006 |
| NCT00447967 | Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients | P2 | completed | 110 | Hellenic Oncology Research Group | Jul 2004 | |
| NCT00215501 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | P1 | completed | 54 | Dana-Farber Cancer Institute | Nov 2001 | |
| NCT00719797 | TRIBE | Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | P3 | completed | 509 | Gruppo Oncologico del Nord-Ovest | Jul 2008 |
| NCT00797485 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | P3 | unknown | 672 | Southern Italy Cooperative Oncology Group | Jul 2008 | |
| NCT00381862 | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | P2 | completed | 54 | OHSU Knight Cancer Institute | Jun 2006 | |
| NCT00343668 | S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer | P2 | unknown | 44 | Korean Cancer Study Group | Sep 2005 | |
| NCT00612638 | Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas | P1 | completed | 96 | Duke University | Jan 2005 | |
| NCT00182806 | Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer | P2 | completed | 38 | Roswell Park Cancer Institute | Sep 2004 | |
| NCT00639769 | Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | P2 | completed | 41 | Vanderbilt-Ingram Cancer Center | Feb 2002 | |
| NCT00290719 | Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery | P1 | terminated | 6 | University of California, San Francisco | Nov 2005 | |
| NCT00507091 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | P1 | completed | 24 | Genzyme, a Sanofi Company | Aug 2005 | |
| NCT00216086 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer | P2 | terminated | 22 | Gabi Chiorean, MD | May 2005 | |
| NCT00191984 | A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer | P2 | completed | 46 | Eli Lilly and Company | Jun 2004 | |
| NCT00136955 | Irinotecan Study For Cervical Cancer | P2 | completed | 41 | Pfizer | Jun 2004 | |
| NCT00193375 | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | P2 | completed | 60 | SCRI Development Innovations, LLC | Aug 2003 | |
| NCT02582970 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | P4 | completed | 40 | Hoffmann-La Roche | May 2005 | |
| NCT00110357 | Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors | P1 | completed | 48 | Eli Lilly and Company | Aug 2005 | |
| NCT00183807 | A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer | P2 | terminated | 6 | University of Southern California | Oct 2003 | |
| NCT00230399 | Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | P2 | completed | 15 | University of Michigan Rogel Cancer Center | Jun 2003 | |
| NCT00396487 | Tailored Treatment in Metastatic Colorectal Cancer | P3 | terminated | 1 | Vejle Hospital | Nov 2006 | |
| NCT00080951 | Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 14 | Alliance for Clinical Trials in Oncology | Mar 2004 | |
| NCT00039468 | Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy | P2 | completed | 26 | Dartmouth-Hitchcock Medical Center | Mar 2002 | |
| NCT00005972 | Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer | P2 | completed | 73 | Alliance for Clinical Trials in Oncology | May 2000 | |
| NCT00449020 | Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer | P2 | completed | 32 | University of Miami | Jan 2004 | |
| NCT00248482 | Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P2 | completed | 6 | Barbara Ann Karmanos Cancer Institute | Feb 2002 | |
| NCT00222443 | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | P1 | completed | 40 | University of Oklahoma | Sep 2004 | |
| NCT00112892 | Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors | P1 | completed | 36 | Roswell Park Cancer Institute | Aug 2004 | |
| NCT00193349 | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer | P2 | completed | 60 | SCRI Development Innovations, LLC | Sep 2002 | |
| NCT00006025 | Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma | P1 | completed | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2001 | |
| NCT00323011 | FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer | P2 | terminated | 5 | University of Southern California | May 2006 | |
| NCT00286130 | Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer | P2 | completed | 150 | Central European Cooperative Oncology Group | Jul 2005 | |
| NCT00675194 | Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer | P2 | completed | 120 | Johannes Gutenberg University Mainz | Oct 2003 | |
| NCT00063141 | Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | P3 | completed | 1,302 | Eli Lilly and Company | Apr 2003 | |
| NCT00345163 | BRAIN | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) | P2 | completed | 167 | Genentech, Inc. | Jul 2006 |
| NCT00005979 | Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer | P3 | completed | 0 | UNICANCER | Jul 1998 | |
| NCT00539877 | Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding | P1 | completed | 17 | Samsung Medical Center | Oct 2004 | |
| NCT00258232 | Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | P2 | completed | 0 | Barbara Ann Karmanos Cancer Institute | Jan 2002 | |
| NCT00509964 | Second-Line Irinotecan vs. ILF for AGC | P2 | unknown | 50 | Gachon University Gil Medical Center | May 2007 | |
| NCT00215982 | Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer | P2 | completed | 24 | H. Lee Moffitt Cancer Center and Research Institute | Dec 2004 | |
| NCT00416767 | Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | P2 | completed | 20 | Federation Francophone de Cancerologie Digestive | May 2004 | |
| NCT00077298 | Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer | P2 | completed | 70 | National Cancer Institute (NCI) | Dec 2003 | |
| NCT00506168 | Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer | P2 | terminated | 37 | National Cancer Center, Korea | Nov 2001 | |
| NCT00616785 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | P2 | unknown | 41 | Yonsei University | Jun 2007 | |
| NCT00513266 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | P2 | unknown | 35 | Centre Hospitalier Universitaire Vaudois | Jun 2007 | |
| NCT00135135 | Therapy for Children With Neuroblastoma | P2 | completed | 23 | St. Jude Children's Research Hospital | Aug 2005 | |
| NCT00072852 | Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine | P2 | completed | 134 | Pfizer | Nov 2003 | |
| NCT00215995 | Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas | P2 | completed | 21 | H. Lee Moffitt Cancer Center and Research Institute | Jul 2003 | |
| NCT00544011 | Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | P2 | unknown | 47 | Hopital Jean Minjoz | Apr 2007 | |
| NCT00320320 | Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer | P2 | terminated | 72 | Gachon University Gil Medical Center | Apr 2005 | |
| NCT00066274 | Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 0 | UNICANCER | Jul 2002 | |
| NCT00319800 | Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC | P2 | unknown | 50 | Gachon University Gil Medical Center | Feb 2006 | |
| NCT00106262 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | P2 | terminated | 38 | Women and Infants Hospital of Rhode Island | Mar 2005 | |
| NCT00320294 | ILF With/Without Cisplatin for Advanced Gastric Cancer | P2 | unknown | 86 | Gachon University Gil Medical Center | Feb 2005 | |
| NCT00401128 | Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | P2 | completed | 9 | The Cleveland Clinic | May 2004 | |
| NCT00256269 | GE | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma | P2 | terminated | 4 | University of California, Irvine | Jun 2005 |
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | P2 | terminated | 24 | Swedish Medical Center | Feb 2005 | |
| NCT00142350 | A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer | P3 | completed | 690 | Japan Clinical Oncology Group | Nov 2000 | |
| NCT00389870 | Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil | P3 | completed | 1,198 | University of Leeds | Dec 2006 | |
| NCT00312000 | Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma | P3 | completed | 820 | Dutch Colorectal Cancer Group | Jan 2003 | |
| NCT00168896 | SCLC | A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage | P2/P3 | unknown | 286 | Charite University, Berlin, Germany | Oct 2001 |
| NCT00254137 | Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | P2 | completed | 92 | Ludwig-Maximilians - University of Munich | Sep 2004 | |
| NCT00389584 | Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors | P1/P2 | completed | 30 | University of California, Davis | Dec 2002 | |
| NCT00544063 | Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer | P1 | unknown | 33 | Institut du Cancer de Montpellier - Val d'Aurelle | Oct 2006 | |
| NCT00003351 | Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer | P2 | completed | 104 | Alliance for Clinical Trials in Oncology | Aug 1998 | |
| NCT00106054 | Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases | P2 | terminated | 2 | Pfizer | Jan 2006 | |
| NCT00083148 | Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer | P1 | completed | 12 | Roswell Park Cancer Institute | Nov 2002 | |
| NCT00006786 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer | P2 | completed | 0 | Eastern Cooperative Oncology Group | Nov 2000 | |
| NCT00008424 | Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants | P1 | completed | 7 | Children's Oncology Group | Oct 2000 | |
| NCT00022308 | Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | P1 | completed | 0 | Fox Chase Cancer Center | Jan 1999 | |
| NCT00062842 | Study of Irinotecan on a Weekly Schedule in Children | P1 | completed | 23 | Baylor College of Medicine | Sep 1998 | |
| NCT00392470 | Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer | P1 | unknown | 20 | Centre Hospitalier Universitaire Vaudois | Aug 2006 | |
| NCT00087282 | Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jun 2004 | |
| NCT00003368 | Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis | P1 | completed | 0 | National Cancer Institute (NCI) | Jun 1998 | |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | P2 | completed | 291 | Children's Oncology Group | Jun 2006 | |
| NCT00303745 | Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | P2 | unknown | 78 | Federation Francophone de Cancerologie Digestive | Jun 2006 | |
| NCT00139711 | Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer | P2 | completed | 138 | Pfizer | Mar 2003 | |
| NCT00026195 | Irinotecan in Treating Aging Patients With Solid Tumors | P1 | completed | 140 | Alliance for Clinical Trials in Oncology | Sep 2001 | |
| NCT00251797 | A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors | P1 | completed | 10 | University of New Mexico | Mar 2000 | |
| NCT00213486 | Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial | P2 | completed | 43 | University Hospital, Rouen | Jan 2003 | |
| NCT00004923 | Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors | P1/P2 | completed | 47 | Yale University | Apr 1999 | |
| NCT00318903 | Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer | P2 | completed | 25 | University of Alabama at Birmingham | Jan 2002 | |
| NCT00012363 | S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus | P2 | completed | 61 | SWOG Cancer Research Network | Apr 2001 | |
| NCT00005951 | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma | P1 | completed | 0 | Duke University | Aug 2000 | |
| NCT00003900 | Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer | P2 | completed | 48 | Alliance for Clinical Trials in Oncology | Oct 1999 | |
| NCT00126256 | Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer | P3 | completed | 570 | Gustave Roussy, Cancer Campus, Grand Paris | Feb 2002 | |
| NCT00004924 | Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer | P2 | completed | 28 | Yale University | Mar 1999 | |
| NCT00233623 | Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | P2 | withdrawn | 190 | AstraZeneca | Jul 2004 | |
| NCT00004139 | Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | P2 | completed | 80 | Alliance for Clinical Trials in Oncology | Sep 1999 | |
| NCT00003616 | Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma | P1/P2 | completed | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 1998 | |
| NCT00408551 | Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver | P2 | unknown | 20 | Goshen Health System | Nov 2005 | |
| NCT00990912 | A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) | P1/P2 | completed | 20 | Bristol-Myers Squibb | Jan 2004 | |
| NCT00251888 | CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto | P1 | completed | 15 | ARCAGY/ GINECO GROUP | Nov 2002 | |
| NCT00220064 | A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours | P2 | completed | 65 | Royal Marsden NHS Foundation Trust | Jul 2000 | |
| NCT00559741 | Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer | P2 | completed | 80 | Institut Cancerologie de l'Ouest | Oct 2005 | |
| NCT00264134 | Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer | P1/P2 | terminated | 40 | Kentuckiana Cancer Institute | Jun 2003 | |
| NCT00030563 | Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver | P2 | completed | 0 | University of Washington | May 2001 | |
| NCT00004005 | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin | P2 | completed | 12 | St. Jude Children's Research Hospital | Sep 1998 | |
| NCT00006095 | Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy | P1 | completed | 20 | Children's Oncology Group | Jul 2000 | |
| NCT00276003 | INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. | P2 | completed | 22 | University of New Mexico | Aug 2002 | |
| NCT00020761 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | P2 | completed | 51 | Jonsson Comprehensive Cancer Center | Apr 2000 | |
| NCT00033306 | BMS-247550 in Treating Patients With Metastatic Colorectal Cancer | P2 | terminated | 2 | University of Alabama at Birmingham | Feb 2002 | |
| NCT00005076 | Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer | P2 | completed | 110 | University of Alabama at Birmingham | Oct 1999 | |
| NCT00048139 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | P2 | completed | 52 | Hoffmann-La Roche | Oct 2001 | |
| NCT00119236 | 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 48 | National Cancer Institute (NCI) | May 2005 | |
| NCT00635323 | Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma | P2 | completed | 73 | Pfizer | Nov 2002 | |
| NCT00006465 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | P1 | completed | 22 | Case Comprehensive Cancer Center | Dec 2000 | |
| NCT00084721 | Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer | P1 | completed | 2 | Roswell Park Cancer Institute | Mar 2005 | |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | P1 | completed | 24 | National Cancer Institute (NCI) | Mar 2005 | |
| NCT00559676 | Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer | P4 | completed | 200 | Centre Hospital Regional Universitaire de Limoges | Mar 2005 | |
| NCT00048126 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | P2 | completed | 57 | Hoffmann-La Roche | Jul 2001 | |
| NCT00020501 | Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver | P3 | completed | 0 | National Institutes of Health Clinical Center (CC) | Mar 2001 | |
| NCT00016861 | Irinotecan in Treating Children With Refractory or Progressive Solid Tumors | P1 | completed | 0 | Texas Children's Cancer Center | Sep 1998 | |
| NCT00003748 | Irinotecan in Treating Patients With Esophageal or Stomach Cancer | P2 | completed | 40 | Jonsson Comprehensive Cancer Center | Aug 1998 | |
| NCT00063960 | Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer | P2 | completed | 94 | Alliance for Clinical Trials in Oncology | Aug 2003 | |
| NCT00073866 | Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer | P1/P2 | completed | 0 | Northwestern University | Jun 2003 | |
| NCT00022698 | Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | P2 | completed | 67 | Hoffmann-La Roche | May 2001 | |
| NCT00209625 | CPT-11 | Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer | P1/P2 | completed | 23 | Hokkaido Gastrointestinal Cancer Study Group | Apr 2000 |
| NCT00020748 | Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer | P1 | completed | 0 | Georgetown University | Aug 2000 | |
| NCT00003594 | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | P3 | completed | 1,691 | Alliance for Clinical Trials in Oncology | Oct 1998 | |
| NCT00134095 | S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer | P2 | unknown | 70 | Fukushima Medical University Hospital | Sep 2004 | |
| NCT00003711 | Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors | P1 | completed | 0 | San Antonio Cancer Institute | Sep 1997 | |
| NCT00025285 | Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | P2 | completed | 46 | Wake Forest University Health Sciences | Nov 2001 | |
| NCT00070434 | S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | P2 | withdrawn | 0 | SWOG Cancer Research Network | Aug 2004 | |
| NCT00004235 | Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach | P2 | completed | 47 | Alliance for Clinical Trials in Oncology | Jan 2000 | |
| NCT00053833 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | P2 | terminated | 2 | SWOG Cancer Research Network | Apr 2003 | |
| NCT00003137 | Irinotecan in Treating Patients With Advanced Cancer of the Stomach | P2 | completed | 70 | Alliance for Clinical Trials in Oncology | Dec 1997 | |
| NCT00003245 | Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | P2 | completed | 50 | M.D. Anderson Cancer Center | Feb 1998 | |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | P3 | unknown | 1,976 | Federation Francophone de Cancerologie Digestive | Jun 2004 | |
| NCT00093353 | N2003-01 | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma | P1 | completed | 30 | New Approaches to Neuroblastoma Therapy Consortium | May 2004 |
| NCT00079352 | Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors | P1 | completed | 24 | National Cancer Institute (NCI) | Apr 2004 | |
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | completed | 47 | National Cancer Institute (NCI) | Apr 2004 | |
| NCT00176774 | Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma | P2 | completed | 24 | University of Michigan Rogel Cancer Center | Feb 2001 | |
| NCT00005638 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Oct 1999 | |
| NCT00003753 | Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Sep 1998 | |
| NCT00003301 | Irinotecan in Treating Patients With Recurrent Malignant Glioma | P1/P2 | completed | 0 | New Approaches to Brain Tumor Therapy Consortium | Jul 1998 | |
| NCT00003111 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | P2 | completed | 10 | Yale University | Apr 1997 | |
| NCT00220649 | Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas | P1 | completed | 25 | St. Luke's-Roosevelt Hospital Center | Mar 2004 | |
| NCT00084877 | Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors | P1 | completed | 36 | National Cancer Institute (NCI) | Mar 2004 | |
| NCT00006000 | SU5416 | SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors | P1 | completed | 0 | Ohio State University Comprehensive Cancer Center | Aug 2000 |
| NCT00057473 | A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors | P2 | completed | 0 | Bristol-Myers Squibb | Feb 2003 | |
| NCT00020917 | Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Feb 2001 | |
| NCT00030862 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Oct 2001 | |
| NCT00024284 | Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors | P1 | completed | 0 | Bristol-Myers Squibb | Jun 2001 | |
| NCT00030797 | Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer | P2 | completed | 75 | Swiss Cancer Institute | Feb 2001 | |
| NCT00008060 | Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer | P3 | completed | 0 | Medical Research Council | May 2000 | |
| NCT00074321 | Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors | P1 | completed | 84 | National Cancer Institute (NCI) | Nov 2003 | |
| NCT00005626 | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | P2 | completed | 10 | H. Lee Moffitt Cancer Center and Research Institute | Feb 1998 | |
| NCT00075738 | Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer | P2 | unknown | 0 | GERCOR - Multidisciplinary Oncology Cooperative Group | Oct 2003 | |
| NCT00025168 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | P2 | completed | 20 | Wake Forest University Health Sciences | Nov 2001 | |
| NCT00066391 | Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer | P2 | completed | 0 | European Organisation for Research and Treatment of Cancer - EORTC | Jun 2003 | |
| NCT00180960 | Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia | P2 | terminated | 100 | Gustave Roussy, Cancer Campus, Grand Paris | Jun 2003 | |
| NCT00005068 | Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors | P1 | completed | 0 | Mayo Clinic | Jan 2000 | |
| NCT00064181 | Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | P3 | completed | 86 | European Organisation for Research and Treatment of Cancer - EORTC | May 2003 | |
| NCT00062127 | Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors | P1 | completed | 35 | National Cancer Institute (NCI) | Apr 2003 | |
| NCT00052494 | Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P1 | completed | 9 | University Health Network, Toronto | Apr 2003 | |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | P2 | unknown | 30 | Children's Cancer and Leukaemia Group | Apr 2003 | |
| NCT00209638 | Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer | P1/P2 | completed | 24 | Hokkaido Gastrointestinal Cancer Study Group | May 2000 | |
| NCT00004068 | Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor | P2 | completed | 53 | St. Jude Children's Research Hospital | Mar 1999 | |
| NCT00053144 | Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia | P1 | completed | 0 | Roswell Park Cancer Institute | Nov 1999 | |
| NCT00003867 | Irinotecan and Capecitabine in Treating Patients With Solid Tumors | P1 | completed | 30 | Montefiore Medical Center | Mar 1999 | |
| NCT00220168 | Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours | P4 | completed | 33 | Royal Marsden NHS Foundation Trust | Jan 2003 | |
| NCT00037180 | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | P2 | terminated | 212 | Pfizer | Apr 2002 | |
| NCT00024141 | Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors | P1 | completed | 0 | Roswell Park Cancer Institute | May 2001 | |
| NCT00819728 | CPT-11 | Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer | P2 | completed | 35 | Sanofi | Jun 2000 |
| NCT00144378 | Irinotecan Versus Only Best Supportive Care for Gastric Cancer | P3 | completed | 44 | Charite University, Berlin, Germany | Oct 2002 | |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | P2 | terminated | 50 | National Cancer Institute (NCI) | Oct 2002 | |
| NCT00004870 | Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | P1/P2 | completed | 0 | The University of Texas Health Science Center at San Antonio | Jun 2000 | |
| NCT00023868 | Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655) | P3 | terminated | 0 | American College of Radiology Imaging Network | Nov 2001 | |
| NCT00047242 | UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors | P1 | completed | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 2002 | |
| NCT00046917 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | P1 | completed | 13 | National Cancer Institute (NCI) | Jul 2002 | |
| NCT00268398 | MIROX | Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases | P3 | completed | 284 | GERCOR - Multidisciplinary Oncology Cooperative Group | Jul 2002 |
| NCT00045604 | Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jul 2002 | |
| NCT00003463 | Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas | P1 | completed | 0 | Duke University | Jul 1998 | |
| NCT00040391 | A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer | P2 | terminated | 0 | Celgene Corporation | Jun 2002 | |
| NCT00075595 | Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer | P2 | unknown | 0 | GERCOR - Multidisciplinary Oncology Cooperative Group | Jun 2002 | |
| NCT00004922 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jun 1999 | |
| NCT00042874 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 77 | National Cancer Institute (NCI) | May 2002 | |
| NCT00037804 | Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction | P1 | completed | 0 | Pfizer | — | |
| NCT00006103 | Combination Chemotherapy in Treating Patients With Colorectal Cancer | P3 | completed | 400 | Alliance for Clinical Trials in Oncology | Jul 2000 | |
| NCT00003427 | Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer | P1 | completed | 36 | Memorial Sloan Kettering Cancer Center | Apr 1998 | |
| NCT00002939 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer | P1 | completed | 21 | University of Chicago | Nov 1996 | |
| NCT00034502 | A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | P1/P2 | completed | 0 | Eli Lilly and Company | — | |
| NCT00039208 | Combination Chemotherapy in Treating Patients With Colorectal Cancer | P2 | completed | 0 | European Organisation for Research and Treatment of Cancer - EORTC | Feb 2002 | |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | P1 | completed | 41 | National Cancer Institute (NCI) | Dec 2001 | |
| NCT00027833 | Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer | P2 | unknown | 0 | Herbert Irving Comprehensive Cancer Center | Dec 2001 | |
| NCT00025363 | Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma | P2 | completed | 150 | National Cancer Institute (NCI) | Nov 2001 | |
| NCT00026364 | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer | P1 | completed | 22 | National Cancer Institute (NCI) | Nov 2001 | |
| NCT00006037 | Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer | P2 | terminated | 18 | University of Southern California | Nov 1999 | |
| NCT00003345 | Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | P2 | completed | 35 | Memorial Sloan Kettering Cancer Center | Oct 1997 | |
| NCT00544778 | Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma | P2 | terminated | 7 | City of Hope Medical Center | Aug 2001 | |
| NCT00003742 | Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Oct 1998 | |
| NCT00003225 | Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer | P1/P2 | completed | 23 | Jonsson Comprehensive Cancer Center | Jul 1997 | |
| NCT00021073 | Combination Chemotherapy in Treating Patients With Advanced Cancer | P1 | completed | 90 | National Cancer Institute (NCI) | May 2001 | |
| NCT00003710 | Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors | P1 | completed | 12 | The University of Texas Health Science Center at San Antonio | Aug 1998 | |
| NCT00144053 | A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer | P3 | completed | 450 | West Japan Thoracic Oncology Group | Apr 2001 | |
| NCT00003055 | Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jun 1997 | |
| NCT02118064 | CC6 | Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma | P2 | completed | 161 | Cancer Advances Inc. | Mar 2001 |
| NCT00003544 | Irinotecan in Treating Patients With Metastatic Colorectal Cancer | P2 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jun 1998 | |
| NCT00003276 | Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer | P2 | completed | 40 | Alliance for Clinical Trials in Oncology | Mar 1998 | |
| NCT00020488 | Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors | P1 | completed | 0 | National Cancer Institute (NCI) | Feb 2001 | |
| NCT00006366 | Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum | P2 | completed | 0 | Radiation Therapy Oncology Group | Feb 2001 | |
| NCT00003843 | Irinotecan in Treating Patients With Colorectal Cancer | — | terminated | 28 | California Cancer Consortium | Oct 1998 | |
| NCT00026273 | Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer | P3 | completed | 0 | Pfizer | Jan 2001 | |
| NCT00003109 | Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors | P1 | completed | 39 | Fox Chase Cancer Center | Dec 1997 | |
| NCT00002933 | Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | P2 | completed | 21 | Case Comprehensive Cancer Center | Sep 1996 | |
| NCT00021281 | Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer | P3 | unknown | 0 | Jonsson Comprehensive Cancer Center | Dec 2000 | |
| NCT00002988 | Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma | P1 | completed | 36 | Duke University | Apr 1997 | |
| NCT00001495 | CPT-11 | A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors | P1 | completed | 40 | National Cancer Institute (NCI) | Nov 1995 |
| NCT00006485 | Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Sep 2000 | |
| NCT00004182 | Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer | P2 | completed | 0 | Northwestern University | Oct 1999 | |
| NCT00005818 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | P1/P2 | completed | 68 | National Cancer Institute (NCI) | Mar 2000 | |
| NCT00005607 | Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus | P2 | unknown | 0 | Robert H. Lurie Cancer Center | Feb 2000 | |
| NCT00003344 | Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer | P1/P2 | completed | 49 | Medical University of South Carolina | Aug 1998 | |
| NCT00006269 | Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer | P3 | terminated | 89 | Novartis | Dec 1999 | |
| NCT00004919 | Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy | P1 | completed | 30 | National Cancer Institute (NCI) | Dec 1999 | |
| NCT00005036 | Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | P3 | completed | 560 | National Cancer Institute (NCI) | Nov 1999 | |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | P2 | completed | 181 | Children's Oncology Group | Oct 1999 | |
| NCT00003995 | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 | P2 | completed | 32 | National Cancer Institute (NCI) | Sep 1999 | |
| NCT00004885 | Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer | P3 | completed | 430 | European Organisation for Research and Treatment of Cancer - EORTC | Jul 1999 | |
| NCT00003835 | Combination Chemotherapy in Treating Patients With Stage III Colon Cancer | P3 | completed | 1,260 | National Cancer Institute (NCI) | May 1999 | |
| NCT00010036 | Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme | P2 | completed | 0 | NYU Langone Health | May 1999 | |
| NCT00006115 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | P2 | unknown | 0 | GERCOR - Multidisciplinary Oncology Cooperative Group | Apr 1999 | |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | P1 | completed | 60 | National Cancer Institute (NCI) | Jan 1999 | |
| NCT00003260 | Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | P3 | unknown | 109 | GERCOR - Multidisciplinary Oncology Cooperative Group | Jan 1998 | |
| NCT00003719 | Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma | P2 | unknown | 27 | Herbert Irving Comprehensive Cancer Center | Jul 1997 | |
| NCT00002902 | Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors | P1 | completed | 0 | Abramson Cancer Center at Penn Medicine | Apr 1997 | |
| NCT00002759 | Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma | P1 | completed | 3 | National Cancer Institute (NCI) | Jun 1996 |
Irinotecan clinical trials: frequently asked questions
- How many Irinotecan clinical trials are there?
- 1344 Irinotecan clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 178 are actively recruiting participants. 638 are marked completed.
- Are Irinotecan clinical trials recruiting in 2026?
- Yes — 178 Irinotecan trials are actively recruiting in 2026, with 2591 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Irinotecan being studied for?
- Irinotecan is being studied for Colorectal Cancer, Metastatic Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Esophageal Cancer and 1223 more. The trials are grouped by indication on this page.
- What phase is Irinotecan in?
- Irinotecan clinical trials span 15 Phase 4, 172 Phase 3, 684 Phase 2, 266 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Irinotecan clinical trials?
- The lead sponsor across the most Irinotecan trials is National Cancer Institute (NCI), with 491 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Irinotecanas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: